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 ABSTRACT 
 
Pleurotus pulmonarius (grey oyster mushroom) is a well-known edible mushroom that 
has been acknowledged as a curative agent for many diseases. The antihypertensive 
potential of Pleurotus pulmonarius mycelium was investigated in vitro via angiotensin 
converting enzyme (ACE) inhibitory activity. The study was commenced with 
cultivation of P. pulmonarius mycelium using small scale liquid submerged 
fermentation for seven days in which brown sugar-spent yeast medium was used as 
substrate. The mycelial yield was separated from the whole broth to produce mycelial 
aqueous extract and broth extract, respectively. A preliminary ACE inhibitory assay was 
performed on the mycelial aqueous extract and broth extract. The result demonstrated 
almost twofold higher anti-ACE activity of the mycelial aqueous extract at the IC50 
value of 0.72 mg/ml. Ammonium sulphate precipitation was therefore carried out on the 
mycelial aqueous extract for protein extraction and fractionations. Proteins were 
fractionated into ten fractions based on gradual ammonium sulphate saturation and 
labelled as F10 to F100. Each fraction was tested for their ACE inhibitory activity and 
result showed the highest activity by F40 with the IC50 value obtained was 0.022 mg/ml, 
which was 32 times stronger than the IC50 value of mycelial aqueous extract. Fraction 
F40 was subjected to RP-HPLC for protein purification using a semi-preparative 
column C18 (10 × 100 mm). Eight apparent chromatogram peaks were observed and 
labelled as P1 to P8. All peaks were evaluated for their ACE inhibitory activity and P6 
demonstrated the highest ACE inhibitory activity at the IC50 value of 0.012 mg/ml. The 
IC50 value of P6 was 60 times stronger than that of the mycelial aqueous extract, and 
considered among the strongest IC50 values for ACE inhibitory activity discovered from 
mushrooms. Proteins from P6 were further analysed via SDS-PAGE. Consequently, 
there were four protein bands emerged via silver staining method. Each band was then 
 excised and treated with trypsin in-gel digestion prior to MALDI-TOF/TOF MS. 
Database search from MALDI-TOF/TOF MS has nominated three potential 
antihypertensive proteins that work via different mechanisms; serine proteinase 
inhibitor-like protein, nitrite reductase-like protein and DEAD/DEAH box RNA 
helicase-like protein. MRPS5-like protein could also be one of the desired proteins due 
to the highest protein score among all other proteins in MALDI database. Fraction P6 
was also subjected to LC-MS/MS to support the protein identification. DEAD/DEAH 
box RNA helicase-like protein was the only protein that has been identified in both 
mass spectrometries.  This study demonstrated the first reported ACE inhibitory activity 
from the mycelium of P. pulmonarius (Fr.) Quél cultivated locally.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABSTRAK 
 
Pleurotus pulmonarius (cendawan tiram kelabu) adalah salah satu cendawan yang boleh 
di makan dan mengandungi pelbagai khasiat penyembuhan. Kebolehan cendawan ini 
sebagai agen penurun tekanan darah diuji secara in vitro menggunakan kaedah 
perencatan aktiviti enzim angiotensin converting enzyme (ACE). Kajian dimulakan 
dengan pengkulturan miselium P. pulmonarius menggunakan teknik fermentasi 
terendam berskala kecil yg dilakukan selama tujuh hari dengan menggunakan media 
gula merah dan yeast terpakai (brown sugar-spent yeast) sebagai substrat. Hasil kultur 
iaitu miselium dan larutannya diasingkan bagi menghasilkan ekstrak miselium terlarut 
(mycelial aqueous extract) dan ekstrak larutan medium (broth extract). Aktiviti 
perencatan enzim ACE telah dilakukan ke atas kedua-dua ekstrak tersebut. Hasil kajian 
mendapati ekstrak miselium terlarut menunjukkan aktiviti perencatan enzim yang lebih 
baik dengan bacaan IC50 sebanyak 0.72 mg/ml, iaitu dua kali ganda lebih baik daripada 
ekstrak larutan medium. Oleh itu, ekstrak miselium terlarut dipilih untuk meneruskan 
ujikaji seterusnya iaitu pengekstrakan dan fraksionasi protein melalui kaedah 
pemendakan ammonium sulphate (ammonium sulphate precipitation). Melalui kaedah 
ini, protein telah dikategorikan kepada sepuluh kumpulan dan di label sebagai F10 
hingga F100. Setiap kumpulan protein diuji aktiviti perencatan enzim ACEnya, dan 
ujian mendapati F40 menunjukkan kadar perencatan enzim tertinggi iaitu pada bacaan 
IC50 sebanyak 0.022 mg/ml, yang mana mencatatkan sebanyak tiga puluh dua lebih 
rendah nilainya berbanding bacaan yang diperolehi daripada ekstrak miselium terlarut. 
Protein-protein dari F40 kemudiannya dibersihkan menggunakan teknik RP-HPLC 
dengan menggunakan turus C18 (10 × 100 mm). Sebanyak lapan puncak (peaks) telah 
diperolehi dan setiap puncak telah diuji aktiviti perencatan enzim ACEnya. Puncak P6 
telah menunjukkan aktiviti perencatan enzim tertinggi iaitu sebanyak IC50 0.012 mg/ml. 
 Nilai ini adalah enam puluh kali lebih rendah daripada bacaan yang direkodkan oleh 
ekstrak miselium terendam. Malah, nilai ini adalah antara nilai terendah yang dicatatkan 
bagi aktiviti perencatan enzim ACE oleh cendawan. Puncak P6 seterusnya melalui 
analisa SDS-PAGE untuk proses pemisahan lanjut protein-protein. Hasil analisa 
mendapati empat gelang (band) terhasil daripada P6.  Setiap gelang telah dicerna 
menggunakan trypsin dan dihantar untuk analisa MALDI-TOF/TOF. Hasil analisa 
mendapati tiga protein yang terlibat di dalam proses penurunan tekanan darah, iaitu 
protein-protein yang menyamai serine proteinase inhibitor, nitrite reductase, dan 
DEAD/DEAH box RNA helicase. Protin MRPS5-like juga perlu diambil kira sebagai 
protein yang dikehendaki berhubung dengan peratusan tertinggi skor protin yang 
ditunjukkan berbanding protein-protein lain di dalam pangkalan data MALDI.  Puncak 
P6 juga telah melalui analisa LC-MS/MS sebagai mengukuhkan hasil carian protein-
protein perencat ACE daripada MALDI-TOF/TOF. Hasil kajian mendapati kewujudan 
DEAD/DEAH box RNA helicase di dalam kedua-dua analisa. Kajian ini membuktikan 
potensi strain tempatan miselium P. pulmonarius (Fr.) Quél terhadap aktiviti penurunan 
tekanan darah, sekaligus mencatat kajian pertama terhadap perencatan enzim ACE bagi 
miseleum spesis tersebut.  
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CHAPTER 1: INTRODUCTION 
 
Hypertension is a chronic medical condition in which the blood pressure level in the 
arteries is consistently above the normal range. It is also referred to as high blood 
pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure defines hypertension as systolic 
blood pressure (SBP) of 140 mm Hg or greater and diastolic blood pressure (DBP) of 90 
mm Hg or greater, or anyone prescribing antihypertensive medication (Barbosa-Filho et 
al., 2006).  
 
According to the World Health Organization (WHO., 2011), hypertension has 
consecutively contributed to the first leading cause of death worldwide. It is known to 
be a common and progressive disorder that causes a major risk for cardiovascular and 
renal diseases due to increasing longevity and prevalence of contributing factors such as 
obesity and unhealthy lifestyle. Even though the treatment of hypertension has proven 
to prevent cardiovascular diseases and to enhance life, hypertension remains scantily 
managed everywhere.  
 
There are many types of drug currently used to treat hypertension. Angiotensin 
converting enzyme (ACE) inhibitors are among the most widely prescribed clinical 
drugs to effectively treat hypertension and certain kidney-related diseases (Wong et al., 
2004). ACE inhibitors offer various advantageous for patients with multiple 
cardiovascular disorders. Their main purpose is to lower blood pressure by promoting 
vasodilatation. Prevention of angiotensin II by ACE inhibitor prevents generation of 
 toxic radicals. Constant treatment with ACE inhibitors resulted in significant 
improvement of endothelial function of arteriosclerosis patients. Mortality rate of 
cardiovascular patients with coronary artery disease and chronic heart failure is reduced 
by long-term treatment with ACE inhibitors because of the blood pressure lowering 
effect and cholesterol reduction (Tiefenbacher, et al., 2003). Other exclusive effects of 
ACE inhibitors include regression of ventricular hypertrophy and vascular smooth 
muscle cell proliferation, enhancement of nitric oxide effects and anti-macrophage 
function (Wong et al., 2007).             
 
Formulation of ACE inhibitors as antihypertensive drugs has evolved enormously.  
From the first discovery of ACE inhibitor in a toxic venom of a Brazillian viper 
(Bothrops jararaca), Cushman and Ondetti had later succeeded on the formulation of a 
synthetic ACE inhibitor (captopril), which has become a revolution in the treatment of 
hypertension (Cushman et al., 1999).  As much as it has proven to be remarkably 
efficacious at lowering blood pressure and show other cardiovascular benefits, it renders 
deleterious side effects to patients. Skin rash, taste disturbance and proteinuria were 
reported as common side effects caused by the presence of sulphydryl binding group in 
synthetic ACE inhibitors (Reid, 1997). Other reported common side effects are 
persistent cough (Mukae, 2000), angioderma and dizziness (Gibbs et al., 1999).  
 
The search for safer ACE inhibitors with less or no side effects is highly anticipated to 
improve the quality of antihypertensive drug-therapy, thus mitigates adverse reactions 
and prevents unnecessary complications caused by the medicine. Hence, natural 
products and food sources provide a vast resource for the development of harmless 
antihypertensive drugs (Kumar et al., 2010). Natural products and their derivatives have 
been a remarkable source of human medicines, both in the mainstream medicine 
 practices and the homeopathic medicine. The advent of technologies in biochemistry 
allows scientists to specify their study on the bioactive compounds of natural resources 
and discover their medicinal properties (Haustedt et al., 2006).     
 
Pleurotus pulmonarius is one of the most well-known edible mushrooms in the South 
East Asian countries including Malaysia. It is renowned for the delectable and succulent 
taste and often added to various dishes.  In addition, P. pulmonarius contains high 
vitamins, minerals, proteins and other bioactive compounds thus make it a nourishing 
choice of food for dietary supplements as well as the eye-opening curative resources in 
drug therapies against many devastating diseases (Shahid et al., 2006). 
 
Pleurotus pulmonarius mycelium exhibits an equivalent therapeutic importance as its 
fruiting body. Many scientific research reported contribution of P. pulmonarius 
mycelium in promoting health, especially via its bioactive compounds and proteins 
activities. Advance in current biotechnologies develop extensive coverage of research in 
mycelia study from crude extract in vitro bioassay to specific analyses up to protein 
identification, relationship edifice between enzymes and their targets, and more in depth 
protein-structure relationship, thus allowing better understanding of the mushroom and 
maximum exploitation in scientific research. 
 
Despite the available discoveries done by scientist vis-à-vis medicinal properties of P. 
pulmonarius, there is still inadequate information available regarding bioactive peptides 
derived from local strains. As the medicinal value and peptide composition of a 
mushroom may be affected by the growth environment, it is important to further 
investigate the medicinal properties of P. pulmonarius in Malaysia, especially towards 
the novel and undiscovered therapeutic value. Hitherto, there is no report on the ACE 
 inhibitory activity from P. pulmonarius mycelium both from local and foreign strains. 
Hence, this study was intended to investigate antihypertensive activity via ACE 
inhibitory action on the commercial strain of P. pulmonarius mycelium.   
 
OBJECTIVES 
The aim of this study was to investigate ACE inhibitory activity of P. pulmonarius 
mycelium cultivated by liquid fermentation. More specific objectives were: 
1) To produce mycelial biomass of P. pulmonarius by liquid fermentation and to 
prepare protein extracts, 
2)  To investigate ACE inhibitory activity of protein extracts from the mycelium 
and cultured broth,  
3) To identify potential ACE inhibitors using a series of protein purification 
methods and followed by proteomic tools, i.e. MALDI-TOFF/TOFF and LC-
MS/MS. 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 2: LITERATURE REVIEW 
 
 2.1 Hypertension 
Hypertension can be classified into two types; essential or primary hypertension and 
secondary hypertension. Essential hypertension is the condition where the underlying 
causes of high blood pressure are unjustified. Approximately, up to 95% of people with 
high blood pressure are in this category. On the other hand, secondary hypertension 
occurs as a result of other disorders, such as kidney disease, diabetes, obstructive sleep 
apnea and aortic coarctation (Oparil et al., 2003).  
  
2.1.1 Causes and symptoms of hypertension 
Hypertension is synonymous with the term „a silent killer‟ because people with this 
pathological condition can be asymptomatic for years, before leading to serious 
disorders such as a sudden fatal heart attack or stroke if it is left untreated for a long 
time. In other words, the majority of people suffering from hypertension may possess a 
late onset condition. However, there are many risk factors that can lead to essential 
hypertension. Obesity is one major factor of hypertension. Also, sedimentary lifestyles, 
increased level of stress, high sodium and alcohol intake, vitamin D deficiency and 
aging are among the factors for essential hypertension. People with a family history of 
hypertension and some genetic inherited mutations may have higher risk of developing 
hypertension (Calhoun et al., 2008). 
 
Studies have elucidated that some disorders such as rennin elevation, insulin resistance 
and metabolic syndrome are thought to cause hypertension (Segura et al., 2007). 
Recently, low birth weight has been observed as a risk factor for adult essential 
 hypertension. In addition, several classes of drugs can increase blood pressure, though 
the effects are highly individualized (Bagby, 2007). 
 
People with mild to moderate essential hypertension are normally asymptomatic. Severe 
hypertension is associated with somnolence, headache, visual disturbance, confusion, 
nausea and vomiting. In children, hypertension may cause fatigue, blurred vision 
headache, epitasis and bell palsy (Pitts & Adams, 1998).  
 
On the contrary, the cause of secondary hypertension is recognizable. 
Pheochromocytoma and hyperaldosteronism are diseases often related to secondary 
hypertension. There are also certain medications that can lead to secondary 
hypertension. Long term intake of corticosteroids group drugs like prednisone and 
prednisolone can lead to Cushing‟s syndrome and hence increase the risk of secondary 
hypertension. Likewise, non-steroidal anti-inflammatory drugs (NSAIDs) can cause 
kidney damage and lead to secondary hypertension if used regularly and continuously 
(Malaysia Hypertension Guideline Working Group, 2008). Other uncommon secondary 
causes of hypertension consist of hyperparathyroidism, aortic coarctation and 
intracranial tumours. It is important to identify the underlying causes and factors in 
secondary hypertension because the treatment is specific (Anderson et al., 1994).   
 
2.1.2 Treatment and medication of hypertension 
Hypertension is commonly multifactorial in aetiology. In benign cases, lifestyle 
modifications including weight loss, regular exercise, moderate alcohol intake, and 
ingestion of a high-fibre, low-fat and low-salt diet is highly recommended, prior to drug 
therapy. If the hypertension is malignant enough to justify immediate use of 
medications, lifestyle changes are initiated concomitantly (Barbosa-Filho et al., 2006). 
 The majority of resistance hypertension patients require antihypertensive agents for 
pharmacological treatment and medication. The aim of treatment is to reduce the high 
morbidity and mortality chances. As well as lowering blood pressure and maintaining at 
<140/90 mmHg for most patients, it must also be able to reduce certain circumstances 
often related to hypertension such as diabetes, kidney diseases and other cardiovascular 
risk factors (Kim et al., 2004). 
 
There are alternatives available to treat hypertension, such as monotherapy and/or 
combined therapy. However, numerous researches demonstrate antihypertensive 
advantage by combining different classes of drugs (Burgess, 2002). The commonly used 
drugs are the typical groups of angiotensin I-converting enzyme (ACE) inhibitors, 
calcium channel blockers, alpha blockers, beta blockers, vasodilators, centrally acting 
agents and diuretics. The choice of drugs used for the treatment is based on certain 
criteria such as age, severity of hypertension and occurrence of other complications (Ali 
et al., 2006). 
  
2.1.3  Mechanism of hypertension on the renin-angiotensin-aldosterone system   
(RAAS) 
Blood pressure is regulated by a variety of different interacting biochemical 
mechanisms. The increase or decrease of blood pressure relies on which pathway 
predominates at a time. Naturally, regulation of blood pressure is highly related with the 
RAAS, which plays a vital role in the maintenance of vascular tone with regard to 
peripheral resistance (Figure 2.1) (Hong et al., 2008). 
 
  
Figure 2.1: Schematic diagram of renin-angiotensin-aldosterone system (Rad, 2006). 
RAAS plays a vital role in the regulation of blood pressure. The system includes series 
of enzymes and hormones, mainly the conversion of angiotensin I to angiotensin II. 
Angiotensin II takes part in many pathways, such as the vascular tone mechanism 
(vasoconstriction) and superoxide formation (endothelial dysfunction). Angiotensin II 
also stimulates the secretion of aldosterone, which increases the absorption of sodium 
and water in the blood, thus increases blood pressure.  
 
Renin is secreted by the juxtaglomerular apparatus of the kidney when blood pressure is 
decreasing. It splits angiotensinogen to produce the inactive decapeptide angiotensin I 
(Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu). In the presence of ACE, angiotensin I is 
converted to an active octapeptide vasoconstrictor and cardiovascular trophic factor, 
angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) (Figure 2.2). Simultaneously, 
kallikrein enzyme catalyzes the inactive bradykininogen into an active hypotensive 
bradykinin, which will turn into inactive fragments by the action of ACE, as another 
course that contributes to the hypertensive effects of ACE activity (Choi et al., 2001).  
 
  
Figure 2.2: The suggested hypertensive mechanism of angiotensin. ACE triggers 
hypertensive effects via conversion of angiotensin I to angiotensin II, and inactivation 
of hypotensive peptide bradykinin (Adapted from Barbosa-Filho et al., 2006). 
 
Angiotensin II plays a role in stimulating the synthesis and release of aldosterone 
(ADH) from the adrenal cortex, as well as triggering vascular smooth muscle 
constriction. Aldosterone secretion is responsible in increasing blood pressure by 
promoting sodium retention (and thereby water retention) in the distal tubules (Figure 
2.2) (Packer et al., 1986). Angiotensin II also promotes the production of superoxide 
anion and hydrogen peroxide in the polymorphonuclear leucocytes, which inactivates 
the endothelial vasodilatory compounds nitric oxide (NO) and prostacyclin (PGI2). 
Production of superoxide rather than NO inhibits cGMP pathway and thus conducts 
vascular dysfunction (Barbosa-filho et al., 2006).  
 
In general, angiotensin II is a hormone that has many effects on the cardiovascular 
system, such as to constrict arteries, raise blood pressure and thicken several 
cardiovascular structures. For the case of cardiovascular disorders, angiotensin II is 
Asp-Arg-Val-Tyr-Lle-His-Pro-Phe-His-Leu-Val-Lle-His-R 
angiotensinogen 
Asp-Arg-Val-Tyr-Lle-His-Pro-Phe-His-Leu 
angiotensin I 
Asp-Arg-Val-Tyr-Lle-His-Pro-Phe 
angiotensin II 
Vasoconstriction Aldosteron secretion 
renin 
ACE 
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg 
bradykinin 
Inactive kinins 
(hypertension) 
vasodilation 
 secreted in abnormally high amount (Catt et al., 1971). A profusion of angiotensin II 
triggers persistent complications to the cardiovascular system thus causes the heart to 
work more intensely to pump blood into the body‟s main arteries. The excessive force 
received by the heart muscle tends to raise problems if the heart has been weakened by 
other problems such as heart attack. High levels of circulating angiotensin II thickens 
the heart and blood vessels, a condition known as hypertrophy. Together with the 
occurrence of vessel constrictions, this is thought to incline accumulation of cholesterol 
level and blockages in the arteries, which can aggravate to strokes and heart attacks 
(Nancy, 2003). 
 
2.1.4   Angiotensin Converting Enzyme (ACE) 
Angiotensin converting enzyme (ACE; kiniase II; EC 3.4.15.1) is an exopeptidase that 
catalyzes the conversion of angiotensin I to angiotensin II by removal of the C-terminal 
dipeptide. ACE is produced predominantly in lung and male reproductive tissues, as 
well as on the plasma membranes of various cell types including microvillar brush 
border epithelial cells (e.g. renal proximal tubule cells), endothelial cells, and 
neuroepithelial cells. Other organs that produce ACE are kidney, brain, intestine and 
adrenal cortex. ACE is an acidic protein with an approximate pI of 4.5, and a zinc 
dependent dipeptidase which demonstrates reliance upon a metal ion for full enzymatic 
activity (Ondetti & Cushman, 1984). 
 
ACE is well known to be a key part of the rennin-angiotensin-aldosteron system 
(RAAS) that regulates blood pressure. Besides acting as a catalyst for the production of 
angiotensin II, it metabolizes several other peptides such as bradykinin and kallidin into 
inactive metabolites. As the ACE activity gives rise to vasoconstriction and decreases 
 vasodilation, the inhibitors of ACE could therefore exhibit potency of treating 
hypertension (Atlas, 2007).  
 
2.1.5 Angiotensin I-converting enzyme (ACE) inhibitors 
Studies with peptidic inhibitors of ACE have been performed since early 60‟s. In depth 
research comprising the structure-activity relationship, enzyme interactions and peptide 
analogue inhibitors have been studied extensively to design potent antihypertensive 
agents that competitively block ACE activity, hence the conversion of angiotensin I to 
angiotensin II, thereby reducing angiotensin II level and followed by reduction of blood 
pressure (Ondetti & Cushman, 1984). Although the structure-function relationship of 
ACE inhibitors is still not clear, they share some similarities in the structures. They are 
rich in hydrophobic amino acids and many of them contain proline, lysine, or arginine 
as C-terminal residues. Common ACE inhibitors are di- or tripeptides, which are 
resistant to the digestive tract endopeptidases and can be easily absorbed to the blood 
(Iwaniak et al., 2008). 
 
Developments of potent derivatives ACE inhibitors as antihypertensive drugs have 
become imperative and are widely used for the treatment of cardiovascular diseases due 
to their ability to improve blood pressure, control patients with hypertension and 
prolong survival rate in patients. Prescription of ACE inhibitors can avert or reverse 
hypertrophy of the heart and vessel walls. They also work to prevent constriction of 
arteries, lower blood pressure and reduce the energetic heart pumping of the patients 
(Loizzo et al., 2007). 
 
Clinical studies have demonstrated that ACE inhibitors significantly reduce the 
morbidity and mortality of patients with myocardial infarction or heart failure, and 
 delay the onset of symptoms in heart failure patients (Tsai et al., 2007). They also 
reduce the frequency of hospitalization. Studies have shown that ACE inhibitors prevent 
imminent heart attacks and deaths from heart disease for patient that is at high risk for 
having heart attacks or developing heart failure. ACE inhibitors are also used to reduce 
heart attacks in patients with diabetes and mild kidney disease (Nancy, 2003) 
  
2.1.6  Angiotensin I-converting enzyme inhibitors from natural products 
The first discovery of ACE inhibitors was from snake venom, which is involved in 
smooth muscles contractions in the guinea pig ileum because of the bradykinin activity. 
The first ACE inhibitor was called bradykinin potentiator due to its mechanism (Cheung 
et al,. 1980; Iwaniak et al., 2008). Later, many synthetic ACE inhibitors such as 
captopril, enalapril and lisinopril have been formulated and used clinically as first line 
antihypertensive drugs.  
 
Albeit the remarkable effect in treating hypertension, synthetic inhibitors can cause 
deleterious side effects. For some patients, they may undergo dizziness, cough and 
allergies (Jang et al., 2011). Others may get worse adverse effects such as taste 
disturbance and disruption of kidney function. Hence, the quest for harmless and cost-
effective naturally occurring ACE inhibitors are highly coveted for the remedies of 
hypertension (Li et al., 2007). 
 
Recent interests have focused on the isolation and identification of ACE inhibitors from 
natural products and foods for the development of more effective ACE inhibitors. These 
sources are known to carry a wide range of functional and biological properties. Several 
ACE inhibitors derived from natural and food products have demonstrated potent 
antihypertensive effects and other positive effects on the metabolism of glucose and 
 lipid, in increasing exercise tolerance and on reducing insulin requirements in diabetes 
(Lee et al., 2004). 
 
ACE inhibitors from milk products are the most intensely studied so far. To date, 
numerous ACE inhibitory peptides have been isolated from milk products. For instance, 
two fermented sour-milk products containing the ACE inhibitory tripeptides, Ile-Pro-
Pro (IPP) and Val-Pro-Pro (VPP) have been launched commercially in Finland and 
Japan, respectively. These products have proven to effectively reduce blood pressure in 
mildly hypertensive human subjects, and reported to cause no side effects (FitzGerald et 
al., 2000).  
 
Several natural products from plant extracts [broccoli (Lee et al., 2006), spinach (Yang 
et al., 2003)], fungi [Grifola frondosa (Choi et al., 2001), Ganoderma lucidum 
(Morigawa et al., 1986), Flammulina velutipes (Melzig et al., 1996)], and algae 
[Sargasum sp. (Tierney et al., 2010), Ishige okamurae (Yoon et al., 2009)], and many 
more that act specifically by inhibiting ACE have also been discovered and proven to be 
amongst the most powerful known vasodilators.  
 
2.5 Mushrooms 
Mushrooms can be defined as macrofungus, a type of fungi that belong to the Fungi 
Kingdom. In general, the life cycle of a mushroom consists of vegetative and 
reproductive phases. Vegetative growth denotes fungal mycelial growth. At this stage, 
mycelium absorbs nutrients from the substrate by the secretion of enzymes and then 
colonizes them.  In an optimum source of light, humidity, temperature, and oxygen, the 
mycelial colony ceases vegetative phase to later grow into fruit bodies, commencing the 
 reproductive phase. The fruit bodies are called mushrooms, which can grow into 
different sizes and structures (Cho, 2004). 
 
Mushrooms generally belong to basidiomycetes, and are estimated to be over 140,000 
of species available on earth, but only 14,000 to 22,000 are yet known (Hawksworth, 
2001). There are at least 2,000 species showing various degrees of edibility, with over 
200 species have been collected from the wild and used for traditional medical 
purposes, and about 35 mushroom species have been cultivated commercially (Sánchez, 
2004).  
 
In general, mushrooms are divided into four major categories, (1) edible mushrooms, 
which are normally fleshy and used as dietary products, e.g. many Pleurotus species, (2) 
medicinal mushrooms, which are considered to have medicinal properties and used as 
active ingredients in many medical treatments, e.g. Ganoderma tsugae, (3) poisonous 
mushrooms, which are proven or suspected to be harmful and poisonous, e.g. Amanita 
muscaria, and (4) other mushrooms, which include a large number of mushrooms 
whose properties remain less identified. However, many types of mushrooms could be 
classified into more than one category, especially the edible mushrooms where they 
could be edible and also medicinal (Stamets, 2000). 
 
Mushrooms play a vital role in nature. They are the premier recyclers in nature that 
work by secreting enzymes to digest organic wastes and returning them back to the 
natural ecosystem. Like other fungi, mushrooms produce digestive exoenzymes by their 
hyphae, in which they digest the food into small molecules that can be absorbed and 
used by the fungus (Archer & Wood, 1994). 
 
 Mushrooms have been appreciated as scrumptious and nourishing foods, due to their 
fine, unique and subtle flavours, as well as good textures. Known as the meat of 
vegetable world, edible mushrooms are used extensively in many cuisines especially in 
the Asian countries such as Japan, Korea, China, Indonesia and Malaysia, as well as 
some European countries. In general, these fungi contain high nutritional value such as 
protein, fibre, minerals and vitamins, thus make them as a healthy dietary source 
(Shahid et al., 2006). 
  
2.5.1 Medicinal properties of mushroom 
Mushrooms share a long history with human civilization. Some mushrooms had been 
exploited in ancient spiritual beliefs and rituals due to their psychoactive and 
hallucinogenic properties (Smith et al., 2002). The psychoactive mushrooms had been 
long employed in native medicine traditions in cultures all around the world. Also 
known as magic mushrooms or shrooms, these mushrooms had been claimed as 
facilitating profound and life-changing insights often articulated as mystical 
experiences.  Recent scientific study done by Griffiths and his co-workers has supported 
the claim, in which the significance of enhanced spiritual experiences is correlated with 
psilocybin, the principal psychoactive component of various hallucinogenic mushrooms 
(Griffiths et al., 2011).  
 
Many societies worldwide recognize that certain mushrooms contain intense health-
promoting benefits, and hence are called medicinal mushrooms. In Oriental countries, 
both edible and non-edible mushrooms have been used for medicinal purposes ever 
since ages ago. Ying et al., has reported that there are approximately 270 species of 
mushrooms that are recognized to have various recuperative properties. This number is 
 thought to increase as the interest in medicinal mushroom studies continues to evolve 
(Smith et al., 2002). 
 
According to scientific studies, mushrooms constitute potent therapeutic activities and 
help in the prevention and treatment of various diseases. Scientists have discovered 
several bioactive compounds in medicinal mushrooms, which demonstrated curative 
efficacy to many diseases, particularly in anticancer and antitumor therapy. The 
research of anticancer and antitumor potential from mushrooms has been extensively 
studied in vitro and in vivo (Ikekawa, 2001). There are also bioactive compounds from 
mushrooms extracts that have already been commercialized and are currently produced 
by Asian pharmaceutical companies. For instance, the main anticancer polysaccharides 
that have been subjected to early clinical tests are lentinan (Lentinus edodes), PSK and 
PSP (Trametes versicolor), Schizophyllan (Schizophylum commune) and Grifon-D 
(Grifola frondosa) (Wasser, 2002). 
 
Mushrooms have also benefited the administration of cardiovascular health 
complications. Some mushroom components such as lipids, fibres, vitamins, protein, 
phenolic compounds and minerals have shown positive results in the treatment and/or 
prevention of cardiovascular diseases. Several mechanisms including the anti-
atherosclerosis effect of some edible mushrooms have been reported, mainly toward the 
improvement of vascular reactivity, anti-oxidative effects and anti-platelet aggregating 
effects. Kaneda and Tokuda (1966) were among the first to report hypocholesterolemic 
effect of Lentinula edodes, Auricularia polytricha, Flammulina velutipes and Agaricus 
bisporus. Whereas for the blood pressure treatment, the low concentration of sodium 
but high amount of potassium in mushrooms substantiates mushrooms intake within an 
 antihypertensive diet, which currently directed to more profound research on the 
antihypertensive study (Guillamón et al., 2010).  
 
Mushrooms also demonstrate their pharmacological and therapeutic actions against 
other numerous diseases and metabolic disturbances as serious as cancer or 
degenerative diseases. Other verified pharmacological activities studied in medicinal 
mushrooms are anti-inflammatory effect, antioxidant activity, antimicrobial activity, 
immunostimulating activity, and activities on metabolic syndrome and its related 
diseases such as diabetes and hypertension (Poucheret et al., 2006). 
 
Medicinal mushrooms have contributed to the main mushrooms cultivation in Asian 
countries and currently penetrating the Western market place, due to a flourishing 
demand for healthier foods and their increased consumption in the mainstream medical 
practices (Sullivan et al., 2006). Throughout the years, more mushroom species are 
studied for their medicinal prospects. This has led to better understanding of mushrooms 
in their physiological and morphological characterizations. In fact, medicinal mushroom 
studies have become a rapidly developing area of biotechnology for biological 
activities, especially in promoting health. 
 
2.6 Pleurotus pulmonarius (Fr.) Quél 
Pleurotus pulmonarius represents a circumscribed group of higher white rot fungi of the 
phylum Basidiomycota. Categorized under the family of Pleurotaceae, it is recognized 
by a grey colour fruit body with decurrent hymenium, bare stipe and eccentric stalk 
attached to the pileus, which opens up like an oyster shell during the morphogenesis. 
Hence, it is often called the “Grey oyster mushroom”. It has cylindrical, smooth white 
 spores print attached to the gills and produces white velvety mycelia when grown on 
agar media (Rajarathnam et al., 1987).  
 
Pleurotus pulmonarius is often erroneously identified as Pleurotus sajor-caju by 
mycologists and mushroom growers. Although they are considered as two closely 
related cultivated oyster mushroom species, they are different in morphological and 
reproductive approach. Pleurotus pulmonarius is categorized under the Order of 
Agaricales which has gills on the hymenium and has monomitic type of hyphae. In 
contrast, P. sajor-caju is categorized under the Order of Polyporales which has pores on 
the hymenium and has trimitic or dimintic hyphae. Hence, in 1975, P. sajor-caju was 
returned to the genus Lentinus by Pegler and addressed as Lentinus sajor-caju. The 
name P. sajor-caju was then removed from the Index Fungorum. However, the name P. 
sajor-caju has been misapplied by mushroom growers and even in scientific papers, 
thus contributed to the persistent confusion (Stamets, 2000). Figure 2.3 shows (a) P. 
pulmonarius fruiting body and (b) P. pulmonarius mycelium growing on an agar plate.   
 
(a)  (b)  
       Figure 2.3: (a) P. pulmonarius fruiting body, (b) P. pulmonarius mycelium.  
 
The first discovery of P. sajor-caju (pulmonarius) was reported on the succulent tissues 
of Euphorbia royleans Boiss., in the foothills of the Himalayas. Like other Pleurotus 
mushrooms, P. pulmonarius is naturally found as a saprophyte, a primary decomposer 
 of hardwood trees.  It grows naturally on dead standing trees or on fallen logs, mostly 
under shady or diffused light. However, due to its high saprophytic colonizing ability, it 
can grow over a wide range of temperatures on different natural resources and 
agricultural wastes (Madan et al., 1987).  The growth parameters of P. pulmonarius are 
shown in Table 2.1. 
        
Table 2.1: Growth parameters environmental requirement of P. pulmonarius (Stamets, 
2000)   
Spawn run Primodial formation Fruit body development 
Incubation temperature:  
24 – 29°C 
Initiation temperature: 
10 – 27°C 
Temperature: 
18 – 24°C 
Relative humidity: 
90 – 100% 
Relative humidity: 
95 – 100% 
Relative humidity: 
95 – 100% 
Duration: 
18 – 14 days 
Duration: 
3 – 5 days 
Duration: 
3 – 5 days 
CO2: < 5000 ppm CO2: 400 – 800 ppm CO2: 400 – 800 ppm 
Fresh air exchanges: 1 per 
hour 
Fresh air exchanges: 
5 – 7 per hour 
Fresh air exchanges: 
5 – 7   
Light requirements: 
n/a 
Light requirements: 
1000 – 1500 (2000) lux 
Light requirements: 
1000 – 1500 (2000) lux 
 
As compared to other edible mushrooms, P. pulmonarius is one of the most successfully 
cultivated mushrooms (Zhang et al., 2002). It is among the easiest, fastest and cheapest 
to grow and requires less preparation time and technology. It can grow in various by-
products as substrates such as banana leaves, peanut leaves, sugarcane leaves, wheat 
and rice straw, thus makes it very economical and significant for commercial purposes. 
Its fruiting body is fairly resistant to diseases and pests attacks. Because of its easiness 
 in cultivation and high yields, the demand for P. pulmonarius is increasing, thus making 
its way to supermarket shelves during any season (Mandeel et al., 2005). Owing to its 
succulent taste and suitability to almost any Asian cuisine, P. pulmonarius has become 
the most popular edible mushroom in Malaysia.  
 
Besides the fruiting body, P. sajor-caju mycelium plays comparable important role in 
human and animal life, mainly in culinary and food products such as food additives and 
mushroom-flavour agents (Chahal, 1989). Having the ability to absorb inorganic 
microelements, degradation of phenolic compounds and lignocellulosic materials, P. 
sajor-caju mycelium has proven its ability in bioremediation and decreasing 
environmental pollution. In fact, mycelia products are believed to be „the wave of the 
future‟ because they ensure standardized quality by way of rapid and undemanding 
production (Lindequist et al., 2005). 
 
Research performed by Ferreira and his co-workers in 2008 showed that P. sajor-caju 
mycelium exhibits potential in the treatment of olive oil mill wastewater. This 
mycelium is also involved in bio pulping, as well as recycling process of environmental 
products such as unused wood residues and its by-products. The advantages of P. sajor-
caju mycelium and its contributions to the waste management enhance economic 
returns needed to support ecosystem management. These values include reducing fuel 
for fire, decreasing pests and disease outbreaks, and increasing biodiversity (Croan, 
2000).  
  
 
 
 
 2.6.1 Medicinal values of Pleurotus pulmonarius 
Pleurotus pulmonarius is one of the commonly recognized and therapeutically valuable 
Basidiomycetes mushrooms. Generally, it contains low fat but abundance of 
carbohydrates, thus making it an ideal food source for weight conscious people and 
patients suffering from cardiovascular diseases. It also contains high level of mineral 
elements (such as calcium, copper, iron, cuprum, magnesium, phosphorus, potassium 
and sodium) and vitamins (B1, B2, B12 and C). Apart from having a very high amount of 
fibre, it also has high content of proteins and peptides. The amount of crude proteins 
found in this species is among the highest in the group of cultivated edible mushrooms. 
Like other Pleurotus species, this mushroom generally contains crude protein that ranks 
below most animal meats, eggs and cheese, but is proved to be similar to, or even higher 
than in vegetables (Bonatti et al., 2004). 
 
A study made by Chahal et al., (1989) over 20 years ago discovered that the mycelia 
biomass of P. sajor-caju consists of essential amino acids that meet the Food and 
Agricultural Organization (FAO) requirements. A preliminary feeding trial experiment 
on rats showed that about 50% of protein in the diet can be replaced by the mycelial 
biomass of P. sajor-caju without any deleterious effects. To date, much recent research 
has been carried out on P. pulmonarius crude extract and the isolated compounds such 
as polysaccharides, protein, peptide and other substances, focusing on various medicinal 
properties.   
 
The crude extract of this species produced low cytotoxicity effects, which may be 
suitable for food and oral therapeutic substances. Also, it has shown efficacy in 
combating aging problems due to the high antioxidant activity. For instance, a study by 
Kanagasabapathy et al., (2011) showed that the crude extract from the fresh fruiting 
 body of P. sajor-caju exhibits good antioxidant activity in vitro, albeit no 
genoprotective effects was detected since it does not prevent hydrogen peroxide-
induced oxidative damage to cellular DNA (Shi et al., 2002). Numerous research has 
been done on the antiviral properties which this species has indicated low antiviral 
activity in vivo when tested against pox virus and infectious bursa disease virus 
(Kidukuli et al., 2010), but good activity against Human Immunodeficiency virus 
(HIV)-1 reverse transcriptase (Gregori et al., 2007) and potent antiviral activity against 
Tobacco Mosaic Virus (Verma et al., 2001). 
 
Research has proven that the translation-inhibiting and ribonuclease activities of P. 
sajor-caju peptides are considerably higher than that of Pleurotus ostreatus and 
Calvatia caelata (Ng et al., 2002). Also, an ubiquitin-like peptide has been isolated 
from this mushroom and the result demonstrated positive N-glycosidase activity and 
good inhibition of cell-free translation. The ribonuclease from this species has been 
reported to have antibacterial and antifungal activities, and exerts antiproliferative 
activity on hepatoma and leukemia cells, as well as anti-mitogenic effect on mouse 
spleen cells (Ng et al., 2004). 
 
2.7 Bioactive peptides 
Components of proteins in food are known to have nutritional, functional and biological 
properties, and contain sequences of bioactive peptides encrypted within their primary 
structures, which could exert a physiological effect in the body. These active peptides 
are also known to contribute to the physicochemical and sensory properties of various 
protein-rich foods, which make these components potential ingredients for health 
enhancement purposes (Korhonen et al., 2003). 
 
 In the past few decades, scientists have intensified their research on medicinal 
properties extracted from crude natural products. Currently, in-depth studies of 
medicinal properties have been developed, focusing more on bioactive proteins and 
peptides derived from both natural products and food bases. Due to the increasing 
commercial interest in the production of bioactive peptides from various sources, 
industrial-scale technologies suitable for their commercial production have also been 
developed and are upgrading concurrently to the development of bioactive peptide 
research and findings (Korhonen et al., 2006).  
 
According to Hartmann et al., (2007), proteins and peptides could be physiologically 
active or bioactive through its natural form or via hydrolysis in vivo or in vitro for their 
release from the host protein, particularly by the three methods: (a) in vivo hydrolysis by 
digestive enzyme like trypsin, (b) in vivo hydrolysis by proteolytic microbial enzymes, 
and (c) in vitro hydrolysis via food ripening and processing such as fermentation by 
isolated or microbial enzymes (Möller et al., 2008). The term food-derived bioactive 
peptide refers to plant or animal-derived peptides that conduct a regulatory function in 
the human body system and may ultimately influence health (Hartmann et al, 2007). 
The naturally occurring food-derived bioactive peptides in traditional foods were 
consumed years ago. Some of them were used as traditional medicines for treating 
various diseases. 
 
Research in the field of bioactive peptides has discovered many food-derived bioactive 
peptides with potent biological activities that are potential to be the active ingredients 
for pharmaceuticals and may contribute to enhancing healthier nutrition for the public. 
A wide range of bioactivities have been identified, including those that have effect on 
the major body systems such as the cardiovascular system (antioxidative, 
 antihypertensive, hypocholesterolemic and antithrombotic), nervous system (opioid 
agonist and antagonist activities), gastrointestinal system (anti-appetizing, mineral-
binding and antimicrobial), and immune system (antimicrobial, immunomodulatory and 
cytomodulatory). Some peptides are multifunctional and can exert various effects and 
properties on different regulatory mechanisms (Meisel, 2004). 
 
2.7.1 Bioactive peptides from mushrooms 
Over the centuries, the medicinal values of mushrooms have been studied and they have 
been found to possess abundant proteins and peptides. Most of the proteins and peptides 
have potentially applicable activities, regardless of whether they are intra-cellular or 
extra-cellular. Thus, whole mushroom extracts (from fruit bodies or mycelium) or 
isolated compounds like peptides may be used as sources of medically valuable 
compound (Ng, 2004). 
 
Numerous researches worldwide have demonstrated that mushroom-derived peptides 
play an important role in the prevention and treatment of perturbing diseases such as 
cancer and hypertension. In depth in vivo studies demonstrating the anti-cancer activity 
in animal models have been done on the extracted, purified glucan polysaccharides and 
polysaccharide-peptides derived from mushrooms. These studies strongly suggest an 
immunomodulating mode of action (Smith et al., 2002). The fruiting body of 
Tricholoma giganteum has shown potent antihypertensive activity in spontaneously 
hypertensive rats (SHR), at a dosage of 1 mg/kg. The peptide was sequenced as Gly-
Glu-Pro (GPP), a novel tripeptide with very low similarity to other ACE inhibitory 
peptide sequences (Lee et al., 2004). Likewise, other medicinal mushrooms such as 
Ganoderma lucidum, Flammulina veluptipes and Grifola frondosa have been reported 
to demonstrate potent antihypertensive activity (Barbosa-Filho et al., 2006).  
  
Mushroom-derived bioactive peptides exhibit antioxidant activity in many species. For 
instance, novel antioxidant peptides from fermented mushroom Ganoderma lucidum 
have been discovered and research has shown that the G. lucidum peptide (GLP) 
inhibits lipid peroxidation in biological systems through its antioxidant, metal chelating 
and free radical scavenging activities (Sun et al., 2004). A polysaccharide-peptide 
complex from Pleurotus abalonus fruiting body has been shown to increase the 
antioxidant enzymes activities including glutathione peroxidase (GPx), catalase (CAT) 
and superoxide dismutase (SOD), thus reduces lipid peroxidation activity when tested 
on senescence-accelerated mice (Li et al., 2007). 
 
Various antifungal peptides that act against different microorganisms have been 
exploited from mushrooms. Agrocybin, Eryngin, Ganodermin and Pleurostin were 
isolated from Agrocybe cylindracea, Pleurotus eryngii, Ganoderma lucidum and 
Pleurotus ostreatus respectively. These peptides have shown inhibitory activities on 
mycelia growth of fungal plant pathogens such as Fusarium oxysporum and 
Mycosphaerella arachidicola (Wang et al., 2004; Ngai et al., 2005) 
  
Mushrooms also contain bioactive peptides that demonstrate antiproliferative activity. 
Agrocybe cylindracea and Hypsizigus marmoreus are among the mushrooms that have 
shown positive antiproliferative activity, together with other different medicinal 
activities discovered from the same peptides (Ngai et al., 2003; Wong et al., 2008). 
Overall, there are abundant research on other bioactive peptides from mushrooms that 
contribute to improve health problems and its recuperation.    
 
 
 CHAPTER 3: MATERIALS AND METHODS 
 
In this study, P. pulmonarius mycelium was investigated for its antihypertensive 
activity. Preliminary assay was performed on the mycelial aqueous extract and broth 
extract and the most active sample was chosen for further analyses. Different steps of 
protein purifications were done in this study. Each purification step was re-assayed to 
determine the most active ACE inhibitors, and finally protein identification was done to 
discover the proteins responsible for the antihypertensive activity. Figure 3.1 shows a 
schematic diagram of the overall process in this study.  
 
Figure 3.1: Schematic diagram of overall process took part in this study. The 
experiment incorporated cultivation process, bioassay activity and superficial protein 
study. 
Protein purification and fractionation by 
ammonium sulfate precipitation 
Protein identification using MALDI-TOF/TOF MS and LC-
MS/MS 
Further protein purification using RP-HPLC 
Antihypertensive assay on the RP-HPLC fractions 
SDS page analysis on the most active RP-HPLC fraction 
Antihypertensive assay on the protein fractions 
Preliminary antihypertensive assay on the mycelial 
water extract and broth extract 
(extract that showed the most active ACE inhibitory 
activity was chosen) 
Cultivation of P. pulmonarius mycelium 
 3.1 Cultivation of Pleurotus pulmonarius mycelium  
3.1.1 Fungal strain 
Pleurotus pulmonarius mycelium stock culture (KUM 61119) was obtained and 
authenticated by Mushroom Research Centre, University of Malaya. Mycelium stock 
cultures were maintained on Malt Extract agar (MEA) plate (Appendix A (1), Table 1, 
page 94) at 25 ± 2°C and sub-cultured routinely.   
 
3.1.2 Preparation of P. pulmonarius inoculum 
Pleurotus pulmonarius mycelium was cultured on the MEA plates under sterile 
condition to avoid contamination. Mycelial plugs (5 mm diameter) were punctured from 
the periphery of the mycelium stock/previous culture by using a sterile cork borer. A 
mycelial plug was placed onto the centre of a MEA plate and incubated for 7 days at 25 
± 2°C.  
 
3.1.3 Growth of P. pulmonarius mycelium by submerged fermentation 
 Following plate culture, P. pulmonarius mycelium was then cultivated by fermentation 
using liquid medium consisting of brown sugar and spent yeast at the percentage ratio 
of 1:2 (Appendix A (2), Table 2, page 94). Each 100 ml of the sterile medium was 
inoculated in 500 ml Erlenmeyer flask with 10 mycelial plugs (diameter size of 5 mm) 
cut from the periphery of 7-day old mycelia cultures. The inoculated flasks were 
incubated at 25 ± 2°C for 7 days on rotary shaker with constant shaking at 150 rpm. At 
harvest, mycelium was separated from the broth medium by filtration. Mycelium was 
washed gently with running tap water and both mycelium and broth medium were then 
freeze dried separately. The freeze dried products were ground and stored at 4 ± 2°C 
prior to use.  
 
 Freeze dried crude mycelium was immersed in distilled water for an hour with constant 
stirring and centrifuged briefly to remove the mycelium and any debris. The 
supernatant, i.e. mycelial aqueous extract was analysed for protein estimation (as shown 
in section 3.4). Freeze dried broth was dissolved in distilled water as stock 
concentration for broth extract and protein estimation was also determined. The 
mycelial aqueous extract and broth extract were used in the preliminary 
antihypertensive assay. Sample that showed better antihypertensive activity was also 
used for further protein extraction by ammonium sulphate precipitation. 
 
3.2 Antihypertensive assay by inhibition of ACE 
Antihypertensive assay was performed by using ACE Kit WST (Dojindo Laboratories, 
Japan). The kit assay was designated based on the amount of 3-hydroxybutyric acid 
(3HB) generated from 3-hydroxylbutylyl-Gly-Gly-Gly by the action of ACE inhibitory 
activity detected in the samples. The activity was evaluated in percentage of inhibition 
(Lam et al., 2007 & 2008).  
 
The ACE Kit WST consists of working solutions (indicator working solution and 
enzyme working solution) and substrate buffer (Appendix A (3), page 95). For the ACE 
inhibitory assay, blank 1, blank 2 and 20 µl of samples were prepared. Then, 20 µl of 
substrate buffer was added to each sample and blanks, followed by 20 µl of deionized 
water to blank 2 only. Next, 20 µl of enzyme working solution was added to each 
sample and blank 1. The microplate was incubated at 37°C for one hour. Following the 
incubation, 200 µl of Indicator working solution was added to each sample and blanks. 
The microplate was incubated at room temperature for 10 minutes, allowing variance 
intensity of yellow colour to develop. The absorbance value was read at 450 nm with 
 ELISA microplate reader. The ACE inhibitory activity was calculated by the following 
equation: 
 
 
 
For the preliminary assay, mycelial aqueous extract and broth extract at the 
concentration of 0.2 mg/ml, 0.5 mg/ml, 1.0 mg/ml, 2.0 mg/ml and 3.0 mg/ml were 
tested for the assay. The IC50 value was evaluated and compared. The most active 
extract was selected and subjected to protein extraction and purification. Captopril was 
used as a positive control using five different concentrations ranging from 1.0×10
-10 
mg/ml to 1.0×10
-6
 mg/ml. All samples were tested in triplicate values. 
 
3.3 Preparation of crude protein extract and protein fractions obtained by 
ammonium sulphate precipitation 
3.3.1 Extraction of P. pulmonarius mycelial proteins  
The crude extract of P. pulmonarius mycelium was dissolved in distilled water in the 
ratio of 1:10. The extract was blended and then stirred vigorously for one hour on ice to 
achieve homogeneity. The supernatant was collected by centrifugation at 5,000 rpm for 
10 minutes at 4 ± 2°C. The supernatant was designated as the source for mycelial 
protein extract.  
 
3.3.2  Protein fractionation by salting out method 
The protein extract of P. pulmonarius mycelium was subjected to salting out process by 
using ammonium sulphate. The process was carried out by fractioning the mycelial 
proteins using 10 to 100% ammonium sulphate saturation (Apendix A (4), Table 3, page 
96). Each of the ammonium sulphate saturation was poured gradually into the protein 
ACE inhibitory activity (inhibition rate %) = (Blank 1 – Sample) × 100 
             (Blank 1 – Blank 2) 
 extract solutions and was constantly stirred for 30 minutes on ice bath before underwent 
centrifugation at 10,000 rpm for 15 minutes at 4 ± 2°C. At each stage of saturation, the 
precipitated protein yield was collected and dissolved in 4 ml distilled water. The 
supernatant was then used for the subsequent increasing salt saturations, until the 100% 
of salt saturation was achieved. The precipitated proteins were categorized according to 
the concentration of the salt saturations at which they were formed, and these protein 
fractions were labelled as F10 to F100.  
 
The protein fractions were then dialyzed four times against distilled water for 48 hours 
by using Snakeskin Dialysis Tubing™ (Thermo Fisher Scientific, Rockford, IL, USA), 
with 3,500 molecular weight cut off (MWCO). The experiment was done at 4 ± 2°C. 
The dialyzed protein fractions were aliquot into 1.5 ml Eppendorf tubes, freeze-dried 
and stored at -20 ± 2°C prior to use.  
 
3.4 Protein estimation  
Concentration of proteins in each fraction was estimated using bicinchoninic acid 
(BCA) method, a detergent-compatible formulation based on bicinchoninic acid for the 
colorimetric detection and quantification of total protein. The assay was carried out 
using BCA™ Protein Assay Kit (PIERCE, Thermo Fisher Scientific, Rockford, IL, 
USA). Bovine serum albumin (BSA) at 2.0 mg/ml in 0.9% saline and 0.05% sodium 
azide was used as standard. Protein concentrations for each protein fraction were 
determined with reference to the BSA standard curve graph (Apendix A (5), Table 4, 
page 97). 
 
 
 
 3.5 Antihypertensive assay of the fractionated mycelial proteins (F10 to F100)  
Mycelial protein fractions were tested for their ACE inhibitory activity at the 
concentration of 50 µg/ml, with the same procedure stated in section 3.2. Protein 
fraction that demonstrated the highest percentage of ACE inhibition was evaluated for 
its IC50 value and selected for further purification by RP-HPLC analysis.  
 
3.6 Purification of the active protein fraction via reverse phase high 
performance liquid chromatography (RP-HPLC)  
3.6.1  Preparation of protein fraction sample for RP-HPLC analysis 
Protein fraction that gave the highest ACE inhibitory activity was subjected to RP-
HPLC for further purification. Five tubes of the freeze dried protein fraction was 
dissolved with 200 µl distilled water respectively and pooled into an Eppendorf tube to 
make a total of 1 ml protein solution. The protein was spun briefly and the supernatant 
was collected for further analyses. The protein was subjected to protein estimation 
(Section 3.4). Protein fraction at the concentration of 2 mg/ml was then filtered with 
0.45 µm, 4 mm disposable syringe filter.  
 
3.6.2 RP-HPLC analysis of F40 protein fraction 
F40 protein fraction was analyzed using a Shimadzu HPLC system equipped with 
System Controller SCL-10Avp, Array detector SPD-10Avp, Liquid Chromatograph 
LC-10AT and degasser DGU-12A. The HPLC protocol was optimized several times 
before the final protocol was achieved. HPLC grade acetonitrile and 0.1% TFA in 
distilled water were used as the mobile phase (Appendix A (6), page 98). The C18 
Chromolith® SemiPrep column (C18, 100 × 10 mm, 2 µm, 130 Å) coupled with guard 
column was used for the fractions separation.  
 Two hundred microlitre of 2 mg/ml F40 protein sample was injected into the injector 
and allowed to run for 30 minutes. Elution of fractions was achieved by the use of 
binary gradient from 0% to 40% acetonitrile at the constant flow rate of 3.9 ml/min. 
Fraction peaks were detected at 220 nm and 254 nm wavelengths. The baseline for each 
wavelength was obtained using the same protocol. Every single symmetrical peak 
shown by the chromatogram was collected and labelled as P1 to P8 for the apparent 
peaks and L1 to L3 for the ambiguous peaks. The collected fractions were then freeze 
dried and stored at -20°C. During series of run extending over several days, column 
precision was maintained by flushing the column with 100% acetonitrile at isocratic 
flow rate of 3.9 ml/min for 40 minutes each time before running the sample. Upon 
completion, the column was also flushed with the aqueous solvent for 10 minutes, 
followed by flushing with acetonitrile for 40 minutes using the same flow rate.  
 
3.7 Re-evaluation of antihypertensive assay on RP-HPLC peaks (P1 to P8) 
The collected RP-HPLC peaks labelled as P1 to P8 were re-evaluated for their ACE 
inhibitory activity at the concentration of 15 µg/ml, using the same protocol as stated in 
Section 3.3. The peak that showed the most active anti ACE activity was evaluated for 
its IC50 value and selected for protein identification assays consisting SDS PAGE 
analysis, MALDI-TOF/TOF MS and LC-MS/MS.  
 
3.8 SDS-PAGE analysis of the most active protein fractions 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) was 
performed on the fractions that demonstrated the highest ACE inhibitory activity in 
each protein fractionation stage. Preparation of stock solutions and buffers is explained 
in Appendix A (7), page 99. 
 
 3.8.1 Preparation of SDS-PAGE gels 
Recipes for the preparation of SDS-PAGE gel solutions are presented in Appendix A 
(7c), Table 4 & 5, page 101. A set of vertical glass plates gel unit was assembled 
vertically, with 0.75 mm spacer strips were placed at both edges in between the glass 
plates. The glass plates were clamped correctly to avoid leaking. The separating gel 
solution was poured carefully into the space by using a micropipette. The top of the gel 
was then overlaid with distilled water. The gel was allowed to polymerize for a 
minimum of one hour. The overlying distilled water was discarded before the stacking 
gel was casted. The separating gel surface was rinsed briefly with sufficient volume of 
stacking gel solution to remove any unpolymerized gel residue. The stacking gel 
solution was poured carefully and a desired size of comb was then inserted into the gel 
formation with concern not to trap any bubble below the teeth of the comb. The gel was 
allowed to polymerize for a minimum of one hour. The polymerized gel with the comb 
in place could be stored overnight at 4 ± 2°C. 
 
3.8.2 Preparation of loading sample   
The 4× sample buffer was first allowed to equilibrate to room temperature before it was 
then mixed with the protein fraction samples in the ratio of 1:3. The samples mixtures 
were heated for three minutes at 100°C before it was loaded into the wells of SDS-
PAGE gel. The samples mixtures were run within two hours to prevent re-oxidation.  
 
3.8.3 SDS-PAGE electrophoresis 
The glass plates unit was placed and clamped into a vertical electrophoresis apparatus 
with the shorter glass plate facing inward of the chamber. The comb was removed 
earlier and rinsed with a little amount of running buffer once or twice. The running 
buffer was then added to the upper and lower buffer chambers. Then, 7 µg in 12 µl of 
 protein samples were loaded into the wells, followed by 4 µl of protein marker to 
another well. The apparatus lid was placed on the apparatus, and the leads were plugged 
into the power supply. Electrophoresis was performed using Bio-Rad Pac 300 at a 
constant voltage of 60 V for the first 15 minutes and followed by a gradual increase of 
voltage from 80 to 100V, to avoid excess heat. When the blue dye of each sample and 
protein marker reached approximately 1 cm from the bottom of the gel, the power 
supply was turned off and the apparatus was dissembled. The gel was then silver stained 
to visualize the proteins. 
 
3.8.4 Silver staining procedure 
The preparation of silver staining solutions is explained in Appendix A (8), page 102. 
The SDS gel was soaked in fixation solution for 30 minutes or overnight. It was then 
replaced by incubation solution for another 30 minutes. The gel was washed three times 
with distilled water for 5 minutes respectively. The gel was then soaked in silver 
solution for 20 minutes, and rinsed with distilled water two times for 2 minutes. 
Developing solution was then poured into the container and the gel was incubated for 4 
minutes, or until the bands appeared. Developing solution was replaced by stopping 
solution for 10 minutes before the gel was washed with distilled water three times for 10 
minutes respectively. The gel was stored in preserving solution. 
 
3.9 Identification of ACE inhibitor proteins from the most active RP-HPLC 
fraction (P6) by MALDI-TOF/TOF MS analysis 
The P6 RP-HPLC fraction was subjected to MALDI-TOF/TOF analysis. Previously, the 
fraction was analyzed with SDS-PAGE analysis and visualized with silver staining. The 
emerging bands were cut and placed into 200 µl Eppendorf tubes individually. Each 
band was subjected to trypsin in-gel digestion at 37°C overnight, followed by desalting 
 using Zip Tip (C18) (EMD Milipore Co., MA, USA). The samples were analyzed using 
4800 Plus MALDI-TOF/TOF MS Proteomics Analyser (Applied Biosystems, CA, 
USA) combined with Mascot database software (Matrix Science Ltd., London, UK). 
Protein identification was carried out using the following acquisition settings: 
Databases- Fungi (SwissProt), Fungi (NCBI), and P. ostreatus (NCBI); protein mass 
range- 0kDa to 100kDa; mass tolerance between 0.5 Da to 1.15 Da- one missed 
cleavage.  
 
3.10 Identification and re-confirmation of ACE inhibitor proteins by LC-
MS/MS analysis 
The P6 RP-HPLC fraction was diluted at 3 µg/ml and sent to ITSIBiosciences USA, for 
LC-MS/MS analysis. Sample was subjected to in-solution tryptic digestion. The raw 
data files were searched using Proteome Discoverer 1.3 (Thermo Scientific) and the 
SEQUEST algorithm. Protein identification was performed using the following 
parameter: Databases- Fungi (SwissProt), Fungi (NCBI), and P. ostreatus (NCBI); 
Modification; Carbamidomethyl Cysteine (static), Oxidation of Methionine (variable), 
three missed cleavage per peptide.  
 
3.11 Statistical analysis 
Mean values for all the parameters tested were obtained and subjected to one-way 
analysis of variance (ANOVA). The mean values were tested for significance using the 
multiple range tests at 95% at least significant difference (LSD). The least significant 
difference was conducted to detect any significant difference in the antihypertensive 
assays of P. pulmonarius mycelial protein fractions and P. pulmonarius mycelial RP-
HPLC fractions. 
 
 
 CHAPTER 4: RESULTS 
 
4.1 Yields of P. pulmonarius mycelium grown in submerged fermentation 
Cultivation of P. pulmonarius mycelium was successfully performed for at least thirty 
batches of sub-cultivation on the MEA plate at 25°C. The mycelium used as inoculums 
showed steady growth on the MEA plate. White-velvety form of mycelium was 
observed to completely colonize the MEA agar surface on day-7 (Figure 4.1 (a)). 
 
Following the plate cultivations, small scale submerged fermentations of P. 
pulmonarius mycelium was then carried out in Brown sugar-spent yeast medium. Ten 
mycelial plugs (5 mm diameter) were pierced from the periphery of the culture using a 
sterile cork borer and inoculated into sterilized 500 ml Erlenmeyer flasks, each 
containing 100 ml of brown sugar-spent yeast liquid media in the percentage ratio of 2:1 
(w/v). Incubation period was 7 days with constant agitation at 150 rpm. From the 
observation, the mycelium grew either in pellet forms or a clump depending on the 
dispersion of the mycelial plugs during shake incubation (Figure 4.1 (b)).  The mycelial 
yield was separated from the whole broth. Both the mycelial biomass and the whole 
broth were freeze dried and ground, then stored at 4°C for subsequent analyses. The 
yield of crude mycelial extract was 4 ± 0.3 g/L per batch. 
 
4.2 Preliminary antihypertensive assay of P. pulmonarius mycelial aqueous 
extract and broth extract 
Antihypertensive assay was performed on P. pulmonarius mycelial aqueous extract and 
broth extract at five different concentrations, i.e. 0.2 mg/ml, 0.5 mg/ml, 1.0 mg/ml, 2.0 
mg/ml and 3.0 mg/ml (Appendix B, Table 1 & 2, page 104). Captopril was used as 
positive control at the concentration from 1.0 × 10
-10
 mg/ml to 1 × 10
-6
 mg/ml.  
             
(a)                                                                  (b) 
Figure 4.1: Fungal cultures of P. pulmonarius mycelium used as inoculums (a) P. 
pulmonarius mycelium grown on MEA plate at day-7, (b) submerged fermentation of P. 
pulmonarius mycelium in brown sugar-spent yeast media at day-7. The mycelium grew 
in pellet form. 
 
The result indicated different outcome of antihypertensive assay between P. 
pulmonarius mycelial aqueous extract and broth extract, but with compatible pattern of 
ACE inhibitory percentage via graph analysis (Figure 4.2). The IC50 values were 
obtained by extrapolation of graph at the 50% ACE inhibitory activity. P. pulmonarius 
mycelial aqueous extract exhibited its IC50 value at 0.72 mg/ml whereas the IC50 value 
for broth extract was at 1.32 mg/ml. The ACE inhibitory activity of P. pulmonarius 
mycelial aqueous extract was almost two times higher than that of the broth extract, by 
means of the IC50 values. However, the IC50 value of captopril was 1 × 10
-8
 mg/ml, 
which was much lower than that of the mycelial aqueous extract. Pleurotus pulmonarius 
mycelial aqueous extract showed better activity than the broth extract, thus was 
subjected to ammonium sulphate precipitation for protein extraction and fractionation. 
 
  
Figure 4.2: Antihypertensive assay of P. pulmonarius mycelial aqueous extract and 
broth extract. Results are expressed as the mean of triplicates values (n=3). The IC50 
values measured were 0.72 mg/ml for mycelia aqueous extract and 1.32 mg/ml for broth 
extract.   
 
4.3 Antihypertensive assay of P. pulmonarius mycelial protein fractions  
Mycelial aqueous extract was fractionated by ammonium sulphate precipitation and 
later was tested for antihypertensive activity at 50 µg/ml. As shown in Figure 4.3, F40 
demonstrated the highest ACE inhibitory activity at 61.2%. In contrast, F30, F80, F90 
and F100 indicated comparably low ACE inhibitory activity. Fraction F40 was chosen 
for further purification by RP-HPLC as the ACE inhibitory result was significantly 
different (p<0.05) from the other protein fractions. The raw data of the experiment is 
presented at Appendix B, Table 3 & Figure 1, page 106. 
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Figure 4.3: ACE inhibition by P. pulmonarius mycelial protein fractions (F10 to F100) 
at the concentration of 50 µg/ml. Results are expressed as the mean of triplicates values 
(n=3). Means with different alphabetical letters denotes the ACE inhibitory activity of 
the samples are significantly different (p<0.05). 
 
The IC50 value of F40 was determined at the concentration of 5 µg/ml, 20 µg/ml, 40 
µg/ml, 80 µg/ml and 150 µg/ml (Appendix B, Table 4, page 107). The result showed an 
IC50 value at 22 µg/ml as shown in Figure 4.4. Fraction F40 was proven to demonstrate 
greater ACE inhibitory activity with an approximately thirty two times higher activity 
than that of P. pulmonarius mycelial aqueous extract by means of the IC50 value.  
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Figure 4.4: Evaluation of IC50 value for fraction F40. Results are expressed as the mean 
of triplicates values (n=3). The IC50 value determined was 22 µg/ml. 
 
4.4 Further purification of fraction F40 via RP-HPLC  
Fraction F40 of P. pulmonarius mycelium was subjected to RP-HPLC analysis for 
further protein purification. In order to ensure no false or contaminant peaks, good 
baselines with no significant peak detected by the same method used for sample running 
must be achieved before every sample collection session. After several optimizations 
involving different flow rates and percentages of mobile phases, an optimum 
chromatogram of eight apparent peaks was detected at the wavelength of 220 nm at the 
constant flow rate of 3.9 ml/min with binary gradient of 0% to 40% acetonitrile in 30 
minutes (Figure 4.5). Preliminary runs during optimization established that there was no 
fraction eluted above 40% acetonitrile for the chosen wavelength. Only 200 µl of 
fraction F40 was loaded for every cycle due to the size of sample loop used in the 
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 HPLC analysis, which resulted in only about 5 µl of 40 to 70 µg of HPLC fractions 
yield for every 2 mg/ml sample run. 
 
The first peak of the RP-HPLC profile showed a high intensity peak at 340 mAU 
merging with a low peak. The two peaks were then pooled and labelled as P1, whereas 
the other peaks were collected individually and labelled as P2, P3, P4, P5, P6, P7 and 
P8. All peaks were eluted within 2 to 11 minutes of the retention time. Apart from the 
mentioned peaks, three ambiguous peaks with low intensity were detected within the 
timeline. The peaks showed inconsistency in every running cycle, hence were pooled 
accordingly and labelled as L1, L2 and L3. The sample was also analysed using the 
wavelength of 254 nm, with the same flow rate, percentage of mobile phases and 
retention time. The result indicated three apparent peaks concurrent to the peaks 
detected by 220 nm wavelength but with different intensity, thus were labelled 
according to the matched peaks from the 220 nm RP-HPLC profile (Figure 4.6).  
 
Antihypertensive assay was performed on peaks P1 to P8. To avoid any predicament of 
results, peaks L1, L2 and L3 were ruled out from the assay due to the inconsistency and 
consistently low intensity of the peaks detected in every running cycle. The most active 
ACE inhibitory bioassay guided RP-HPLC peak was then subjected to subsequent 
procedures intended for protein identification and profiling. 
 
 
 
 
  
Figure 4.5: HPLC analysis of fraction F40 performed in 30 minutes at constant flow rate of 3.9 ml/min at 220 nm (a) Baseline with no significant peak 
detected (b) Elution of sample peaks. For each run, 200 µl of 2 mg/ml sample was injected at a binary gradient of 0% to 40% acetonitrile. Eluents were 
labelled as P1, P2, P3, P4, P5, P6, P7 and P8 for the apparent peaks. On the other hand, the ambiguous peaks which show no consistent in emergence 
were labelled as L1, L2 and L3. 
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Figure 4.6: HPLC analysis of fraction F40 performed in 30 minutes at constant flow rate of 3.9 ml/min at 254 nm (a) Baseline with no significant peak 
detected (b) Elution of sample peaks. For each run, 200 µl of 2 mg/ml sample was injected at a binary gradient of 0% to 40% acetonitrile. Three 
highest peaks were detected and labelled as P3, P4 and P5 according to their resemblance with the peaks detected at 220 nm. 
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 4.5 Antihypertensive assay of the RP-HPLC fractions  
Fraction F40 of P. pulmonarius mycelium was further resolved by RP-HPLC. As a 
result, eight peaks were observed and labelled as P1 to P8. Antihypertensive assay was 
then carried out on all of the RP-HPLC fractions. For these fractions, 15 µg/ml samples 
were used for the assay as the percentage of ACE inhibition was postulated to increase 
with the increase of protein purity. As shown in Figure 4.7, P6 showed the highest ACE 
inhibitory activity at 57.7%, which the result was significantly different from the other 
fractions (p<0.05). In contrast, all other fractions exhibited comparable activity of ACE 
inhibition. The lowest ACE inhibitory activity for the RP-HPLC fraction was shown by 
fraction P1 at 19.6%. The raw data of the experiment is presented in Appendix B, Table 
5 & Figure 2, page 108. 
 
 
Figure 4.7: ACE inhibition by RP-HPLC fractions, P1 to P8. Results are expressed as 
the mean of duplicates values (n=2). Means with different alphabetical letters denotes 
the ACE inhibitory activity of the samples are significantly different (p<0.05). 
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 The IC50 value of P6 was evaluated at the concentration of 5 µg/ml, 20 µg/ml, 40 µg/ml, 
60 µg/ml, 80 µg/ml and 150 µg/ml. The lowest ACE inhibitory activity was detected at 
30.1% while the highest activity was at 96.8% (Appendix B, Table 6, page 109).  As 
shown in Figure 4.8, the IC50 value was obtained by extrapolation of graph and the 
value was depicted at 12 µg/ml.  
 
 
Figure 4.8: Evaluation of IC50 value for RP-HPLC fraction P6. Results are expressed as 
the triplicates of mean values (n=3). The IC50 value determined was 12 µg/ml.  
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 The IC50 values of P. pulmonarius mycelial aqueous extract, F40 and P6 were 
compared. There was an increase of ACE inhibitory activity following every 
purification step. In detail, P6 showed almost two times higher inhibitory activity than 
that of the F40, and sixty times greater ACE inhibitory activity when compared to the 
mycelial aqueous extract. Thus, it was confirmed that further protein purifications show 
greater efficacy of the ACE inhibitory activity. Table 4.1 shows the comparison of IC50 
values of ACE inhibitory activity in every purification step. 
 
Table 4.1 Comparison of IC50 values in different stages of ACE inhibitory assay 
Protein source IC50 value (µg/ml) 
Mycelial aqueous extract 720 
Fraction F40 
(Ammonium sulphate) 
22 
Fraction P6 
(RP-HPLC) 
12 
The IC50 values were determined within tested concentration of 0 to 3 mg/ml (n=3) for 
mycelia aqueous extract and 0 to 150 µg/ml for F40 and P6 (n=3).  
 
4.6 SDS-PAGE analysis of the bioactive RP-HPLC fraction P6 
Fractions F40 and P6 were screened by SDS-PAGE for three reasons (a) to observe any 
analogous band between the two fractions, (b) to determine sample purity, and (c) to 
separate proteins based on their molecular mass prior to MALDI-TOF/TOF MS. 
Because P6 was a further purified product from F40, it was postulated that P6 should 
demonstrate if not single, several bands similar to F40.  
 
 From the SDS-PAGE result, F40 sample was resolved into several protein bands by the 
18% polyacrylamide gel. There were four bands with the estimated molecular mass of 
62 kDa, 57 kDa, 36 kDa and <7000Da, appeared in both samples. The bands were 
labelled as H1, H2, H3 and H4 respectively. Silver-stained SDS-PAGE gel is shown in 
Figure 4.9. The bands were cut and saturated in distilled water for protein identification 
by MALDI-TOF/TOF MS. 
 
 
Figure 4.9: SDS-PAGE of F40 and P6. PM; Prestained broad range protein marker, 
F40; fraction F40 of P. pulmonarius mycelium, P6; bioassay guided RP-HPLC fraction. 
Protein bands of interest are labelled as H1, H2, H3 and H4, respectively. 
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 4.7  Identification of proteins obtained from P6 by MALDI-TOF/TOF MS 
The H1, H2, H3 and H4 bands from the polyacrylamide gel were cut out and sent for 
MALDI-TOF/TOF MS for identification of proteins responsible for the 
antihypertensive effect in the sample. Mascot search engine was used to identify the 
protein. Three databases used in the protein search were Fungi (NCBI), Fungi 
(SwissProt) and Pleurotus ostreotus (SwissProt). The protein profile for each protein 
band is presented in Table 4.2. Each protein identified by the databases was investigated 
for their correlation with antihypertensive mechanism based on the earlier reported 
studies. As a result, three proteins related to antihypertensive mechanisms were 
identified. As shown in Table 4.3, the proteins were serine proteinase inhibitor-like 
protein from H4 (P. ostreatus; SwissProt), DEAD/DEAH box RNA helicase-like 
protein from H4 (Fungus; NCBI), and nitrite reductase-like protein from H3 (Fungus; 
SwissProt). 
 
4.8 Protein validation by LC-MS/MS 
Fraction P6 was sent for LC-MS/MS analysis to validate proteins identified by MALDI-
TOF/TOF MS. The databases used for protein profiling by LC-MS/MS were Fungus 
(NCBI) and P. ostreatus (SwissProt). As a result, five proteins were identified by P. 
ostreatus (SwissProt) database, i.e. manganese peroxidase, DNA polymerase, DNA-
directed RNA polymerase, RNA polymerase II second largest subunit and putative 
ribosomal protein (Appendix B, Table 7.1, page 110). In addition, there were 865 
proteins identified from Fungi databases, nine of which demonstrated two uni que 
peptides (Appendix B, Table 7.2, page 110). Out of the total number, only five proteins 
were similar to the proteins identified by MALDI-TOF/TOF MS. However, only one 
antihypertensive protein presented in both mass spectrometry analyses, which was 
DEAD/DEAH box RNA helicase. A detail of the proteins is presented in Table 4.4. 
 Table 4.2 Protein profiles from MALDI-TOF/TOF MS 
DATABASE: NCBI (fungus) 
Protein band  Description  Accession  Protein score MW (kDa) Peptide matched 
H1 
predicted protein  gi|154319345 54 8579.4 6 
hypothetical protein SNOG_14294 gi|169622156 52 8668.6 5 
PHD transcription factor gi|327354476 48 106605 14 
lea domain containing protein gi|320588713 48 15309.9 7 
hypothetical protein Kpol_526p14 gi|156843100 48 36116.4 8 
hypothetical protein UM00912.1 gi|71004786 48 46294.6 9 
Pc20g03180 gi|255944205 47 61667.3 10 
dynamin GTPase gi|70992441 46 91991.2 12 
predicted protein gi|170111974 46 39129.7 8 
interferon-induced GTP-binding 
protein Mx 
gi|331243271 46 77328.5 11 
  
DATABASE: NCBI (fungus) 
Protein band  Description  Accession  Protein score MW (kDa) Peptide matched 
H2 
predicted protein gi|154276998 56 46321.8 9 
translation elongation factor 2 gi|169806469 51 97744.2 12 
nucleolar complex protein 2 gi|331225687 51 50584.8 9 
hypothetical protein SS1G_10595 gi|156043185 51 150374.2 15 
DEHA2B11836p gi|294655336 51 64389.1 10 
hypothetical protein FOXB_01093 gi|342889206 51 11455.1 6 
hypothetical protein BC1G_02690 gi|154318602 50 73416.3 11 
hypothetical protein PTT_19968 gi|330946371 49 55944.7 9 
pyruvate carboxylase gi|225562373 47 132181.7 13 
pyruvate carboxylase gi|325092290 47 131444.3 13 
  
 
DATABASE: NCBI (fungus) 
Protein band  Description  Accession  Protein score MW (kDa) Peptide matched 
H3 
hypothetical protein 
TRAVEDRAFT_42575 
gi|392572024 83 17104.1 9 
hypothetical protein FG01414.1 gi|46109064 83 84247.8 18 
Pc12g12820 gi|255933239 77 137849.2 23 
predicted protein gi|302882311 69 205521.3 21 
predicted protein gi|115433306 69 57075.5 13 
hypothetical protein FG08719.1 gi|46128683 66 276017 30 
orotidine-5'-phosphate decarboxylase gi|344301052 65 29532.1 10 
predicted protein  gi|340520552 65 28370.9 10 
ZYRO0G03300p gi|254585155 64 116056.9 17 
hypothetical protein PGTG_10451 gi|403168926 64 56455.5 13 
  
DATABASE: NCBI (fungus) 
Protein band  Description  Accession  Protein score MW (kDa) Peptide matched 
H4 
MRPS5-like protein gi|401840118 85 35112.1 14 
mrps5p gi|401626773 78 35027.2 13 
Mrps5p gi|365761907 75 35093.1 13 
hypothetical protein FOXB_08951 gi|342879236 73 276051 31 
hypothetical protein FG08719.1 gi|46128683 70 276017 31 
hypothetical protein TPHA_0G02630 gi|367003601 69 78569.5 15 
DEAD/DEAH box RNA helicase gi|242767802 67 129739.3 18 
hypothetical protein PGUG_05568 gi|190348916 66 97199.7 15 
intronic ORF at intron of small subunit 
ribosomal RNA gene 
gi|400201847 65 46421.3 12 
probable 26S proteasome non-ATPase 
regulatory subunit p58 
gi|319411607 64 66945.9 13 
  
DATABASE: SwissProt (fungus) 
Protein band  Description  Accession  Protein score MW (kDa) Peptide matched 
H1 
ATPase synthesis protein 25, 
mitochondrial 
sp|D4B478|ATP25_ARTBC 40 78896.4 10 
Uncharacterized zinc-finger protein 
C4F10.19c 
sp|O36031|YEKJ_SCHPO 38 17814.8 5 
Mitochondrial import inner 
membrane translocase subunit TIM16  
sp|Q6C331|TIM16_YARLI 38 16546.7 5 
Autophagy-related protein 11  sp|Q75B79|ATG11_ASHGO 36 122401.2 13 
Ribosome biogenesis protein ERB1  sp|P0CS34|ERB1_CRYNJ 35 93635.9 11 
40S ribosomal protein S3  sp|O60128|RS3_SCHPO 34 27763.7 7 
ARS-binding factor 2, mitochondrial sp|Q02486|ABF2_YEAST 33 21548.4 6 
Guanine nucleotide-binding protein 
subunit gamma 
sp|Q6FJ50|GBG_CANGA 33 10416.2 4 
40S ribosomal protein S1  sp|P0CQ58|RS3A_CRYNJ 32 29382.7 7 
tRNA (guanine(37)-N1) 
methyltransferase 
sp|Q5KBP2|TRM5_CRYNJ 31 61617.9 8 
  
 DATABASE: SwissProt (fungus) 
Protein band  Description  Accession  Protein score MW (kDa) Peptide matched 
H2 
Ribosome production factor 2 
homolog 
sp|Q9UUG1|RPF2_SCHPO 44 36049.1 8 
Protein SDS24 sp|P38314|SDS24_YEAST 40 57493.5 8 
Vacuolar membrane protein PEP3 sp|P27801|PEP3_YEAST 39 108014.4 12 
ATP-dependent RNA helicase 
DBP10 
sp|Q6FNA2|DBP10_CANGA 34 109608 10 
Uncharacterized mitochondrial 
protein urf-LM 
sp|Q35138|URFLM_NEUCR 31 36924.2 6 
RNA exonuclease 3 sp|Q6CJB5|REXO3_KLULA 30 55606.7 8 
Decaprenyl-diphosphate synthase 
subunit 1 
sp|O43091|DPS1_SCHPO 29 42419.1 6 
Peptidyl-prolyl cis-trans isomerase B sp|Q5B4R3|PPIB_EMENI 29 23392.1 5 
Saccharopine dehydrogenase sp|Q870G1|LYS1_EMENI 29 41357.1 6 
114 kDa U5 small nuclear 
ribonucleoprotein component 
sp|P36048|SN114_YEAST 29 114482.5 9 
  
 
 
DATABASE: SwissProt (fungus) 
Protein band  Description  Accession  Protein score MW (kDa) Peptide matched 
H3 
rRNA biogenesis protein rrp36  RRP36_ASPOR 61 40140.3 12 
ATP synthase subunit 4, mitochondrial ATPF_NEUCR 54 26317.1 8 
Heat shock protein homolog SSE1 HSP7F_LACK1 49 77140.5 12 
Acetyl-coenzyme A synthetase ACSA_PHYBL 49 75298.4 11 
Nitrite reductase NIR_EMENI 48 123994.2 15 
Phosphatidylinositol transfer protein sfh5 SFH5_ASPNC 46 52350.1 10 
Structure-specific endonuclease subunit 
SLX4 
SLX4_AJEDR 45 93607.9 13 
Orotidine 5'-phosphate decarboxylase PYRF_ASPFU 43 30362.5 7 
Multiprotein-bridging factor 1 MBF1_KLULA 43 16435.9 7 
Formation of crista junctions protein 1 FCJ1_CANTT 43 62715.9 10 
  
DATABASE: SwissProt (fungus) 
Protein band  Description  Accession  Protein score MW (kDa) Peptide matched 
H4 
E3 ubiquitin-protein ligase BRE1 BRE1_CANGA 48 80348.8 14 
Ubiquinone biosynthesis protein COQ4 COQ4_LACBS 45 34155.3 8 
DNA replication complex GINS 
protein PSF1 
PSF1_PHANO 42 23788.9 7 
Orotidine 5'-phosphate decarboxylase PYRF_ASPFU 42 30362.5 7 
Altered inheritance of mitochondria 
protein 9 
AIM9_CANGA 40 73930.2 12 
Polynucleotide 5'-hydroxyl-kinase  GRC3_DEBHA 39 78024.3 10 
Orotidine 5'-phosphate decarboxylase PYRF_KODOH 38 28888.9 7 
Regulator of rDNA transcription 
protein 5 
RRT5_CANGA 38 49790.4 8 
Serine/threonine-protein kinase TEL1 ATM_YARLI 38 259222.8 18 
Pre-mRNA-splicing factor SYF2 SYF2_YARLI 38 23171 7 
  
 
 
 
 
 
 
 
DATABASE: SwissProt (P. ostreatus) 
Protein band  Description  Accession  Protein score MW (kDa) Peptide matched 
H3 
Ostreolysin sp|P83467|OSTL_PLEOS 8 5491.9 1 
Calmodulin sp|O94739|CALM_PLEOS 5 16813.9 1 
H4 
Ostreolysin sp|P83467|OSTL_PLEOS 8 5491.9 1 
Serine proteinase inhibitor sp|Q7M4T5|PIA2_PLEOS 6 8190.1 1 
 Table 4.3   Putative antihypertensive proteins 
Protein 
band/database 
Protein name Peptide sequence* Accession 
Protein score 
(%) 
Theoretical 
MW 
H3 
(SwissProt; fungus) 
nitrite reductase-like 
protein 
GIEGSKPTR 
YSVIFYIR 
DFGLIATEK 
LGIAAEMER 
LMEFAANHK 
GGFVIDESLR 
TIADVKSCTK 
SCVGTTWCR 
SGTCKTIADVK 
GDIDQDPNRR 
VGLSSYFEHR 
KIEDLYLNPK 
AMTDLEDFGSVK 
NIR_EMENI 48 123,994.2 
 GDVVESVKSGTCK 
RNFELNGEQAGR 
H4 
(SwissProt;  
P. ostreatus) 
 
serine proteinase 
inhibitor-like protein 
NGGVSDDKIR sp|Q7M4T5|PIA2_PLEOS 6 8190.1 
H4 
(NCBI; fungus) 
DEAD/DEAH box RNA 
helicase-like protein 
GLDVKQLK 
LEAWKQK 
LSRAGVMR 
DCKPFLK 
ELMRLLK 
KGEEIFAK 
NMEALARK 
DQIAELKR 
ARWAVTNR 
KPSMTKSAK 
gi|242767802 67 12,9739.3 
 ANRLSVAPSK 
AVCAYGGAPIK 
YSVDIAKALK 
YSVDIAKALK 
DDHNYRPLK 
GAEIVVCTPGR 
SPSPVGSTYSSSK 
ITVHKTEKPAGGK 
AASAIQSASAPTPGIPK 
* Peptide sequences denote sequences matched by MASCOT search engine with the databases used in MALDI TOF/TOF MS.  
 
 
 
 
 
 
  
Table 4.4  Analogous proteins identified in LC-MS/MS
1
 and MALDI-TOF/TOF MS 
Protein name Peptide sequences
2
 Accession Theoretical MW (kDa) 
DEAD/DEAH box RNA helicase FIKTVSEDEVPTHLR 358374223 72.4 
Pre-mRNA-processing ATP-dependent RNA 
helicase 
YDTDDASPRSAHSGSGTGRSSR 342319919 168.1 
serine/threonine-protein kinase QDRPRSRQSSPDHEGPSR 322699933 89.5 
peptidyl-prolyl isomerase ADELNSKNTmFGRVAGDTIYNLQK 351642550 62.7 
translation elongation factor 2 KDVVFNmLDKLEVTLK 358030862 66.5 
1
 Proteins details shown are according to data obtained from LC-MS/MS. 
2
 Peptide sequences denote sequences detected by LC-MS/MS. 
 
  
 
CHAPTER 5: DISCUSSION 
 
5.1 Cultivation of P. pulmonarius mycelium via liquid submerged 
fermentation 
Production of mycelial biomass is increasingly being dominated by species that is 
edible and having medicinal properties. Many technologies and cultivation techniques 
are invented to achieve the high demand of mycelial biomass production for scientific 
research on nutritional and pharmaceutical products. Submerged fermentation is among 
the most popular technique that has been widely developed especially for large scale 
production of mycelial biomass. It is a technique whereby fermentation is performed 
using liquid medium as a nutrient source and mycelium is used in the active 
physiological state. This technique is employed in mycelium production to achieve such 
purposes: (1) liquid spawn for fruiting body production on solid substrate; (2) biomass 
aimed for its nutritional values; and (3) biomass and/or extruded metabolites that exhibit 
pharmaceutical potentials (Smith et al., 2002). 
 
In this research, submerged liquid fermentation was selected for P. pulmonarius 
mycelial biomass production mainly due to its ability to retain protein content and to 
preserve nutritional composition of the biomass, as well as its benefit in producing 
mycelium at shorter time as compared to solid state fermentation. This study reported 4 
± 0.3 g/L of dried mycelial biomass obtained by small scale submerged fermentation 
using flasks. Kim et al., (2002) reported maximum dry mycelial biomass of P. sajor-
caju between 2.84 g/L to 7.82 g/L within five to ten days in an automated 5-L 
bioreactor, whereas Confortin et al., (2008) reported dry mycelial biomass at 5.5 g/L 
 and 8.18 g/L on different carbon sources when cultivated in 5-L bioreactor. Therefore, 
the yield of mycelial biomass in this study was slightly above average for small scale 
fermentation. In particular, crude protein extract that composed of 5 g dried mycelial 
biomass produced up to 2 mg/ml fractionated proteins out of the salting-out process. 
After RP-HPLC, the proteins from each RP-HPLC peak reached the utmost 
concentration at around 0.07 mg/ml only. Hence, several cycles of cultivations were 
fulfilled to accommodate sample stock throughout the study.   
 
5.2 Antihypertensive activity of P. pulmonarius  
Medicinal and/or edible mushrooms have gained interest in bioactive protein and 
peptide studies for various therapeutic effects including antihypertensive activity. In this 
study, P. pulmonarius mycelium exhibited positive in vitro antihypertensive activity. 
Hence, the study has underlined the importance of mushroom mycelia cultivated by 
liquid fermentation as natural ACE inhibitor resources.  Extensive study was performed 
in which intracellular proteins in the mycelial aqueous extract and extracellular proteins 
that were released in the broth were tested separately for ACE inhibitory activity. The 
result showed approximately twice more potent ACE inhibitory effect in the 
intracellular proteins of P. pulmonarius mycelium (IC50 = 0.72 mg/ml). The anti-ACE 
activity reported was immensely stronger than water extracts of mycelia from six 
different mushrooms, i.e. Catathelasma ventricosum, Lactarius camphorates, Pholiata 
adipose, Phellinus linteus, Thelephora ganbajun and Tricholoma giganteum, with their 
IC50 values ranged from 1.28 to 5.25 mg/ml (Yan et al., 2013). 
 
As a way to unearth the proteins that contributed to the anti-ACE activity, a series of 
protein purifications were performed in this study. The aim of protein purifications was 
to focus on proteins with ACE inhibitory property, thus eliminate unrelated proteins and 
 other compounds. Accordingly, proteins from mycelial aqueous extract were 
fractionated via salting-out method by means of ammonium sulphate concentration 
ranging from 10% to 100%. Amongst ten fractions, F40 showed the best ACE 
inhibitory activity with the IC50 value of 22 µg/ml. This fraction was estimated to 
consist of proteins with high to moderate hydrophobicity as it required 40% (w/v) of 
salt in order to precipitate out the proteins. This result corresponded to earlier studies 
which discovered potent anti-ACE activity in the presence of abundant hydrophobic 
amino acid residues (Wu et al., 2006). 
 
Fraction F40 was further purified by RP-HPLC. A semi-preparative C18 HPLC (10 × 
100 mm) column was used for further purification of F40 due to its advantage to 
separate small molecular proteins, peptides or small molecules (Hearn et al., 1979). 
From the RP-HPLC protocol employed in this experiment, an optimum chromatogram 
of eight apparent peaks was eluted at 220 nm, and labelled as P1 to P8. Evaluation of 
ACE inhibitory activity at 15 µg/ml of samples demonstrated the strongest anti-ACE 
activity by P6, in which the value was also significantly different compared to the other 
peaks (p<0.05).  The IC50 value determined was 12 µg/ml.  
 
Interestingly, an active ACE inhibitor P6 in this study demonstrated among the 
strongest inhibitory effect compared to the naturally occurring ACE inhibitory peptides 
discovered from other medicinal mushrooms. The IC50 value of P6 was stronger than an 
active tripeptide of Tricholoma giganteum (IC50 = 0.04 mg/ml) (Lee et al., 2004), 
Grifola frondosa (IC50 = 0.13 mg/ml) (Choi et al., 2000) and an active pentapeptide of 
Pholiota adiposa (IC50 = 0.044 mg/ml) (Koo et al., 2006). P6 also showed better ACE 
inhibitory activity compared to two oligopeptides ACE inhibitors analyzed from 
 Pleurotus cornucopiae which showed the IC50 values of 0.46 and 1.14 mg/ml (Jang et 
al., 2011). 
 
In addition, this study has demonstrated an increase in ACE inhibitory effects 
correspond to each protein purification step. The IC50 values of the inhibitory activity 
showed thirty times reduction between the mycelial aqueous extract and fraction F40 
from salting-out method by ammonium sulphate precipitation, and sixty times reduction 
when compared to the RP-HPLC fraction P6 (IC50 = 720 mg/ml > 22 µg/ml > 12 
µg/ml). This suggests potent ACE inhibitory proteins that can exhibit an independent 
inhibitory action and may indicate specific protein inhibitor for ACE. This characteristic 
is vital for the discovery of good hypotensive agents (Hong et al., 2008). Likewise, 
captopril was used as positive control for ACE inhibitory activity in this study. The 
result showed an extremely low IC50 value compared to the activity shown by P. 
pulmonarius mycelium. This result was well inferred since captopril is an established 
clinical drug currently used for the treatment of hypertension, despite the commonly 
reported adverse effects.  
 
An active ACE inhibitor P6 was analysed by SDS-PAGE as a prerequisite for protein 
identification using MALDI-TOF/TOF MS. Besides, fraction F40 was also screened 
along with P6 for two supplementary reasons; a) to observe any analogous band 
between the two fractions, and b) to determine sample purity. Result showed several 
bands migrated along the resolving gel in F40 with four similar bands reoccurred in P6. 
This substantiated the role of reversed phase HPLC in further purifying the fraction as 
fewer bands emerged in fraction P6 as compared to fraction F40. The four bands from 
P6 were excised out and subjected to protein identification by MALDI-TOF/TOF MS.  
 
 5.3 Protein profiling by MALDI-TOF/TOF MS and LCMS/MS 
Mass spectrometry (MS) has become one of the key technologies in the proteomics field 
due to its high sensitivity, automation and throughput for protein analysis. Among the 
MS platforms, MALDI-TOF/TOF mass spectrometry offers high sample throughput 
and the flexibility to connect with different off-line sample fractionation techniques. 
The identification of isolated protein is characterized by the matching of peptide mass 
fingerprint (PMF) against the protein sequence database (Wojcik et al., 2003).  The 
quest for antihypertensive proteins in this study has utilized this technique supported by 
tandem mass spectrometry (MS/MS), in which polypeptides sequence tagging was 
performed to allow protein identification by sequence similarity screening of classical 
bioinformatics databases subsequent to PMF. 
 
Fraction P6 demonstrated enhanced anti-ACE activity by sixty times compared to the 
mycelial aqueous extract, and was selected for protein profiling and identification. The 
fraction was subjected to SDS-PAGE for protein separation prior to MALDI-TOF/TOF 
MS. SDS-PAGE result showed four distinct bands labelled as H1, H2, H3 and H4. All 
bands were then subjected to MALDI-TOF/TOF MS. Result from the Mascot search 
using three different databases hit overall proteins with an average to low protein scores. 
 
In proteomic study, the success of protein identification from mass spectrometry i.e. 
MALDI-TOF/TOF and LC-MS/MS is highly reliant on the size of database and the 
error rate within, the mass accuracy, the control over the digest chemistry and the 
number of matching peptides and their molecular weight (Suckau et al., 2003). In case 
of fungal protein database, a curated database is extremely required as the available 
databases are inadequate for both genomic and proteomic study of fungal proteins. In 
particular, protein database for mushrooms species is still poorly covered. For instance, 
 only 25 to 50 proteins are found under P. pulmonarius via high quality databases such 
as Swiss-Prot and UniProt.  This may contribute to low scores mass spectrometry result. 
Another consideration is the databases used in this study are not from the same species, 
also due to the same frailty. Thus, the proteins are not totally similar in comparison and 
this may cause inaccuracy of the matched sequences and again contributed to low 
protein scores.  
 
In this study, only one-dimensional chromatography was used for protein separation, i.e. 
RP-HPLC. Hence, sample P6 was expected to still contain mixture of proteins and 
peptides. When the sample underwent SDS-PAGE, a single protein band might also 
contain proteins with similar molecular weight. The impurity of sample, together with 
the limitation of databases may affect protein scores and cause imprecision of protein 
identification.  
 
According to Petsko et al., (2004), a protein that shows more than 40% sequence 
similarity is hypothetically of correct match. Several proteins with scores more than 
40% have been identified from MALDI profile, but the highest score was shown by 
MRPS5-like protein from band H4, at only 85%, supported by two more hits of mrps5p 
proteins that scores 78% and 75% from the same protein band (Table 4.2, page 52). 
MRPS5 is a mitochondrial ribosomal protein (MRP) from the 5SP family. Generally, 
this protein is known to involve in protein synthesis within the mitochondrion. Proteins 
comprising the mitochondrial ribosome display a wide variation in sequence and some 
biochemical properties when compare with different species. This causes recognition of 
the protein by sequence homology is quite tricky. Also, individual MRPs were 
characterized functionally by mutational studies due to the same reason (Graack et al., 
1998). 
 Several disorders associated with MRP genes are Leigh Syndrome, multiple 
mitochondria dysfunctions, and non-syndromic hearing loss (O‟Brien et al., 2005). 
However, the connection of this protein with antihypertensive property is beyond our 
comprehension as there is so far no information reported. Further investigations 
including protein purification, verification of this protein as an ACE inhibitor by bio-
assay and in vivo studies and in depth proteomic analyses on the protein are highly 
required to confirm this finding.     
 
Given the drawback vis-à-vis protein impurity and implausible protein scores, to 
identify antihypertensive proteins based on the protein score alone is somewhat 
precarious. Hence, the search for antihypertensive proteins were expanded by narrowing 
down the protein profile based on the earlier antihypertensive studies reported by other 
researchers. However, it is noted that some information regarding the other proteins, 
especially the hypothetical proteins might be missing due to this methodology.  
Accordingly, three proteins pertaining antihypertensive activity were discovered, i.e.  
Serine proteinase inhibitor-like protein and DEAD/DEAH box RNA helicase-like 
protein from band H4 and nitrite reductase-like protein from band H3. There was as yet 
no ACE inhibitory or antihypertensive related protein identified from band H1 and H2.   
 
Fraction P6 was also subjected to LC-MS/MS to validate the proteins identified from 
MALDI-TOF/TOF MS. The high sensitivity and reliability of LC-MS/MS, plus the 
identification method that based on independent sequencing of peptide has made it 
suitable to analyse very complex mixture. The result showed an abundance of proteins 
identified by LC-MS/MS, with all of them showed low protein scores and most of them 
hit only one unique peptide sequenced by MS/MS. Out of the total hits, there were five 
proteins appeared in both proteomic tools, i.e. DEAD/DEAH box RNA helicase, Pre-
 mRNA-processing ATP-dependent RNA helicase, serine/threonine-protein kinase, 
peptidyl-prolyl isomerase, and translation elongation factor 2.  Intriguingly, only one 
protein which has been shown to have antihypertensive property was identified by both 
mass spectrometries, which was DEAD/DEAH box RNA helicase-like protein.  
 
Although theoretically a LC-MS/MS is commonly used for proteomic analysis of 
complex mixtures or samples, the ability is limited by one-dimensional RP-HPLC 
method used in this study, due to the difficulty to separate a very large number of 
proteins and peptides in the sample.  Again, an inadequate database is another limiting 
factor for protein identification by LCMS/MS.  
  
5.4  Proteins with antihypertensive activity found in P. pulmonarius mycelium 
5.4.1 Serine proteinase inhibitor-like protein 
Serine proteinases (synonym as serine protease) are serine-type endopeptidases that are 
well-known as a group of proteolytic enzymes. The classical mechanism of serine 
proteinases involves a catalytic triad of Serine, which is activated by a proton relay 
involving acidic residue (e.g. aspartic acid and glutamate) and basic residue (usually 
histidine). The serine proteinases include digestive enzymes and generally participate in 
development, blood coagulation, inflammation, and various other processes (Gan, 
1994).  
 
In human, serine proteinases play an important role in the RAAS system (figure 5.1). 
Among the serine proteinases, chymase is a major serine proteinase implicated for the 
formation of cardiac Angiotensin II via ACE-independent enzymatic pathway. Chymase 
is an Angiotensin II-forming enzyme as efficient as ACE. It cleaves Angiotensin I at the 
same site as ACE to form Angiotensin II, but is highly resistant to ACE inhibitors. 
 According to Wolny et al., (1996), earlier studies have shown the incomplete blockade 
of RAAS via ACE inhibitors, as the plasma Angiotensin II levels return to normal 
despite ACE inhibitor therapy. Wolny and colleagues suggested that chymase was 
responsible for the incomplete blockade. The same notion coincided with Park et al., 
(2009), who further suggested that ACE-independent mechanisms predominate in 
diabetic kidneys thus accountable for the ineffectiveness of ACE inhibitors in some 
diabetic-related hypertension patients. As chymase is completely inhibited by serine 
proteinase inhibitors, discovery of serine proteinase inhibitors could be a potentially 
important therapeutic target in the treatment of hypertension, especially diabetic-related 
hypertension and nephropathy. As ACE-independent Angiotensin II is strongly 
upregulated in the human diabetic kidney, particularly in mesangial cells and in vascular 
smooth muscle cells, serine proteinase inhibitors could also contribute to the healing of 
structural remodelling associated with cardiovascular diseases such as vascular injuries 
and peripheral vascular disease, as well as protection from renal vascular disease 
(Lorenz, 2010). Serpin and aprotinin are among the well-known serine proteinase 
inhibitors that have been studied for the restorative purposes of hypertension. 
 
The 6% protein score corresponds to the similarity of sample sequence with fragment 
11 to 19 of a total 76-amino acid of serine proteinase inhibitor from P. ostreatus, with 
two different amino acids present in the second and fifth residues. According to Erjavac 
et al., (2012), information about proteases from mushrooms is limited. Many proteases 
found in mushrooms exhibit unique characteristics and could be exclusive to 
Basidiomycetes. This opens the opportunity for more discoveries of novel proteases, 
and also a good source of protease inhibitors, albeit the even lesser information 
available on the protein inhibitors.  
 
  
Figure 5.1: The RAAS system that includes conversion of angiotensin I to angiotensin II by 
ACE and serine proteinases (The illustration is adapted from Peterson et al., 2002) 
 
Detailed study on serine proteinase inhibitor from mushroom is yet to be enhanced. 
Two low-molecular-weight inhibitors of endogenous serine proteinase from P. ostreatus 
has been the most comprehensively studied so far. Discovered by Dohmae and 
colleagues in 1995, these proteinase inhibitors with respective molecular weights of 
8307 and 8244 Da showed concise similarity with the long-known yeast proteinase B 
inhibitor. These proteinase inhibitors showed similar mechanism of action to 
propeptides of subtilisin family proteinases due to their structural resemblance (Dohme 
et al., 1995). Another serine proteinase inhibitor was found from the fruiting body of 
Lentinus edodes. This proteinase inhibitor showed inhibition of activated factor XI 
when tested against microbial and mammalian serine proteinases, including human 
enzymes of blood coagulation and fibrinolysis. This inhibitor did not show any 
significant similarity to any major groups of serine proteinase inhibitors, also to non-
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 inhibitor proteins in the available databases, and thus was hypothesised to represent a 
novel serine proteinase inhibitor family (Odani et al., 1999). 
 
The identification of a sequence corresponds to serine proteinase inhibitor is beyond 
expectation, as our objective was to investigate antihypertensive activity via ACE 
inhibitory mechanism. Yet, it is interesting to discover another antihypertensive 
potential with comparable advantages. As the mechanism of angiotensin II formation is 
similar between ACE and serine proteinase, it is possible that the in vitro experiment is 
valid for both ACE inhibitory and serine proteinase inhibitory assay. Although serine 
proteinase is fully resistant to ACE inhibitor, there is no report affirming the resistance 
of ACE towards serine proteinase inhibitor. In fact, a neutral serine proteinase inhibitor 
called leupeptin was reported to inhibit ACE activity in human T-lymphocytes though 
no effects were shown by chymostatin (chymase inhibitor) and E-64 (calpain inhibitor) 
(Petrov et al., 2000).  Hence, it is possible if the protein plays synergistic inhibitor effect 
for serine proteinase and ACE. Further investigation is necessary to attest this inference.  
 
5.4.2 Nitrite reductase-like protein 
Nitric oxide (NO) has been identified as the endothelium-derived relaxing factor, and 
later was characterized as a vasoregulatory molecule, thus featured in the regulation of 
blood pressure and flow, smooth muscle cell proliferation and migration, platelet 
aggregation, and leucocytes adhesion to the endothelium. Many studies reported 
benefits of NO mediated mechanisms for the treatment of cardiovascular disorders 
including hypoxia, pulmonary or systemic hypertension, ischemia, atherosclerosis and 
vasospasm (Alef et al., 2011).  
 
 In short, the production of NO is mediated by two pathways. The first endogenous NO 
pathway discovered decades ago is the NOS-dependent pathway. NO is synthesized by 
nitric oxide synthases (NOS). There are two constitutively expressed NOS isoforms 
(endothelial NOS; eNOS, and neuronal NOS; nNOS) and one inducible isoform 
(iNOS). eNOS is the most important isoform in regulating NO production to influence 
the cardiovascular system. More recently, scientists have demonstrated that NO 
formation can take place independently of the NOS pathway (NOS-independent 
pathway). This pathway involves the conversion of nitrate (NO3
-
) to nitrite (NO2
-
) and 
then to NO, via reduction activity by both non-enzymatic and highly regulated 
enzymatic mechanisms (Zuckerbraun et al., 2011). Figure 5.2 is illustrated to 
understand the NOS-dependent and NOS-independent pathways for the production of 
NO, as well as the connection of NO to other mechanisms. 
 
The reduction of nitrite to NO in the NOS-independent pathway occurs both in the 
blood and tissues. The non-enzymatic conversion is mediated by acidic reduction, while 
the enzymatic conversion is regulated by nitrite reductase enzymes. This enzyme was 
reported to show maximum reductase activity with faster response especially during the 
hypoxic condition, thus underpins vasodilation, maintain blood flow and oxygen 
demand to the cells (Gladwin et al., 2006). Other study done by Pinder et al., (2009) 
demonstrated maximum dilation on the aortic ring of rabbit under hypoxic condition 
when treated with plasma nitrite, as the result of nitrite reductase activity. Several nitrite 
reductase enzymes have been discovered in human including xanthine oxidoreductase 
(XOR), aldehyde oxidase, deoxyhemoglobin, deoxymyoglobin and cytochrome c 
oxidase, while Webb et al., (2008) reported the ability of eNOS to mediate nitrite 
reductase activity within circulation under hypoxic condition.  
 
  
Figure 5.2: NOS-dependent and NOS-independent pathways for the production of nitric oxide 
(NO). Reduction process takes place in the NOS-independent pathway include nitrate reductases 
and nitrite reductases enzymes. Conversion of nitrite (NO2
-
) to NO by nitrite reductase enzymes 
can occur under hypoxic condition (low pH and oxygen supply), where the NOS-dependent 
pathway works very limited. NO can then have a myriad of biological effects, including 
vasodilation, modulation of smooth muscle cell proliferation, and cytoprotective effects (The 
illustration is adapted from John et al., 2009) 
 
Ghosh et al., (2013) reported enhanced vasodilator activity of nitrite and lowering blood 
pressure effect in the spontaneously hypertensive rats (SHR). A clinical study was also 
implemented and result showed improved efficacy of inorganic nitrate and nitrite as a 
consequence of increased erythrocytic (XOR)-nitrite reductase activity. This study 
suggests the concept of dietary nitrate supplementation as an effective and economical 
antihypertensive therapy. Although there are overlapping and integrated mechanisms 
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 involving NO pathways alongside the other undiscovered pathways that put 
physiological role of nitrite and nitrite reductases only in its infancy, studies suggest 
that nitrite reductase mechanism and the global role of nitrite may be a major stable 
reservoir of NO in the circulation and being harness to treat many diseases especially 
the ones associated with deleterious cardiovascular consequences.  
 
It is known that eNOS/NO pathway interacts with RAAS system in many 
circumstances. The most studied system involving both pathways is the mechanisms 
underlying vascular (endothelial) dysfunction by oxidative stress and its related diseases 
such as aging, diabetes, arteriosclerosis and hypertension. Generally, Angiotensin II 
stimulates superoxide (O2
-
) formation from the vascular NADPH oxidase via AT1 
receptor. This results in uncoupling of eNOS, which lead to more superoxide production 
rather than NO. This inhibits cGMP pathway and thus conducts endothelial dysfunction. 
Presence of ACE inhibitor could not only reduce Angiotensin II, but also increase in 
eNOS expression, which may be mediated via another vasodilator and NO release 
device, a bradykinin-mediated mechanism (Imanishi et al., 2009). 
 
In regard to our result, the presence of nitrite reductase enzyme-like protein might be 
the responsible protein for the ACE inhibitory activity in addition to the known function 
studied by other researchers. Although there is no supporting data about the synergistic 
effect of nitrite reductase to ACE inhibitor, there is still room for further investigation 
due to overlapping and complicated mechanisms liaised in cardiovascular system.  
 
A concern due to variation of estimated molecular mass for nitrite reductase between 
MALDI and the SDS-PAGE band (H3) is fathomed. A study by Prodouz et al., (1981) 
has shown that native nitrite reductase was denatured into a single homodimeric subunit 
 in the presence of guanidine HCl and ß-mercaptoehtanol in SDS-PAGE. Another SDS-
PAGE analysis by Steensma et al., (2001) has indicated degradation of cytochrome cd1 
nitrite reductase. The result was confirmed by mass spectrometric analysis that showed 
reduced molecular mass and the cleavage of the c domain residues, in which resulted 
the presence of no full-length protein domain. Similarly, Bowsher et al., (1988) also 
found a degradation product of nitrite reductase screened by SDS-PAGE. Certainly, 
degradation of protein samples are among the most common problems that contribute to 
variation of protein mass in SDS-PAGE. Large protein size or protein with subunits 
may also indicate partial existence in the gel due to denaturation (Hjelmeland et al., 
1981). 
 
5.4.3 DEAD/DEAH box RNA helicase-like protein 
RNA helicases are known mostly for RNA metabolisms such as pri-mRNA splicing, 
ribosome biogenesis and translation initiation, as well as in the mediation of antiviral 
immune response. Defective RNA helicases have been linked to serious disorders like 
cancer, neurodegenerative disorders and infectious diseases (Steimer et al., 2012). 
Recently, hypertensive related diseases such as cardiomyocyte hypertrophy has been 
linked to the regulation of RNA helicase. Sahni et al., (2010) has postulated 
antihypertensive effect of DEAD/DEAH box helicase through the regulation of cardiac 
cellular mechanisms. The process is regulated by CHAMP (cardiac helicase activated 
by MEF2 protein), a type of RNA helicase that acts through general cell cycle 
machinery by inhibiting cell cycle progression.  
 
MEF2 protein is a cardiac transcription factor that responsible to activate CHAMP. 
Other than MEF2, cardiac transcription factors are GATA4 and homeobox transcription 
factor Csx/Nkx
2-5
 (Akazawa et al., 2003). CHAMP is localized primarily to the 
 cytoplasm of cardiomyocetes and control proliferation of cardiomycete by regulating 
the mRNAs of proteins involved in cell cycle progression. According to Liu and Olsen 
(2002), antiproliferative activity of CHAMP was mediated by a cell cycle inhibitor 
p21
CIP1
 and ATPase domain. The upregulation of p21
CIP1
 inhibited cyclin-dependent 
kinase (CDK) activity thus suppressed cell growth progression and proliferation of 
hypertrophic coronary. In regard to hypertrophy, this antiproliferative effect would 
weaken the wall stress, prevent or reverse the hypertrophic phenotype and thus 
circumvent the subsequent development of heart failure.  This would also improve 
diastolic function and pressure overload in hypertensive patients (Frey et al., 2003).  
 
Given that multiple pathways can elicit a similar molecular response or vice versa, it is 
postulated that DEAD/DEAH box helicase-like protein characterized here is responsible 
for ACE inhibitory activity as well as other antihypertensive effect via cellular 
mechanism. More detail investigation on the molecular pathway, structural and 
pharmacological properties of this protein is necessary to ensure the ACE inhibitory 
property.  
 
Protein identification by LC-MS/MS has discovered DEAD/DAH box RNA helicase as 
one of the protein substances in P. pulmonarius mycelium. The unsatisfactory protein 
scores and coverage given by MALDI-TOF/TOF (67%) and LC-MS/MS (2%) may due 
to different species databases used as citation for protein identification, as postulated 
earlier. Additionally, the conserved core regions of DEAD family proteins are normally 
flanked by extension of sequences at both N-terminal and C-terminal of the proteins, 
which determine specific function of the individual protein but cause less common in 
sequences comparisons within the protein family (You et al., 1999). Nevertheless, 
detection of DEAD/DEAH box RNA helicase-like protein in both proteomic tools may 
 substantiate the presence of this protein as one of the ACE inhibitors in P. pulmonarius 
mycelium.   
 
Noticeably, there was discrepancy of estimated molecular masses of DEAD/DEAH box 
RNA helicase demonstrated in MALDI and band H4 of SDS-PAGE. This may due to 
protein degradation that happened intracellulary or during SDS-PAGE procedure. 
Apparently, You et al., (1999) has observed the degraded form of HCV core protein, a 
member of DEAD box family proteins via indirect immunofluorescence staining.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER 6: CONCLUSION AND FUTURE WORK 
 
P. pulmonarius mycelium protein, specifically the intracellular group of protein derived 
from mycelial biomass demonstrated potential in vitro antihypertensive assay. Our 
present study elucidated antihypertensive effect based on the ability to inhibit ACE 
activity at the IC50 value of 0.012 mg/ml, which indicated among the lowest IC50 value 
of ACE inhibitory activity derived from mushrooms. Protein identifications by MALDI-
TOF/TOF and LC-MS/MS have brought about three proteins that were possibly 
responsible for the anti-ACE activity based on earlier studies reported; serine proteinase 
inhibitor-like protein, DEAD/DEAH box RNA helicase-like protein and nitrite 
reductase-like protein. The MRPS5-like protein should also be considered due to the 
highest protein score from MALDI. Some limitations are considered in this study, such 
as the inability to further purified the identified ACE inhibitory proteins and limited of 
existing curated mushroom databases for mass spectrometry analyses.  
 
This research may become groundwork to more in depth investigations on the ACE 
inhibitory proteins derived from P. pulmonarius mycelium. Detailed and comprehensive 
proteomic approaches such as 2D gel electrophoresis, 2D chromatography and ECI-
LCMS/MS are anticipated in future protein works. An anti-ACE bioassay guided study 
of each identified protein and their peptide sequence is a fine approach to uncover ACE 
inhibitory proteins/peptides prior to more detailed in vivo study. A thorough 
mechanistic research is necessary to elucidate the blood pressure machinery involved in 
the identified proteins. Evaluations on the gastrointestinal digestion, physiochemical, 
cytotoxicity and other pharmaceutical considerations are anticipated prior to the 
ratification of new antihypertensive products. Nevertheless, this research has discovered 
potential naturally occurring ACE inhibitors that should cause minimal or no side 
 effects and has offered better understanding of P. pulmonarius and its medicinal 
benefits. 
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 APPENDIX A: MATERIALS & METHODS 
 
1) Preparation of Malt Extract agar (MEA) plate  
Table 1 Recipe for the preparation of MEA agar 
Material Amount 
Malt Extract Agar 25 g 
Distilled water 400 ml 
 
Malt extract agar powder was mixed with distilled water. The solution was stirred 
homogeneously and then autoclaved at 121 ± 2°C for 15 minutes. The MEA was let 
cooled at approximately 45 to 55 ± 2°C before poured into sterile Petri dishes. The 
MEA plates were stored at 25± 2°C prior to use. 
 
2) Preparation of Brown sugar-spent yeast medium (per 1000 ml) 
Table 2 Recipe for the preparation of Brown sugar- spent yeast medium broth 
Material Amount 
Brown sugar 10.0 g 
Spent Yeast 20.0 g 
Malt Extract 20.0 g 
Distilled water 1000 ml 
 
The mixture was slightly heated to dissolve all of the ingredients and stirred 
concurrently to achieve homogeneity. Aliquot of each 100 ml of the medium was 
transferred into 500 ml Erlenmeyer flasks. The sealed flasks were autoclaved at 121 ± 
2°C for 15 minutes. 
 3) Antihypertensive assay 
Antihypertensive assays were performed according to the technical manual provided in 
the ACE Kit (http://www.dojindo.eu.com/TechnicalManual/Manual_A502.pdf). 
  
a) Preparation of Enzyme working solution 
Enzyme B was dissolved with 2 ml distilled water to make Enzyme B solution. Then, 
1.5 ml of Enzyme B solution was added to Enzyme A to make Enzyme working 
solution. Enzyme A and B vials were capped under vacuum pressure. Therefore, 
disposable syringes were used when adding deionized water and Enzyme B solution to 
the respective vial. The enzyme working solution was stable at -20°C for two weeks and 
stable for three days if stored in a refrigerator.  
 
b) Preparation of Indicator working solution 
Enzyme C and Coenzyme was dissolved with 3 ml deionized water. In order to prepare 
Indicator working solution, each 2.8 ml of Enzyme C solution and Coenzyme solution 
was added to Indicator solution. Enzyme C and Coenzyme vials were capped under 
vacuum pressure. Deionized water was added through a rubber septum with a 
disposable syringe. The indicator working solution was stable at -20°C for two weeks 
and stable for three days if stored in a refrigerator.  
 
 
 
 
 
 
 
 4) Semi-purification of protein by salting out method 
Table 3 Amount of ammonium sulphate required for protein precipitation 
This table indicates the amount of ammonium sulphate (at 4 °C) to be added to one litre 
of solution to produce a desired change in the presence saturation of ammonium sulfate. 
Saturated solution is 4.1 M and required 716.8 g of salt per litre. This table was 
calculated from the provided formula from http://www.encorbio.com/protocols/AM-
SO4.htm 
 
 
 
 
 
 
Initial percentage 
of saturation for 
ammonium 
sulphate (%) 
 
Percentage  saturation (%) at 4°C 
10 20 30 40 50 60 70 80 90 100 
Solid ammonium sulphate (grams) to be added to 1 litre of solution 
0 53 110 170 233 301 373 450 533 621 717 
10  55 113 175 241 311 386 466 552 645 
20   57 117 181 249 322 400 483 573 
30    58 120 187 257 333 414 502 
40     60 124 193 266 345 430 
50      62 129 200 276 358 
60       64 133 207 287 
70        67 138 215 
80         69 143 
90          71.7 
100          - 
 5) Protein estimation by using Bicinchoninic acid (BCA) assay kit 
a) Preparation of Diluted Albumin (BSA) Standards 
The Albumin Standard (BSA) at the concentration of 2 mg/ml per ampule was diluted 
into several vials. Distilled water was used as diluents. Preparation of the standards was 
as shown in Table 4. 
 
Table 4 Preparation of Bovine Serum Albumin (BSA) Standards for protein estimation 
using BCA assay kit 
Vial 
Volume of 
diluents (µl) 
Volume and Source of 
BSA 
Final BSA 
concentration 
(µg/ml) 
A 0 300 µl of stock 2000 
B 125 375 µl of stock 1500 
C 325 325 µl of stock 1000 
D 175 175 µl of vial B dilution 750 
E 325 325 µl of vial C dilution 500 
F 325 325 µl of vial E solution 250 
G 325 325 µl of vial F solution 125 
H 400 100 µl of vial G solution 25 
I 400 0 0 
 
b) Preparation of the BCA™ Working Reagent (WR) 
i. The following formula was used to determine the total volume of WR required: 
 (# Standards + # sample) × (# replicates) × (volume of WR per sample) = total WR 
  
 In this study, the Microplate Procedure was used for each protein estimation assay. 
Therefore, 200 µl of WR per sample was used in the calculation. 
ii. Preparation of WR Reagent was done by mixing 50 parts of BCA™ Reagent A 
with 1 part of BCA™ Reagent B (Reagent A:B, 50:1). 
 
c) Microplate procedure (Sample to WR ratio = 1:8) 
Microplate wells were loaded with 25 µl of standards and samples respectively. Then, 
200 µl of WR was added to each well. The plate was mixed thoroughly on a plate 
shaker for thirty seconds. The plate was then incubated at 37°C for thirty minutes. The 
plate was cooled to room temperature before the optical density was read by an ELISA 
Plate Reader at the absorbance value of 562 nm. A standard curve graph was plotted by 
means of the BSA Standards reading. Protein concentrations were obtained via 
extrapolation from the standard curve graph. 
 
6) Preparation of mobile phases for RP-HPLC 
(a) Organic solvent 
HPLC grade acetonitrile was filtered using Whatman® nylon membrane filter (0.45 µm, 
47 mm). 
 
(b) Aqueous solvent 
For the aqueous solvent, 0.1% TFA was added into distilled water. The solution was 
filtered using Whatman® cellulose membrane filter (0.45 µm, 47 mm).  
 
The mobile phases were degassed to purge any trapped bubble in the tube prior to every 
HPLC analysis 
 
 7) Preparation of SDS-PAGE stock solutions and buffers 
(a) Preparation of stock solutions for glycine – SDS-PAGE system 
- Solution A (monomer acrylamide and bisacrylamide [30.8%T, 2.7%Cbis]) 
Thirty grams of acrylamide and 0.8 g of N, N‟-methylenebisacrylamide were dissolved 
in 100 ml distilled water. In order to remove trace of ionic impurities from non-ionic 
acrylamide solution, the solution was deionised by small amount of amberlite IRN-
150L, a homogenous mixture of strong cationic and anionic resins. The solution was 
stirred for an hour, and then filtered to remove the amberlite. Solution A was stored in 
dark and kept at 4 ± 2°C. The solution was used within 3 months only. 
 
- Solution B (4× running buffer [1.5 M Tris-HCl, pH 8.8]) 
In order to prepare the stock of solution B, 18.17 g of Tris base was dissolved and made 
up to 100 ml with distilled water. The solution was adjusted to pH 8.8 using 
concentrated HCl, and kept at 4 ± 2°C. 
 
- Solution C (10% (w/v) SDS) 
To prepare the stock of solution C, 10 g of SDS was dissolved and made up to 100 ml 
with distilled water. The solution was kept at room temperature. 
 
- Solution D (stacking gel buffer [0.5 M Tris-HCl, pH 6.8]) 
For making solution D, 6.06 g of Tris base was dissolved and made up to 100 ml with 
distilled water. The solution was adjusted to pH 6.8 using concentrated HCl, and kept at 
at 4 ± 2°C. 
 
 
 
 - 10% APS (10% (w/v) ammonium persulfate) 
In order to prepare the 10% of APS solution, 0.1 g ammonium persulfate was dissolved 
into 1 ml distilled water. The solution was prepared freshly prior to use.  
 
- TEMED (N, N, N’, N’-tetramethylenediamine) 
TEMED was stored at room temperature and took directly from the bottle when needed.  
  
- 4× SDS-PAGE sample buffer (0.1% (w/v) bromophenol blue, 10% (w/v) 
glycerol, 2% (w/v) SDS, 1% (w/v) DTT 62.5 Mm Tris-HCl pH 6.8) 
Twenty milligrams of bromophenol blue, 2 ml of glycerol, 400 mg of SDS and 200 mg 
of dithiothreitol (DTT) were mixed homogenously. Then, 2.5 ml of this solution was 
made up to 20 ml with distilled water and stored at -20 ± 2°C in aliquots. 
 
- Running buffer (tank buffer [25 mM Tris, 198 mM glycine, 0.1% (w/v) 
SDS, pH 8.3]) 
To prepare the stock of running buffer, 3.03 g Tris base, 14.4 g glycine and 1 g SDS 
were mixed and made up to 1 L with distilled water. The solution was stored at room 
temperature. The buffer was filtered and reused a few times. 
  
(b) Preparation of Prestained SDS-PAGE Protein Marker (Broad range, Bio-
Rad®) 
The Protein Marker was shaken well and aliquoted into Eppendorf tubes to avoid 
possibilities of contamination. The tubes were kept in -20 ± 2°C as stocks. The marker 
to be used was heated to 95 – 100 ± 2°C for 3 to 5 minutes. The tube was spun shortly 
prior to use.  
 
 (c) Preparation of glycine SDS-PAGE gels solutions 
- Recipe for the preparation of separating gel (18% gel) 
For the preparation of 18% separating gel with 0.75 mm thick, the related stock 
solutions were mixed together following their respective concentration as stated in 
Table 4 below. The 10% APS and TEMED were added freshly into the solution before 
it was poured into the gel – casting apparatus. 
 
Table 4 Recipe for 18% separating gel for SDS-PAGE analysis. 
Stock solution Volume of stock solution (ml) 
Solution A 5.34 
Solution B 2.50 
Solution C 0.10 
Distilled water 2.01 
10% APS 0.005 
TEMED 0.0033 
Total volume 10.00 
Solution A, B, and C was used for the making of separating gel. 
 
- Recipe for the preparation of 4% stacking gel  
A 0.75 mm thick of 4% stacking gel was used for the SDS-PAGE analysis. To make the 
gel, solution A, D and C was mixed together (Table 5). Distilled water was then added 
into the solution. The freshly prepared 10% APS and TEMED were added into the 
solution right before the solution was poured into the gel – casting apparatus.  
 
 
  
Table 5 Recipe for 4% stacking gel for SDS-PAGE analysis. 
Stock solution Volume of stock solution(ml) 
Solution A 0.33 
Solution D 0.63 
Solution C 0.03 
Distilled water 1.53 
10% APS 0.013 
TEMED 0.0025 
Total volume 2.5 
Solution A, D, and C was used for the making of stacking gel. 
 
8) Preparation of silver staining solutions 
(a) Fixing solution (40% (v/v) ethanol, 10% (v/v) acetic acid)   
Hundred millilitre of ethanol and 25 ml of acetic acid were mixed and made up to 250 
ml with distilled water. The solution was kept at room temperature. 
 
(b) Incubation solution (30% (v/v) ethanol, 0.5 M sodium acetate, 8 mM 
sodium thiosulphate) 
Ethanol (75 ml) was mixed with 0.5 g sodium thiosulphate and 17 g sodium acetate. 
The solution was made up to 250 ml with distilled water. The solution was kept at room 
temperature. 
  
  
(c) Silver solution (5.9 mM silver nitrate) 
To prepare the silver solution, 0.625 g silver nitrate was added into 250 ml distilled 
water. The solution was kept at room temperature. 
 
(d) Developing solution (0.24 M sodium carbonate, 0.04% (v/v) 37% 
formaldehyde, 2.8% (v/v) 5% sodium thiosulfate) 
Sodium carbonate (6.25 g) was mixed with 0.1 ml 37% formaldehyde and 7 µl of 5% 
sodium thiosulfate. The solution was made up to 250 ml. The solution was freshly 
prepared prior to use and kept at room temperature. 
 
(e) Stopping solution (40 mM EDTA-Na2.2H2O) 
Stopping solution was made by adding 3.65 g of EDTA-Na2.2H2O into distilled water 
and was made up to 250 ml. The solution was kept at room temperature. 
 
(f) Preserving solution (30% (v/v) ethanol, 4.6% (v/v) 87% glycerol) 
In order to prepare the preserving solution, 75 ml of ethanol was mixed with 11.5 ml of 
glycerol. The solution was made up to 250 ml with distilled water, and kept at room 
temperature. 
 
 
 
 
 
 
 
  
APPENDIX B: RAW DATA 
 
Table 1 Antihypertensive assay of P. pulmonarius mycelial aqueous extract 
Sample 
Conc. 
(µg/ml) 
% of ACE 
inhibition 
Min of ACE inhibitory (%) ± 
S.E.M. 
P
. 
p
u
lm
o
n
a
ri
u
s 
m
y
ce
li
a 
cr
u
d
e 
ex
tr
ac
t 
3000 
73.7 
73.4  ±  0.70 72.6 
73.9 
2000 
61.4 
60.3  ±  1.1 59.2 
60.4 
1000 
50.4 
52.6  ±  2.8 55.8 
51.7 
500 
49.8 
47  ±  2.5 45.6 
45.5 
200 
33.8 
36.6  ±  3.9 34.95 
40.96 
BLANK 1   
  
1.486 ± 0.03 
B1-B2= 1.416 
BLANK 2 0.07 ± 0.00 
S.E.M = Standard error of means for triplicate values (n=3). 
 
 
 
 
 
 
  
Table 2 Antihypertensive assay of P. pulmonarius whole broth crude extract 
Sample Conc. (µg/ml) 
% of ACE 
inhibition 
Min of ACE inhibitory (%) ± 
S.E.M. 
P
. 
sa
jo
r-
ca
ju
 m
y
ce
li
a 
b
ro
th
 c
ru
d
e 
ex
tr
ac
t 
3000 
72 
70 ± 1.9 69.6 
68.2 
2000 
67.9 
66.4  ± 1.4 66.1 
65.1 
1000 
39.2 
41.6  ± 3.5 40 
45.7 
500 
31.4 
31.6  ± 0.6 
 32.3 
31.2 
200 
16.3 
15  ± 1.1 14.8 
14.1 
BLANK 1   
  
1.486 ± 0.03 
B1-B2= 1.416 
BLANK 2 0.07 ± 0.00 
S.E.M = Standard error of means for triplicate values (n=3). 
 
 
 
 
 
 
 
 
  
Table 3 Antihypertensive assay of P. pulmonarius mycelial protein fractions 
Fraction % of ACE inhibition Min of ACE inhibitory (%) ± S.E.M. 
F10 
39.4 
39.5 ± 3.60 43.2 
36 
F20 
43 
42.9 ± 0.70 42.2 
43.6 
F30 
37.6 
37.5 ± 3.20 34.2 
40.6 
F40 
60.9 
61.2 ± 2.36 63.7 
59 
F50 
40.7 
38.6 ± 2.67 39.5 
35.6 
F60 
48 
48.1 ± 1.55 49.7 
46.6 
F70 
43.5 
42.3 ± 1.55 40.5 
42.7 
F80 
35.7 
32.5 ± 3.10 32.3 
29.5 
F90 
28.8 
31.2 ± 2.08 32.4 
32.4 
F100 
35.9 
33.1 ± 2.71 30.5 
32.8 
BLANK 1 1.609 ± 0.02 
B1-B2= 1.55 
BLANK 2 0.059 ± 0.00 
S.E.M = Standard error of means for triplicate values (n=3). Samples were protein 
fractions from ammonium sulphate precipitation tested at 50 µg/ml. 
 
  
Figure 1 One-way ANOVA for antihypertensive activity of P. pulmonarius mycelial 
protein fractions, F10 to F100 (n=3). 
 
Table 4 IC50 value for antihypertensive assay of fraction F40 
Sample Conc. (µg/ml) 
% of ACE 
inhibition 
Min of ACE inhibitory (%) ± 
S.E.M. 
F40 
150 
90.6 
90.3 ± 0.23 90.2 
90.2 
80 
81.7 
81.9 ± 1.76 83.7 
80.2 
40 
65.6 
66.2 ± 1.31 65.3 
67.7 
20 
49.5 
48.1 ± 2.42 49.5 
45.3 
5 
33.8 
35.1 ± 3.39 32.6 
38.98 
BLANK 1   
  
1.486 ± 0.03 
B1-B2= 1.416 
BLANK 2 0.07 ± 0.00 
S.E.M = Standard error of means for triplicate values (n=3). 
 
 
One-way ANOVA: % inhibition versus sample  
Source  DF       SS      MS      F      P 
sample   9  2142.99  238.11  38.07  0.000 
Error   20   125.09    6.25 
Total   29  2268.08 
S = 2.501   R-Sq = 94.48%   R-Sq(adj) = 92.00% 
                         Individual 95% CIs For Mean Based on 
                         Pooled StDev 
Level  N    Mean  StDev  --+---------+---------+---------+------- 
 10    3  39.533  3.602           (--*--) 
 20    3  42.933  0.702              (--*--) 
 30    3  37.467  3.202        (--*--) 
 40    3  61.200  2.364                                (--*--) 
 50    3  38.600  2.666          (--*--) 
 60    3  48.100  1.552                   (--*--) 
 70    3  42.233  1.553             (--*--) 
 80    3  32.500  3.105   (---*--) 
 90    3  31.200  2.078  (--*--) 
100    3  33.067  2.710    (--*--) 
                         --+---------+---------+---------+------- 
                          30        40        50        60 
Pooled StDev = 2.501 
 Table 5 Antihypertensive assay of the RP-HPLC fractions 
Fraction % of ACE inhibition Min of ACE inhibitory (%) ± S.E.M. 
P1 
21.1 
19.6 ± 2.12 
18.1 
P2 
32.4 
30.3 ± 2.97 
28.2 
P3 
33.9 
30.8 ± 4.38 
27.7 
P4 
43.5 
44.7 ± 1.63 
45.8 
P5 
30.7 
33.1 ± 3.32 
35.4 
P6 
53.2 
57.7 ± 6.29 62.1 
P7 
37 
32.3 ± 6.65 
27.6 
P8 
31.3 
28.6 ± 3.75 
26 
BLANK 1 1.301 
B1-B2= 1.224 
BLANK 2 0.077 
S.E.M = Standard error of means for duplicate values (n=2). The assay was performed 
at the concentration of 15 µg/ml protein. 
 
Figure 2 One-way ANOVA for antihypertensive activity of RP-HPLC fractions P1 to 
P8 (n=2). 
 
 
One-way ANOVA: % INHIBITION versus SAMPLE  
Source  DF      SS     MS      F      P 
SAMPLE   7  1866.7  266.7  14.81  0.001 
Error    8   144.1   18.0 
Total   15  2010.7 
S = 4.244   R-Sq = 92.84%   R-Sq(adj) = 86.57% 
                         Individual 95% CIs For Mean Based on 
                         Pooled StDev 
Level  N    Mean  StDev  --+---------+---------+---------+------- 
P1     2  19.600  2.121  (----*----) 
P2     2  30.300  2.970          (---*----) 
P3     2  30.800  4.384          (----*---) 
P4     2  44.650  1.626                   (----*---) 
P5     2  33.050  3.323           (----*----) 
P6     2  57.650  6.293                            (---*----) 
P7     2  32.300  6.647           (----*---) 
P8     2  28.650  3.748        (----*----) 
                         --+---------+---------+---------+------- 
                          15        30        45        60 
Pooled StDev = 4.244 
 Table 6 IC50 value for antihypertensive assay of RP-HPLC fraction P6 
Sample Conc. (µg/ml) 
% of ACE 
inhibition 
Min of ACE inhibitory (%) ± 
S.E.M. 
 
150 
97.5 
96.8 ± 0.62 96.6 
96.3 
80 
92.9 
93.5 ± 1.37 92.6 
95.1 
60 
87.8 
87.9 ± 0.17 88.1 
87.8 
40 
83.5 
82.4 ± 1.10 81.3 
82.5 
20 
69.2 
65.9 ± 2.86 64.2 
64.3 
5 
33.9 
30.1 ± 3.27 28.5 
28 
BLANK 1   
  
1.486 ± 0.03 
B1-B2= 1.416 
BLANK 2 0.07 ± 0.00 
S.E.M = Standard error of means for triplicate values (n=3).  
 
 Table 7.1 Protein identification by LC-MS/MS (Database NCBI-P. ostreatus) 
Accession Description Score Coverage 
# 
Proteins 
# Unique 
Peptides 
MW 
[kDa] 
4512252 manganese peroxidase 6.99 4.83 3 1 36.9 
13811419 DNA polymerase 3.75 1.91 1 2 116.8 
158251728 DNA-directed RNA polymerase 3.05 1.16 1 2 141.4 
354992137 
RNA polymerase II second  
largest subunit 
2.42 4.37 1 1 77.5 
270056459 putative ribosomal protein 2.24 4.03 1 2 116.8 
 
Table 7.2 Protein identification by LC-MS/MS (Database NCBI & SwissProt-Fungi) 
Accession Description Score Coverage 
# 
Proteins 
# Unique 
Peptides 
# 
Peptides 
# PSMs # AAs 
MW 
[kDa] 
74582443 
RecName: Full=Nucleoporin nup211; AltName: 
Full=Nuclear pore protein nup211 
7.41 1.96 1 2 2 3 1837 211.3 
406862336 
3-isopropylmalate dehydratase [Marssonina 
brunnea f. sp. 'multigermtubi' MB_m1] 
20.79 2.07 106 2 2 8 774 84.6 
402076267 
hypothetical protein GGTG_10944 
[Gaeumannomyces graminis var. tritici R3-111a-
1] 
9.45 2.39 1 2 2 3 1295 139.7 
401623462 phr1p [Saccharomyces arboricola H-6] 5.52 5.66 11 2 2 2 565 66.2 
149387660 
hypothetical protein PICST_36839 
[Scheffersomyces stipitis CBS 6054] 
5.30 2.84 1 2 2 2 1761 202.2 
351638400 
D-lactate dehydrogenase [Magnaporthe oryzae 
70-15] 
4.59 5.22 2 2 2 2 575 61.6 
 384489611 
hypothetical protein RO3G_05538 [Rhizopus 
delemar RA 99-880] 
7.13 3.54 2 2 2 3 961 108.8 
380093319 
putative SPO11 protein [Sordaria macrospora k-
hell] 
5.20 15.36 2 2 2 2 384 42.8 
1246898 SAH [Kluyveromyces lactis] 67.38 2.47 1 2 2 18 608 69.2 
119400279 
ubiquitination network signaling protein, putative 
[Aspergillus clavatus NRRL 1] 
2.96 2.46 1 1 1 1 1018 109.6 
325529975 
RecName: Full=Phosphatidylethanolamine N-
methyltransferase; Short=PEAMT 
4.81 1.36 1 1 1 2 953 108.4 
74701377 
RecName: Full=COP9 signalosome complex 
subunit 5 
2.63 3.69 1 1 1 1 406 44.1 
68052138 
RecName: Full=DASH complex subunit DAM1; 
AltName: Full=Outer kinetochore protein DAM1 
2.12 4.89 1 1 1 1 307 34.9 
338818226 
RecName: Full=Genetic interactor of prohibitins 
3, mitochondrial; AltName: Full=Found in 
mitochondrial proteome protein 38; Flags: 
Precursor 
2.77 3.82 2 1 1 1 550 62.9 
152032522 
RecName: Full=ATP-dependent RNA helicase 
HAS1 
2.70 6.62 1 1 1 1 559 62.6 
17368407 
RecName: Full=Mating type protein A-1; 
Short=Mt A-1 
2.80 7.69 2 1 1 1 286 32.4 
74689911 
RecName: Full=Putative nicotinamide N-
methyltransferase 
2.04 4.76 1 1 1 1 273 30.7 
74582917 
RecName: Full=FACT complex subunit pob3; 
AltName: Full=Facilitates chromatin 
transcription complex subunit pob3 
17.66 3.13 1 1 1 6 512 57.4 
17380272 
RecName: Full=Probable proteasome subunit 
beta type-3 
2.51 10.29 1 1 1 1 204 22.6 
74609191 
RecName: Full=Mediator of RNA polymerase II 
transcription subunit 13; AltName: 
Full=Mediator complex subunit 13 
2.01 0.82 1 1 1 1 1345 151.1 
380354494 Num1 protein [Candida orthopsilosis] 2.07 0.52 1 1 1 1 2104 237.1 
 380353899 ABC transporter [Candida orthopsilosis] 2.66 1.19 1 1 1 1 1512 169.6 
380352465 Coq6 protein [Candida orthopsilosis] 2.04 2.89 1 1 1 1 485 53.9 
380351451 
integral peroxisomal membrane protein [Candida 
orthopsilosis Co 90-125] 
2.79 3.11 2 1 1 1 483 54.5 
380351275 Nsp1 protein [Candida orthopsilosis Co 90-125] 2.19 1.90 1 1 1 1 897 92.8 
380353894 Prp8 protein [Candida orthopsilosis] 3.12 0.75 2 1 1 1 2413 279.5 
408397860 
hypothetical protein FPSE_02873 [Fusarium 
pseudograminearum CS3096] 
2.84 1.35 1 1 1 1 1406 159.6 
408389150 PKS9 [Fusarium pseudograminearum CS3096] 2.80 0.61 1 1 1 1 2642 286.6 
407924038 
hypothetical protein MPH_05670 
[Macrophomina phaseolina MS6] 
2.74 16.48 1 1 1 1 182 20.1 
407922846 
hypothetical protein MPH_06904 
[Macrophomina phaseolina MS6] 
17.65 7.51 1 1 1 7 173 19.1 
407929337 
Borealin-like protein [Macrophomina phaseolina 
MS6] 
2.79 4.62 1 1 1 1 346 37.0 
407917147 
hypothetical protein MPH_12326 
[Macrophomina phaseolina MS6] 
3.03 1.40 1 1 1 1 2073 229.1 
407920196 
Sugar/inositol transporter [Macrophomina 
phaseolina MS6] 
2.78 5.45 1 1 1 1 459 52.1 
407917439 
hypothetical protein MPH_12130 
[Macrophomina phaseolina MS6] 
5.10 21.54 1 1 1 2 65 7.1 
358374223 
DEAD box RNA helicase HelA [Aspergillus 
kawachii IFO 4308] 
2.71 2.31 2 1 1 1 648 72.4 
358365480 
eukaryotic translation initiation factor 2c 
[Aspergillus kawachii IFO 4308] 
2.66 2.67 1 1 1 1 900 101.4 
406861659 
nuclear condensin complex subunit [Marssonina 
brunnea f. sp. 'multigermtubi' MB_m1] 
2.59 1.18 1 1 1 1 1103 122.2 
406867006 
hypothetical protein MBM_01997 [Marssonina 
brunnea f. sp. 'multigermtubi' MB_m1] 
3.06 1.55 1 1 1 2 1031 115.6 
406865168 
bromodomain protein [Marssonina brunnea f. sp. 
'multigermtubi' MB_m1] 
2.82 1.71 1 1 1 1 701 76.8 
406864243 WD repeat-containing protein 5B [Marssonina 2.52 3.08 1 1 1 1 519 57.0 
 brunnea f. sp. 'multigermtubi' MB_m1] 
406862792 
intracellular protein transport-like protein 
[Marssonina brunnea f. sp. 'multigermtubi' 
MB_m1] 
2.08 1.15 1 1 1 1 1219 135.0 
406859479 
hypothetical protein MBM_09300 [Marssonina 
brunnea f. sp. 'multigermtubi' MB_m1] 
3.63 3.62 1 1 1 2 276 28.1 
406859978 
collagen-like protein 2 [Marssonina brunnea f. 
sp. 'multigermtubi' MB_m1] 
2.16 5.76 1 1 1 1 295 33.6 
406699303 
Muconate cycloisomerase 1 [Trichosporon asahii 
var. asahii CBS 8904] 
2.78 3.37 1 1 1 1 683 72.8 
406699148 
hypothetical protein A1Q2_03342 [Trichosporon 
asahii var. asahii CBS 8904] 
2.00 3.72 1 1 1 1 296 30.8 
406699110 
cleavage and polyadenylation specific protein 
[Trichosporon asahii var. asahii CBS 8904] 
2.80 2.46 2 1 1 1 1339 146.6 
406605025 
hypothetical protein BN7_3110 
[Wickerhamomyces ciferrii] 
1.81 2.78 1 1 1 1 395 44.8 
406602147 
AFG3 family protein [Wickerhamomyces 
ciferrii] 
2.81 2.65 1 1 1 1 905 101.6 
405118307 
hypothetical protein CNAG_06718 
[Cryptococcus neoformans var. grubii H99] 
2.74 5.34 1 1 1 1 281 30.7 
403418291 predicted protein [Fibroporia radiculosa] 2.54 6.17 1 1 1 2 389 40.5 
403174635 
hypothetical protein PGTG_15003 [Puccinia 
graminis f. sp. tritici CRL 75-36-700-3] 
2.58 5.69 1 1 1 1 299 33.6 
402471066 
hypothetical protein EDEG_00911 [Edhazardia 
aedis USNM 41457] 
2.53 3.08 1 1 1 2 876 103.7 
402226202 
hypothetical protein DACRYDRAFT_103206 
[Dacryopinax sp. DJM-731 SS1] 
2.64 5.85 1 1 1 1 376 41.4 
402221924 
FAD/NADP-binding domain-containing protein, 
partial [Dacryopinax sp. DJM-731 SS1] 
2.04 3.08 1 1 1 1 390 43.6 
402216504 
ARM repeat-containing protein [Dacryopinax sp. 
DJM-731 SS1] 
2.66 1.86 1 1 1 1 1077 118.4 
402225957 hypothetical protein DACRYDRAFT_97650 2.27 1.56 1 1 1 1 1092 116.2 
 [Dacryopinax sp. DJM-731 SS1] 
372464244 
hypothetical protein KAFR_0E03720 
[Kazachstania africana CBS 2517] 
18.97 5.93 1 1 1 7 236 25.7 
402077888 
hypothetical protein GGTG_10084 
[Gaeumannomyces graminis var. tritici R3-111a-
1] 
2.11 2.92 1 1 1 1 343 36.3 
401884280 
hypothetical protein A1Q1_02581 [Trichosporon 
asahii var. asahii CBS 2479] 
2.35 1.18 2 1 1 1 936 102.6 
401880699 
protein kinase [Trichosporon asahii var. asahii 
CBS 2479] 
3.26 0.81 2 1 1 2 984 106.0 
401826144 
DNA-directed RNA polymerase subunit beta 
[Encephalitozoon hellem ATCC 50504] 
2.80 2.01 1 1 1 1 1396 156.9 
401827927 
glycyl-tRNA synthetase [Encephalitozoon 
hellem ATCC 50504] 
2.78 3.11 1 1 1 1 579 66.9 
401780129 
hypothetical protein NDAI_0G02910 
[Naumovozyma dairenensis CBS 421] 
2.08 0.83 1 1 1 1 967 110.9 
302308091 AER023Cp [Ashbya gossypii ATCC 10895] 3.15 2.02 1 1 1 1 1039 115.1 
188219314 
unnamed protein product [Podospora anserina S 
mat+] 
2.02 0.95 2 1 1 1 1051 119.8 
58270472 
hypothetical protein CNH02180 [Cryptococcus 
neoformans var. neoformans JEC21] 
7.96 0.49 1 1 1 3 2638 293.4 
58259255 
imidazoleglycerol phosphate synthase 
[Cryptococcus neoformans var. neoformans 
JEC21] 
2.51 3.39 1 1 1 1 619 66.4 
401626680 YBL095W [Saccharomyces arboricola H-6] 2.70 6.67 1 1 1 1 270 30.3 
401623854 tcb2p [Saccharomyces arboricola H-6] 3.03 1.44 1 1 1 1 1179 132.3 
400602476 
hypothetical protein BBA_00947 [Beauveria 
bassiana ARSEF 2860] 
2.50 14.29 1 1 1 1 168 18.5 
 
400598811 
PP-loop family protein [Beauveria bassiana 
ARSEF 2860] 
2.59 2.89 1 1 1 1 658 75.3 
400593204 
hybrid PKS-NRPS protein [Beauveria bassiana 
ARSEF 2860] 
2.85 0.55 1 1 1 1 4016 441.0 
 350297019 
hypothetical protein NEUTE2DRAFT_54039 
[Neurospora tetrasperma FGSC 2509] 
3.06 35.94 1 1 1 1 64 7.1 
378733582 
prostaglandin-endoperoxide synthase, variant 
[Exophiala dermatitidis NIH/UT8656] 
2.84 1.28 1 1 1 1 1174 132.5 
367006661 
mitochondrial 54S ribosomal protein YmL25 
[Tetrapisispora phaffii CBS 4417] 
2.00 7.64 1 1 1 1 157 18.6 
387593570 
hypothetical protein NEQG_01284 [Nematocida 
parisii ERTm3] 
1.53 5.95 1 1 1 1 168 19.6 
356891207 
hypothetical protein Ecym_6378 [Eremothecium 
cymbalariae DBVPG#7215] 
23.63 1.01 1 1 1 8 1589 183.4 
342320721 
Proteophosphoglycan ppg4 [Rhodotorula glutinis 
ATCC 204091] 
2.12 0.88 1 1 1 1 1471 153.7 
342319919 
Pre-mRNA-processing ATP-dependent RNA 
helicase PRP5 [Rhodotorula glutinis ATCC 
204091] 
2.01 1.43 1 1 1 1 1534 168.1 
356890435 
hypothetical protein Ecym_5213 [Eremothecium 
cymbalariae DBVPG#7215] 
2.61 5.53 1 1 1 1 416 47.4 
336375288 
hypothetical protein SERLA73DRAFT_69472 
[Serpula lacrymans var. lacrymans S7.3] 
2.21 7.09 1 1 1 1 141 16.2 
311329978 
hypothetical protein PTT_07749 [Pyrenophora 
teres f. teres 0-1] 
28.75 3.10 2 1 1 10 549 60.5 
398407441 
hypothetical protein MYCGRDRAFT_20718, 
partial [Zymoseptoria tritici IPO323] 
2.51 1.79 1 1 1 1 892 97.8 
398397549 cellobiohydrolase [Zymoseptoria tritici IPO323] 2.51 3.15 1 1 1 1 444 46.4 
398396400 
hypothetical protein MYCGRDRAFT_19839, 
partial [Zymoseptoria tritici IPO323] 
2.73 1.31 1 1 1 1 1839 204.5 
341038467 
xanthine dehydrogenase-like protein 
[Chaetomium thermophilum var. thermophilum 
DSM 1495] 
2.18 0.71 1 1 1 1 1406 154.5 
340959936 
KH RNA-binding domain-containing protein 
[Chaetomium thermophilum var. thermophilum 
DSM 1495] 
2.78 1.83 1 1 1 1 983 109.7 
 340960865 
putative pyridoxal phosphate binding protein 
[Chaetomium thermophilum var. thermophilum 
DSM 1495] 
2.67 3.84 1 1 1 1 521 57.9 
340960631 
hypothetical protein CTHT_0036820 
[Chaetomium thermophilum var. thermophilum 
DSM 1495] 
2.39 1.17 1 1 1 1 1023 115.6 
340959195 
palmitoyltransferase-like protein [Chaetomium 
thermophilum var. thermophilum DSM 1495] 
2.76 3.37 1 1 1 1 742 82.9 
340939314 
ubiquitin carboxyl-terminal hydrolase-like 
protein [Chaetomium thermophilum var. 
thermophilum DSM 1495] 
2.52 1.49 1 1 1 1 1008 111.6 
340923665 
putative mitochondrial large ribosomal RNA 
protein [Chaetomium thermophilum var. 
thermophilum DSM 1495] 
2.70 5.96 1 1 1 1 638 70.3 
328857828 
hypothetical protein MELLADRAFT_63029 
[Melampsora larici-populina 98AG31] 
36.35 6.88 1 1 1 13 218 24.3 
328850965 
family 3 glycosyltransferase [Melampsora larici-
populina 98AG31] 
2.64 3.70 1 1 1 1 730 82.5 
328850574 
hypothetical protein MELLADRAFT_112479 
[Melampsora larici-populina 98AG31] 
2.13 1.83 3 1 1 1 602 67.1 
328849478 
hypothetical protein MELLADRAFT_113351 
[Melampsora larici-populina 98AG31] 
2.61 4.64 1 1 1 1 345 39.1 
303303007 
leucyl aminopeptidase [Encephalitozoon 
intestinalis ATCC 50506] 
2.56 2.45 1 1 1 1 489 52.8 
303302660 
hypothetical protein Eint_090230 
[Encephalitozoon intestinalis ATCC 50506] 
4.69 4.41 1 1 1 2 272 31.6 
303302623 
Willebrand factor type A domain-containing 
AAA ATPase [Encephalitozoon intestinalis 
ATCC 50506] 
2.62 0.67 1 1 1 1 2818 324.7 
347010253 
hypothetical protein MYCTH_2304281 
[Myceliophthora thermophila ATCC 42464] 
2.85 1.17 1 1 1 1 1792 196.5 
347006219 
amidohydrolase-like protein [Myceliophthora 
thermophila ATCC 42464] 
2.57 4.83 1 1 1 1 580 61.6 
 346325503 
isovaleryl-CoA dehydrogenase IvdA, putative 
[Cordyceps militaris CM01] 
2.52 7.32 1 1 1 1 396 42.5 
346322878 
hypothetical protein CCM_03849 [Cordyceps 
militaris CM01] 
2.91 3.97 1 1 1 1 504 56.5 
346319278 
ribosomal RNA-processing protein 12 
[Cordyceps militaris CM01] 
3.21 1.27 2 1 1 1 1261 137.7 
347014196 
hypothetical protein MYCTH_2312075 
[Myceliophthora thermophila ATCC 42464] 
2.59 1.37 1 1 1 1 1754 191.3 
346318636 
hypothetical protein CCM_08281 [Cordyceps 
militaris CM01] 
2.75 4.01 1 1 1 1 424 47.4 
328773405 
hypothetical protein BATDEDRAFT_15601 
[Batrachochytrium dendrobatidis JAM81] 
2.23 3.10 1 1 1 1 548 58.6 
326474976 
hypothetical protein TESG_06349 [Trichophyton 
tonsurans CBS 112818] 
2.61 4.22 1 1 1 1 379 41.4 
327350627 
NAD(P) transhydrogenase [Ajellomyces 
dermatitidis ATCC 18188] 
16.68 1.31 9 1 1 6 1067 111.8 
326466042 
RNA polymerase II mediator complex subunit 
Nut1 [Trichophyton rubrum CBS 118892] 
3.07 1.97 1 1 1 1 1064 117.9 
322708927 
hypothetical protein MAA_04281 [Metarhizium 
anisopliae ARSEF 23] 
2.23 1.20 1 1 1 1 1003 105.8 
322708838 
Fungal specific transcription factor, putative 
[Metarhizium anisopliae ARSEF 23] 
2.57 2.52 1 1 1 1 715 81.1 
322700132 
mitochondrial cytochrome b2, putative 
[Metarhizium acridum CQMa 102] 
2.11 3.11 1 1 1 1 483 52.7 
322699933 
serine/threonine-protein kinase prp4 
[Metarhizium acridum CQMa 102] 
2.59 2.26 1 1 1 1 796 89.5 
322703396 
chitin binding protein [Metarhizium anisopliae 
ARSEF 23] 
2.11 4.11 1 1 1 1 365 41.3 
322699684 
hypothetical protein MAC_02607 [Metarhizium 
acridum CQMa 102] 
2.80 0.52 1 1 1 1 3442 359.6 
322693163 
UDP-glucose 4-epimerase, putative 
[Metarhizium acridum CQMa 102] 
2.15 4.04 1 1 1 1 371 40.5 
 320591518 
er glycosyl hydrolase [Grosmannia clavigera 
kw1407] 
2.88 2.23 1 1 1 1 1120 122.5 
320591362 
FAD-binding domain containing protein 
[Grosmannia clavigera kw1407] 
3.07 4.17 1 1 1 1 672 71.6 
320589851 
ubiquitin specific peptidase y chromosome 
[Grosmannia clavigera kw1407] 
2.76 3.61 1 1 1 1 665 73.8 
320589512 
inositol kinase kinase [Grosmannia clavigera 
kw1407] 
2.63 0.57 1 1 1 1 2089 231.9 
320587198 
c6 zinc finger domain containing protein 
[Grosmannia clavigera kw1407] 
3.61 4.99 1 1 1 1 601 67.1 
310800066 
acetyltransferase [Glomerella graminicola 
M1.001] 
2.68 6.50 1 1 1 1 369 39.0 
310799802 
cytochrome P450 [Glomerella graminicola 
M1.001] 
2.13 2.12 1 1 1 1 518 59.0 
310798679 
hypothetical protein GLRG_08851 [Glomerella 
graminicola M1.001] 
2.52 7.59 1 1 1 1 395 46.6 
310796707 
TBC domain-containing protein [Glomerella 
graminicola M1.001] 
2.76 2.06 1 1 1 1 924 102.4 
310796003 
hypothetical protein GLRG_06608 [Glomerella 
graminicola M1.001] 
2.35 3.21 1 1 1 1 405 45.6 
310793340 
hypothetical protein GLRG_03945 [Glomerella 
graminicola M1.001] 
6.48 1.53 1 1 1 3 1890 206.9 
310790676 
bZIP transcription factor [Glomerella 
graminicola M1.001] 
2.13 1.81 2 1 1 1 609 67.5 
310793983 
hypothetical protein GLRG_04588 [Glomerella 
graminicola M1.001] 
5.94 2.63 1 1 1 2 760 82.7 
310793445 exonuclease [Glomerella graminicola M1.001] 2.63 3.58 1 1 1 1 699 77.1 
310790185 
TfdA family Taurine catabolism dioxygenase 
TauD [Glomerella graminicola M1.001] 
2.79 4.11 1 1 1 1 414 46.2 
396499553 
hypothetical protein LEMA_P008110.1 
[Leptosphaeria maculans JN3] 
2.19 2.04 1 1 1 1 734 80.6 
396480333 predicted protein [Leptosphaeria maculans JN3] 3.11 3.07 1 1 1 1 748 82.2 
 396478770 
hypothetical protein LEMA_P102650.1 
[Leptosphaeria maculans JN3] 
2.65 2.20 1 1 1 1 998 106.5 
396462504 
similar to vacuolar protein sorting protein 
(VPS11) [Leptosphaeria maculans JN3] 
2.86 1.74 1 1 1 1 978 109.1 
396483807 
similar to VanZ domain protein [Leptosphaeria 
maculans JN3] 
2.95 11.00 1 1 1 1 200 22.4 
396480355 
similar to 
gi|121919568|sp|Q0U3A4.1|SET9_PHANO 
RecName: Full=Histone-lysine N-
methyltransferase SET9; AltName: Full=SET 
domain protein 9 [Leptosphaeria maculans JN3] 
2.31 1.64 1 1 1 1 670 77.1 
396479463 
similar to HEAT repeat protein [Leptosphaeria 
maculans JN3] 
3.01 1.61 1 1 1 1 1059 116.9 
396459675 
similar to transcriptional corepressor of histone 
genes (Hir3) [Leptosphaeria maculans JN3] 
4.14 0.54 1 1 1 2 2054 229.8 
344233939 
hypothetical protein CANTEDRAFT_96903 
[Candida tenuis ATCC 10573] 
2.06 2.03 2 1 1 1 541 60.6 
336379807 
hypothetical protein SERLADRAFT_452101 
[Serpula lacrymans var. lacrymans S7.9] 
4.62 1.00 7 1 1 2 1103 127.0 
300110818 
hypothetical protein SCHCODRAFT_231239 
[Schizophyllum commune H4-8] 
2.89 2.99 1 1 1 1 602 68.6 
300109529 
cAMP-dependent protein kinase A catalytic 
subunit [Schizophyllum commune H4-8] 
2.02 2.08 1 1 1 1 432 49.5 
300110469 
EXP1-like protein [Schizophyllum commune 
H4-8] 
2.54 3.23 1 1 1 1 526 58.9 
300108223 
hypothetical protein SCHCODRAFT_107087, 
partial [Schizophyllum commune H4-8] 
2.82 1.21 1 1 1 1 1072 120.7 
238845953 
branched-chain amino acid aminotransferase 
[Arthroderma otae CBS 113480] 
2.71 8.54 1 1 1 1 363 39.4 
238845915 
conserved hypothetical protein [Arthroderma 
otae CBS 113480] 
5.32 2.62 1 1 1 2 1146 128.7 
238840370 carbapenem antibiotics biosynthesis protein carD 2.27 2.90 1 1 1 1 483 53.0 
 [Arthroderma otae CBS 113480] 
238843813 
fibronectin type III domain-containing protein 
[Arthroderma otae CBS 113480] 
8.12 1.97 1 1 1 3 661 72.7 
238841621 
predicted protein [Arthroderma otae CBS 
113480] 
2.75 2.35 1 1 1 1 638 73.7 
238839487 PIG-P [Arthroderma otae CBS 113480] 2.28 4.30 1 1 1 1 372 41.0 
346979415 nitrate transporter [Verticillium dahliae VdLs.17] 2.65 3.68 1 1 1 1 516 55.8 
346975189 
SNF7 family protein [Verticillium dahliae 
VdLs.17] 
3.02 5.56 2 1 1 1 342 36.9 
346973883 
NAP1-binding protein [Verticillium dahliae 
VdLs.17] 
2.16 3.97 1 1 1 1 453 49.4 
346979146 
Sec7 domain-containing protein [Verticillium 
dahliae VdLs.17] 
2.54 1.58 2 1 1 1 1453 158.3 
326483341 
hypothetical protein TEQG_06257 
[Trichophyton equinum CBS 127.97] 
2.10 1.87 6 1 1 1 803 87.0 
325091847 
conserved hypothetical protein [Ajellomyces 
capsulatus H88] 
5.12 5.82 1 1 2 2 739 84.1 
311338198 
leucine rich repeat protein [Arthroderma 
gypseum CBS 118893] 
1.51 1.16 1 1 1 1 517 58.4 
326481992 
hypothetical protein TEQG_05010 
[Trichophyton equinum CBS 127.97] 
2.62 6.27 1 1 1 1 367 40.8 
325091992 
eukaryotic translation initiation factor 3 
[Ajellomyces capsulatus H88] 
2.16 1.50 3 1 1 1 868 96.9 
325090136 
conserved hypothetical protein [Ajellomyces 
capsulatus H88] 
2.80 2.84 3 1 1 1 811 90.1 
325087970 predicted protein [Ajellomyces capsulatus H88] 3.70 3.75 2 1 1 1 480 52.5 
311344619 
calcium-transporting ATPase 3 [Arthroderma 
gypseum CBS 118893] 
5.19 1.14 1 1 1 2 1049 114.6 
261360628 
homogentisate 1,2-dioxygenase [Verticillium 
albo-atrum VaMs.102] 
2.17 6.83 2 1 1 1 278 30.5 
261358560 
predicted protein [Verticillium albo-atrum 
VaMs.102] 
2.54 13.01 2 1 1 1 146 16.1 
 261361269 
conserved hypothetical protein [Verticillium 
albo-atrum VaMs.102] 
2.53 1.22 4 1 1 1 1392 155.4 
261361263 
phenolpthiocerol synthesis polyketide synthase 
ppsA [Verticillium albo-atrum VaMs.102] 
2.54 1.41 1 1 1 1 1911 208.1 
240277585 
conserved hypothetical protein [Ajellomyces 
capsulatus H143] 
2.12 6.16 2 1 1 1 276 31.5 
240281867 
hypothetical protein HCDG_00949 [Ajellomyces 
capsulatus H143] 
2.13 5.28 2 1 1 1 284 29.9 
239608866 
DNA methyltransferase Dim-2 [Ajellomyces 
dermatitidis ER-3] 
2.94 1.62 2 1 1 1 1233 138.3 
239586916 
PH domain-containing protein [Ajellomyces 
dermatitidis SLH14081] 
2.52 2.20 2 1 1 1 819 89.6 
226294680 
predicted protein [Paracoccidioides brasiliensis 
Pb18] 
2.54 6.32 1 1 1 1 380 42.7 
226292236 
conserved hypothetical protein [Paracoccidioides 
brasiliensis Pb18] 
2.76 1.08 2 1 1 1 1858 207.1 
226286518 
conserved hypothetical protein [Paracoccidioides 
sp. 'lutzii' Pb01] 
2.31 2.66 3 1 1 1 638 70.6 
226284292 
predicted protein [Paracoccidioides sp. 'lutzii' 
Pb01] 
2.16 6.86 1 1 1 1 175 19.4 
226279964 
dolichyl pyrophosphate Glc1Man9GlcNAc2 
alpha-1,3-glucosyltransferase [Paracoccidioides 
sp. 'lutzii' Pb01] 
5.64 2.70 1 1 1 2 518 58.9 
225681880 
predicted protein [Paracoccidioides brasiliensis 
Pb03] 
2.80 2.89 1 1 1 2 380 42.0 
225679360 
DUF500 and UBA/TS-N domain-containing 
protein [Paracoccidioides brasiliensis Pb03] 
2.71 3.32 2 1 1 1 662 72.5 
226295345 
nucleolar protein NOP58 [Paracoccidioides 
brasiliensis Pb18] 
3.16 2.39 2 1 1 1 880 95.2 
226291337 
conserved hypothetical protein [Paracoccidioides 
brasiliensis Pb18] 
2.83 0.78 3 1 1 1 2429 266.3 
226278925 predicted protein [Paracoccidioides sp. 'lutzii' 3.00 3.53 1 1 1 1 709 79.5 
 Pb01] 
225681973 
acetate kinase [Paracoccidioides brasiliensis 
Pb03] 
2.96 4.21 1 1 1 1 404 44.7 
225678183 
hypothetical protein PABG_06554 
[Paracoccidioides brasiliensis Pb03] 
2.57 4.45 2 1 1 1 292 31.6 
 
218713484 
squalene monooxygenase Erg1 [Talaromyces 
stipitatus ATCC 10500] 
2.53 3.46 1 1 1 1 491 53.7 
218722129 
SNF2 family helicase/ATPase PasG, putative 
[Talaromyces stipitatus ATCC 10500] 
2.06 1.68 1 1 1 1 895 100.7 
218720728 
TBC domain protein, putative [Talaromyces 
stipitatus ATCC 10500] 
2.11 2.33 1 1 1 1 729 82.0 
218720684 
uridine nucleosidase Urh1, putative 
[Talaromyces stipitatus ATCC 10500] 
2.68 5.14 1 1 1 1 370 39.5 
210072913 
DUF1212 domain membrane protein Prm10, 
putative [Penicillium marneffei ATCC 18224] 
3.35 1.78 1 1 1 1 897 97.9 
210071983 
exonuclease, putative [Penicillium marneffei 
ATCC 18224] 
2.21 4.21 1 1 1 1 309 34.9 
210064835 
calcineurin Ca2+-binding regulatory subunit 
CnaB [Penicillium marneffei ATCC 18224] 
2.52 8.85 1 1 1 1 192 21.7 
210073584 
conserved hypothetical protein [Penicillium 
marneffei ATCC 18224] 
2.61 3.53 1 1 1 1 566 63.9 
187980898 
conserved hypothetical protein [Pyrenophora 
tritici-repentis Pt-1C-BFP] 
2.67 14.45 1 1 1 1 173 19.1 
187978532 
inner centromere protein, ARK binding region 
protein [Pyrenophora tritici-repentis Pt-1C-BFP] 
15.83 1.11 2 1 1 6 1169 128.7 
187973903 
4-coumarate-CoA ligase 1 [Pyrenophora tritici-
repentis Pt-1C-BFP] 
5.91 3.70 1 1 1 2 648 72.3 
187972443 
pre-mRNA-processing ATP-dependent RNA 
helicase PRP5 [Pyrenophora tritici-repentis Pt-
1C-BFP] 
2.06 1.37 1 1 1 1 1165 129.3 
187985153 
HET domain containing protein [Pyrenophora 
tritici-repentis Pt-1C-BFP] 
2.52 2.83 1 1 1 1 637 68.5 
 187985045 
NAD dependent epimerase/dehydratase family 
protein [Pyrenophora tritici-repentis Pt-1C-BFP] 
2.74 2.92 2 1 1 1 377 43.0 
187976373 
external NADH-ubiquinone oxidoreductase 1, 
mitochondrial precursor [Pyrenophora tritici-
repentis Pt-1C-BFP] 
2.76 2.60 2 1 1 1 577 64.9 
187975847 
conserved hypothetical protein [Pyrenophora 
tritici-repentis Pt-1C-BFP] 
2.96 2.89 1 1 1 1 658 75.1 
187973308 
predicted protein [Pyrenophora tritici-repentis Pt-
1C-BFP] 
2.00 0.56 1 1 1 1 2856 304.6 
164651506 predicted protein [Laccaria bicolor S238N-H82] 19.88 1.60 1 1 1 7 1002 114.1 
164647316 
hypothetical protein LACBIDRAFT_313890 
[Laccaria bicolor S238N-H82] 
2.06 1.60 1 1 1 1 562 62.8 
256735415 
hypothetical protein NECHADRAFT_65808 
[Nectria haematococca mpVI 77-13-4] 
2.55 1.85 1 1 1 1 1192 133.6 
256734138 
predicted protein [Nectria haematococca mpVI 
77-13-4] 
2.93 1.23 1 1 1 1 2035 228.0 
238878703 
conserved hypothetical protein [Candida albicans 
WO-1] 
1.61 2.57 3 1 1 1 350 38.3 
159123282 
glucanase, putative [Aspergillus fumigatus 
A1163] 
2.57 5.11 1 1 1 1 470 55.1 
159129739 
conserved hypothetical protein [Aspergillus 
fumigatus A1163] 
3.22 1.79 1 1 1 1 839 94.4 
149387820 
predicted protein [Scheffersomyces stipitis CBS 
6054] 
2.81 1.23 1 1 1 1 1542 174.4 
149387477 
Suppressor of Sulfoxyde Ethionine resistance, 
partial [Scheffersomyces stipitis CBS 6054] 
2.29 1.99 1 1 1 1 552 63.6 
149387035 
Acetyl-CoA hydrolase (Acetyl-CoA deacylase) 
(Acetyl-CoA acylase) [Scheffersomyces stipitis 
CBS 6054] 
2.01 2.29 1 1 1 1 524 58.4 
149385347 
substrate-specific activator of APC-dependent 
proteolysis [Scheffersomyces stipitis CBS 6054] 
2.60 5.24 1 1 1 1 592 65.3 
395333478 hypothetical protein DICSQDRAFT_132050 2.43 1.87 1 1 1 1 588 66.1 
 [Dichomitus squalens LYAD-421 SS1] 
340522547 
calcium/calmodulin dependent protein kinase C 
[Trichoderma reesei QM6a] 
2.09 2.02 1 1 1 1 643 72.2 
340522073 predicted protein [Trichoderma reesei QM6a] 2.39 4.44 1 1 1 1 293 32.9 
237904372 
conserved hypothetical protein [Uncinocarpus 
reesii 1704] 
2.14 2.30 1 1 1 1 435 48.1 
237901318 predicted protein [Uncinocarpus reesii 1704] 4.82 2.85 1 1 1 2 526 59.0 
237905049 
hypothetical protein UREG_04296 
[Uncinocarpus reesii 1704] 
2.07 3.39 1 1 1 1 620 69.3 
237903455 
conserved hypothetical protein [Uncinocarpus 
reesii 1704] 
2.63 1.62 1 1 1 1 987 111.0 
154693593 
hypothetical protein SS1G_09197 [Sclerotinia 
sclerotiorum 1980 UF-70] 
2.21 8.74 1 1 1 1 183 19.6 
119415495 
RAD52 DNA repair protein RADC [Neosartorya 
fischeri NRRL 181] 
2.05 2.83 1 1 1 1 565 60.8 
119414334 
hypothetical protein NFIA_038470 [Neosartorya 
fischeri NRRL 181] 
2.71 6.83 1 1 1 1 322 36.6 
119412832 
sphingosine kinase (SphK), putative 
[Neosartorya fischeri NRRL 181] 
2.05 2.88 2 1 1 1 486 52.5 
119412820 
calcium channel subunit Cch1 [Neosartorya 
fischeri NRRL 181] 
2.14 0.42 1 1 1 1 2124 240.4 
119406408 
1,3-beta-glucanosyltransferase Gel2 
[Neosartorya fischeri NRRL 181] 
3.09 2.53 2 1 1 1 475 51.5 
119404353 
hypothetical protein ACLA_001400 [Aspergillus 
clavatus NRRL 1] 
10.53 5.19 1 1 1 4 231 25.8 
119413867 oxidoreductase [Neosartorya fischeri NRRL 181] 2.60 3.23 1 1 1 1 371 42.1 
119411525 
hypothetical protein NFIA_066320 [Neosartorya 
fischeri NRRL 181] 
3.01 10.17 1 1 1 1 236 26.9 
119407471 
C6 zinc finger domain protein [Neosartorya 
fischeri NRRL 181] 
2.80 12.99 1 1 1 1 177 20.4 
119398060 
ATP-dependent Clp protease, putative 
[Aspergillus clavatus NRRL 1] 
2.88 2.61 1 1 1 1 613 66.8 
 114196282 predicted protein [Aspergillus terreus NIH2624] 2.58 2.76 1 1 1 1 762 83.7 
114195918 predicted protein [Aspergillus terreus NIH2624] 2.23 3.22 1 1 1 1 435 48.8 
114193610 
conserved hypothetical protein [Aspergillus 
terreus NIH2624] 
2.69 3.54 1 1 1 1 622 70.5 
119397485 
conserved hypothetical protein [Aspergillus 
clavatus NRRL 1] 
2.65 3.12 1 1 1 1 577 65.4 
119397053 
cell wall proline rich protein, putative 
[Aspergillus clavatus NRRL 1] 
3.23 2.49 1 1 1 1 923 99.4 
114196349 
conserved hypothetical protein [Aspergillus 
terreus NIH2624] 
2.12 4.99 1 1 1 1 561 61.1 
114190723 
hypothetical protein ATEG_07039 [Aspergillus 
terreus NIH2624] 
5.68 2.98 1 1 1 2 1075 120.5 
114189921 predicted protein [Aspergillus terreus NIH2624] 2.12 0.73 1 1 1 1 2610 289.4 
86196845 
hypothetical protein MGCH7_ch7g890 
[Magnaporthe oryzae 70-15] 
1.64 2.89 2 1 1 1 381 43.1 
86196797 
hypothetical protein MGCH7_ch7g842 
[Magnaporthe oryzae 70-15] 
2.51 3.90 2 1 1 1 461 48.0 
86196352 
hypothetical protein MGCH7_ch7g397 
[Magnaporthe oryzae 70-15] 
2.16 1.03 2 1 1 1 1355 150.4 
 
393234120 
ARM repeat-containing protein [Auricularia 
delicata TFB-10046 SS5] 
2.60 2.20 1 1 1 1 908 102.4 
393229486 
subtilisin-like protein [Auricularia delicata TFB-
10046 SS5] 
7.53 1.12 1 1 1 3 893 95.3 
393221458 
hypothetical protein FOMMEDRAFT_152281 
[Fomitiporia mediterranea MF3/22] 
2.55 5.84 1 1 1 1 291 33.1 
393227786 
alpha/beta-hydrolase [Auricularia delicata TFB-
10046 SS5] 
2.82 4.65 1 1 1 1 344 38.3 
393227316 
hypothetical protein AURDEDRAFT_188867 
[Auricularia delicata TFB-10046 SS5] 
2.07 2.27 1 1 1 1 1012 113.2 
393223621 
hypothetical protein AURDEDRAFT_178529 
[Auricularia delicata TFB-10046 SS5] 
2.61 8.76 1 1 1 1 217 25.1 
393220819 HCP-like protein [Fomitiporia mediterranea 2.41 1.73 1 1 1 1 752 81.3 
 MF3/22] 
351642517 
hypothetical protein MGG_03268 [Magnaporthe 
oryzae 70-15] 
2.10 6.04 1 1 1 1 265 28.4 
351640818 
chromodomain helicase DNA binding protein 1 
[Magnaporthe oryzae 70-15] 
2.10 0.91 1 1 1 1 1649 185.1 
351647188 
inner centromere protein [Magnaporthe oryzae 
70-15] 
2.88 1.38 1 1 1 1 1378 150.2 
160705133 
hypothetical protein SNOG_15358 
[Phaeosphaeria nodorum SN15] 
2.18 6.52 1 1 1 1 322 35.9 
392864421 
hypothetical protein CIMG_12902 [Coccidioides 
immitis RS] 
2.23 6.95 1 1 1 1 187 20.6 
392597957 
hypothetical protein CONPUDRAFT_116467 
[Coniophora puteana RWD-64-598 SS2] 
2.64 6.52 1 1 1 1 368 43.2 
392595538 
cysteine desulfurase [Coniophora puteana RWD-
64-598 SS2] 
2.73 5.71 1 1 1 1 420 45.9 
392593698 
hypothetical protein CONPUDRAFT_52939 
[Coniophora puteana RWD-64-598 SS2] 
5.37 4.56 1 1 1 2 395 43.9 
392590520 
Aldo keto reductase [Coniophora puteana RWD-
64-598 SS2] 
4.77 4.75 1 1 1 2 337 37.3 
392587469 
hypothetical protein CONPUDRAFT_168555 
[Coniophora puteana RWD-64-598 SS2] 
2.05 2.20 1 1 1 1 500 56.6 
392586661 
NAD(P)-binding protein [Coniophora puteana 
RWD-64-598 SS2] 
2.28 4.91 1 1 1 1 285 31.2 
392597486 
mRNA transport regulator [Coniophora puteana 
RWD-64-598 SS2] 
2.16 1.39 1 1 1 1 932 102.9 
392592858 
tRNA modification GTPase TrmE [Coniophora 
puteana RWD-64-598 SS2] 
3.20 4.35 1 1 1 1 552 60.4 
392586797 
hypothetical protein CONPUDRAFT_146671 
[Coniophora puteana RWD-64-598 SS2] 
2.06 0.88 1 1 1 1 1247 138.5 
392578355 
hypothetical protein TREMEDRAFT_60409 
[Tremella mesenterica DSM 1558] 
2.55 10.25 1 1 1 1 283 30.2 
392567948 FAD/NAD-P-binding domain-containing protein 10.08 2.21 1 1 1 4 634 69.3 
 [Trametes versicolor FP-101664 SS1] 
392567838 
hypothetical protein TRAVEDRAFT_19515 
[Trametes versicolor FP-101664 SS1] 
2.66 3.56 1 1 1 1 477 51.7 
49655010 
DEHA2E00352p [Debaryomyces hansenii 
CBS767] 
2.73 31.11 1 1 1 1 90 10.4 
391869640 
multidrug resistance-associated protein 
[Aspergillus oryzae 3.042] 
2.51 1.66 2 1 1 1 1205 132.7 
391868192 solute carrier protein [Aspergillus oryzae 3.042] 2.96 5.92 1 1 1 1 355 38.6 
391870299 
inositol polyphosphate multikinase [Aspergillus 
oryzae 3.042] 
2.82 2.01 3 1 1 1 994 111.5 
391863518 putative transporter [Aspergillus oryzae 3.042] 2.74 3.00 3 1 1 1 534 58.9 
390597784 
hypothetical protein PUNSTDRAFT_126991 
[Punctularia strigosozonata HHB-11173 SS5] 
2.12 3.33 1 1 1 1 450 50.1 
390596503 
WD40 repeat-like protein [Punctularia 
strigosozonata HHB-11173 SS5] 
2.01 0.80 1 1 1 1 1756 192.5 
390595452 
glucoamylase [Punctularia strigosozonata HHB-
11173 SS5] 
2.55 3.79 1 1 1 1 581 61.2 
390594179 
RdRP-domain-containing protein [Punctularia 
strigosozonata HHB-11173 SS5] 
2.30 2.06 1 1 1 1 973 110.5 
390600647 
Metallo-dependent phosphatase [Punctularia 
strigosozonata HHB-11173 SS5] 
2.53 3.98 1 1 1 1 503 54.8 
390599308 
hypothetical protein PUNSTDRAFT_133889 
[Punctularia strigosozonata HHB-11173 SS5] 
2.78 2.97 1 1 1 1 1143 127.0 
389739375 
alpha/beta-hydrolase [Stereum hirsutum FP-
91666 SS1] 
2.04 1.82 1 1 1 1 1155 126.0 
389738766 
hypothetical protein STEHIDRAFT_163216 
[Stereum hirsutum FP-91666 SS1] 
2.74 17.50 1 1 1 1 120 12.5 
389749352 
ATP-dependent DNA helicase [Stereum 
hirsutum FP-91666 SS1] 
4.72 2.24 1 1 1 2 669 74.7 
389743707 
hypothetical protein STEHIDRAFT_122829 
[Stereum hirsutum FP-91666 SS1] 
2.51 1.64 1 1 1 1 1279 138.1 
388857684 uncharacterized protein [Ustilago hordei] 2.35 1.96 1 1 1 1 767 82.7 
 388856278 
related to RRP9-protein associated with the U3 
small nucleolar RNA [Ustilago hordei] 
2.70 2.71 1 1 1 1 702 75.7 
388858089 related to WD40 protein Ciao1 [Ustilago hordei] 2.70 3.50 1 1 1 1 457 49.4 
388858000 uncharacterized protein [Ustilago hordei] 2.61 3.14 1 1 1 1 573 66.0 
388856295 
related to cyclin dependent kinase C [Ustilago 
hordei] 
2.73 1.39 1 1 1 1 1148 123.6 
388583656 
hypothetical protein WALSEDRAFT_55860 
[Wallemia sebi CBS 633.66] 
8.86 2.00 1 1 1 3 649 72.9 
388582418 
SIR2-domain-containing protein [Wallemia sebi 
CBS 633.66] 
2.08 2.15 1 1 1 1 651 72.3 
388580829 
hypothetical protein WALSEDRAFT_60595 
[Wallemia sebi CBS 633.66] 
2.65 1.15 1 1 1 1 1222 139.7 
388583474 
NAD(P)-binding protein [Wallemia sebi CBS 
633.66] 
2.80 4.70 1 1 1 1 362 40.4 
388583340 kinase-like protein [Wallemia sebi CBS 633.66] 2.53 4.00 1 1 1 1 725 80.4 
388580234 
Dbl-like domain-containing protein [Wallemia 
sebi CBS 633.66] 
2.75 1.67 1 1 1 1 1260 144.0 
317460807 
conserved hypothetical protein [Cryptococcus 
gattii WM276] 
2.15 0.71 1 1 1 1 1826 199.9 
317460494 
Gamma-glutamyltranspeptidase 1 precursor, 
putative [Cryptococcus gattii WM276] 
4.80 2.56 1 1 1 2 741 79.8 
240134244 
vacuolar protein sorting-associated protein 21 
[Candida tropicalis MYA-3404] 
2.95 10.73 1 1 1 1 205 22.3 
240132724 
conserved hypothetical protein [Candida 
tropicalis MYA-3404] 
2.71 12.05 1 1 1 1 249 26.4 
220699788 
spindle pole body component, putative 
[Aspergillus flavus NRRL3357] 
2.55 3.43 2 1 1 1 903 97.5 
220699492 
conserved hypothetical protein [Aspergillus 
flavus NRRL3357] 
2.91 3.24 3 1 1 1 740 83.3 
212003447 
isoleucyl-tRNA synthetase 
[Schizosaccharomyces japonicus yFS275] 
4.32 1.33 1 1 1 2 981 111.4 
211999487 meiosis protein mei2 [Schizosaccharomyces 14.10 3.02 1 1 1 5 729 79.4 
 japonicus yFS275] 
190408541 
conserved hypothetical protein [Saccharomyces 
cerevisiae RM11-1a] 
2.32 6.30 4 1 1 1 349 38.2 
384498570 
hypothetical protein RO3G_13772 [Rhizopus 
delemar RA 99-880] 
2.59 1.45 1 1 1 1 1383 157.0 
238851525 
hypothetical protein CLUG_05116 [Clavispora 
lusitaniae ATCC 42720] 
2.52 6.85 1 1 1 1 219 25.5 
225561598 peroxin 11C [Ajellomyces capsulatus G186AR] 2.26 6.41 1 1 1 1 359 39.5 
225558752 
conserved hypothetical protein [Ajellomyces 
capsulatus G186AR] 
5.38 8.63 1 1 1 2 197 21.6 
150412647 
peptide methionine sulfoxide reductase msrA 
[Ajellomyces capsulatus NAm1] 
2.05 4.89 1 1 1 1 225 25.5 
146452879 
predicted protein [Lodderomyces elongisporus 
NRRL YB-4239] 
2.41 1.15 1 1 1 1 1304 149.7 
146451281 
hypothetical protein LELG_03716 
[Lodderomyces elongisporus NRRL YB-4239] 
2.68 3.11 1 1 1 1 578 66.5 
387514838 
hypothetical protein TBLA_0G03370 
[Tetrapisispora blattae CBS 6284] 
2.57 2.69 1 1 1 1 1039 119.0 
343771189 
hypothetical protein NDAI_0J02790 
[Naumovozyma dairenensis CBS 421] 
2.05 2.76 1 1 1 1 471 52.9 
342301567 
hypothetical protein NCAS_0C03470 
[Naumovozyma castellii CBS 4309] 
2.67 3.37 1 1 1 1 563 62.3 
199424882 YALI0A13233p [Yarrowia lipolytica CLIB122] 2.15 0.80 1 1 1 1 1372 142.0 
385305724 
spindle-like protein [Dekkera bruxellensis 
AWRI1499] 
2.74 5.94 1 1 1 1 320 36.5 
385302581 
hypothetical protein AWRI1499_3418 [Dekkera 
bruxellensis AWRI1499] 
2.59 5.40 1 1 1 1 315 35.5 
385301814 
hypothetical protein AWRI1499_4148 [Dekkera 
bruxellensis AWRI1499] 
2.79 11.64 1 1 1 1 146 16.7 
385301153 
actin-related protein [Dekkera bruxellensis 
AWRI1499] 
2.91 8.14 1 1 1 1 381 42.7 
385303582 atp-binding cassette sub-family f member 2 2.70 4.50 1 1 1 1 556 62.6 
 [Dekkera bruxellensis AWRI1499] 
385303251 
hypothetical protein AWRI1499_2764 [Dekkera 
bruxellensis AWRI1499] 
5.89 3.22 1 1 1 3 435 47.4 
49649804 YALI0E14234p [Yarrowia lipolytica CLIB122] 2.52 0.92 1 1 1 1 1637 181.1 
49647384 YALI0C06446p [Yarrowia lipolytica CLIB122] 2.11 2.77 1 1 1 1 541 59.8 
49644037 KLLA0E21055p [Kluyveromyces lactis] 3.13 13.03 1 1 1 1 261 25.7 
49641801 KLLA0C10505p [Kluyveromyces lactis] 2.69 3.78 1 1 1 1 582 64.3 
199425291 YALI0C16709p [Yarrowia lipolytica CLIB122] 2.29 0.95 1 1 1 1 1364 152.0 
49646473 YALI0B07513p [Yarrowia lipolytica CLIB122] 2.58 3.10 1 1 1 1 807 91.0 
49646362 YALI0B04466p [Yarrowia lipolytica CLIB122] 2.25 7.35 1 1 1 1 204 23.0 
49644282 KLLA0F01463p [Kluyveromyces lactis] 2.13 2.43 1 1 1 1 781 89.2 
49643658 KLLA0E12717p [Kluyveromyces lactis] 2.63 2.24 1 1 1 1 446 51.3 
380483371 
mRNA-capping enzyme subunit beta 
[Colletotrichum higginsianum] 
2.55 3.00 1 1 1 1 600 67.2 
380480593 
Pro-kumamolisin, partial [Colletotrichum 
higginsianum] 
3.48 3.25 1 1 1 1 615 66.9 
380493677 cytochrome P450 [Colletotrichum higginsianum] 2.69 4.16 1 1 1 1 529 59.3 
380491345 
nucleolar GTP-binding protein 1 [Colletotrichum 
higginsianum] 
2.56 2.74 1 1 1 1 658 75.3 
380487753 
F-box protein pof6 [Colletotrichum 
higginsianum] 
2.87 9.97 1 1 1 1 291 32.9 
380483501 
hypothetical protein CH063_02385 
[Colletotrichum higginsianum] 
7.32 2.55 1 1 1 3 549 62.5 
380473153 
hypothetical protein CH063_15178 
[Colletotrichum higginsianum] 
2.54 14.61 1 1 1 1 89 9.7 
380091455 
unnamed protein product [Sordaria macrospora 
k-hell] 
2.05 10.91 1 1 1 1 165 17.0 
202953213 
DEHA2F12100p [Debaryomyces hansenii 
CBS767] 
2.13 4.38 1 1 1 1 320 36.8 
238935857 
KLTH0F06182p [Lachancea thermotolerans 
CBS 6340] 
17.61 4.38 1 1 1 7 320 35.2 
378756463 hypothetical protein NERG_00127 [Nematocida 2.62 22.22 1 1 1 1 99 11.8 
 sp. 1 ERTm2] 
378754744 
hypothetical protein NERG_02176 [Nematocida 
sp. 1 ERTm2] 
21.91 1.03 1 1 2 8 2925 339.8 
378754490 
hypothetical protein NERG_02331 [Nematocida 
sp. 1 ERTm2] 
8.08 2.30 1 1 1 4 740 82.1 
378756376 
hypothetical protein NERG_00040 [Nematocida 
sp. 1 ERTm2] 
2.82 5.06 1 1 1 1 474 53.1 
358376728 
ankyrin repeat protein [Aspergillus kawachii IFO 
4308] 
2.86 1.82 3 1 1 1 713 81.1 
358368841 
cell polarity protein [Aspergillus kawachii IFO 
4308] 
2.90 1.97 1 1 1 1 915 101.4 
359384527 Piso0_000675 [Millerozyma farinosa CBS 7064] 34.12 1.33 1 1 1 13 903 102.9 
353242732 
hypothetical protein PIIN_08302 [Piriformospora 
indica DSM 11827] 
25.80 2.46 1 1 1 13 488 52.3 
353239774 
related to pyridoxine 4-dehydrogenase 
[Piriformospora indica DSM 11827] 
9.08 3.87 1 1 1 4 284 32.0 
353237027 
hypothetical protein PIIN_02868 [Piriformospora 
indica DSM 11827] 
2.01 2.78 1 1 1 1 324 34.7 
353235165 
probable SAC1-recessive suppressor of secretory 
defect [Piriformospora indica DSM 11827] 
5.45 1.97 1 1 1 2 661 75.1 
353242228 
hypothetical protein PIIN_07842 [Piriformospora 
indica DSM 11827] 
2.54 2.93 1 1 1 1 615 66.2 
353241116 
related to alpha-1,3-mannosyltransferase 
[Piriformospora indica DSM 11827] 
2.43 1.52 1 1 1 1 527 60.3 
353227370 
hypothetical protein PIIN_00525 [Piriformospora 
indica DSM 11827] 
2.72 2.51 1 1 1 1 1197 134.1 
372124511 Tsr1 [Penicillium citrinum] 2.87 11.27 6 1 1 1 204 22.7 
372121198 
RNA polymerase II largest subunit [Penicillium 
italicum] 
2.51 4.72 1 1 1 1 318 35.0 
284799168 
RNA polymerase II second largest subunit, 
partial [Saccharata proteae] 
2.57 3.85 1 1 1 1 390 44.0 
367017822 hypothetical protein TDEL_0H03390 2.46 4.44 1 1 1 1 383 44.6 
 [Torulaspora delbrueckii] 
367017944 
hypothetical protein TDEL_0H04000 
[Torulaspora delbrueckii] 
2.04 0.72 3 1 1 1 1665 186.2 
367011343 
hypothetical protein TDEL_0C00720 
[Torulaspora delbrueckii] 
2.97 2.03 1 1 1 2 1037 118.2 
367002516 
hypothetical protein TPHA_0F00720 
[Tetrapisispora phaffii CBS 4417] 
4.46 0.86 1 1 1 2 1283 148.0 
361127473 
hypothetical protein M7I_4740 [Glarea 
lozoyensis 74030] 
8.34 8.61 1 1 1 3 302 32.7 
361127404 
putative Phthiocerol synthesis polyketide 
synthase type I PpsC [Glarea lozoyensis 74030] 
2.02 0.75 1 1 1 1 2136 232.7 
361126897 
putative Oxidoreductase ucpA [Glarea lozoyensis 
74030] 
10.68 5.00 1 1 1 4 300 32.7 
361125628 
putative Glycerophosphodiester 
phosphodiesterase GDE1 [Glarea lozoyensis 
74030] 
2.53 1.71 2 1 1 1 997 110.4 
358377880 
hypothetical protein TRIVIDRAFT_211134 
[Trichoderma virens Gv29-8] 
2.82 2.95 1 1 1 1 576 63.1 
358057047 
hypothetical protein E5Q_03628 [Mixia 
osmundae IAM 14324] 
2.63 7.02 1 1 1 1 299 31.2 
358030862 
translation elongation factor 2, partial 
[Gonapodya sp. JEL183] 
40.82 2.68 1 1 1 14 597 66.5 
354544733 
hypothetical protein CPAR2_800100 [Candida 
parapsilosis] 
2.67 2.98 2 1 1 1 738 82.2 
325071333 
nonreducing polyketide synthase, partial 
[Talaromyces pinophilus] 
2.78 11.49 3 1 1 1 235 25.2 
350634963 
hypothetical protein ASPNIDRAFT_37334 
[Aspergillus niger ATCC 1015] 
2.60 4.21 2 1 1 1 570 63.5 
347841073 hypothetical protein [Botryotinia fuckeliana] 2.90 3.95 1 1 1 1 557 62.9 
347831388 
similar to PAP2 domain-containing protein 
[Botryotinia fuckeliana] 
2.09 7.54 1 1 1 1 305 34.3 
347829875 hypothetical protein [Botryotinia fuckeliana] 2.51 5.48 2 1 1 1 383 42.6 
 345567919 
hypothetical protein AOL_s00054g907 
[Arthrobotrys oligospora ATCC 24927] 
2.55 6.11 1 1 1 1 229 24.8 
345567135 
hypothetical protein AOL_s00076g422 
[Arthrobotrys oligospora ATCC 24927] 
2.81 3.70 1 1 1 1 432 49.0 
343428734 
related to long chain fatty alcohol oxidase 
[Sporisorium reilianum SRZ2] 
2.52 4.67 1 1 1 1 771 82.6 
343426524 
related to Glioma tumor suppressor candidate 
region gene 2 protein [Sporisorium reilianum 
SRZ2] 
2.81 3.33 1 1 1 1 451 50.4 
343425088 
probable gamma-glutamylcysteine synthetase 
[Sporisorium reilianum SRZ2] 
2.91 3.25 1 1 1 1 707 79.4 
342874503 
hypothetical protein FOXB_12957 [Fusarium 
oxysporum Fo5176] 
5.07 2.65 1 1 1 2 680 74.8 
328350784 
putative secreted protein [Komagataella pastoris 
CBS 7435] 
2.65 22.67 1 1 1 1 150 17.4 
328352264 
SWI5-dependent HO expression protein 4 
[Komagataella pastoris CBS 7435] 
2.00 1.92 1 1 1 1 729 82.9 
328351308 
Topoisomerase 1-associated factor 1 
[Komagataella pastoris CBS 7435] 
2.55 1.69 1 1 1 1 1185 136.0 
328351147 
Uncharacterized protein yetA [Komagataella 
pastoris CBS 7435] 
2.62 1.37 1 1 1 1 873 98.7 
328350103 
Transcription factor tau 138 kDa subunit 
[Komagataella pastoris CBS 7435] 
2.04 0.90 1 1 1 1 1225 139.5 
126212874 
NAD-dependent malate dehydrogenase 
[Scheffersomyces stipitis CBS 6054] 
3.24 7.12 1 1 1 1 337 35.9 
317144458 
tubulin-specific chaperone [Aspergillus oryzae 
RIB40] 
2.72 3.12 3 1 1 1 609 68.2 
317143045 
DNA repair protein (Rad57) [Aspergillus oryzae 
RIB40] 
2.81 3.67 2 1 1 1 600 65.1 
317137884 
hypothetical protein AOR_1_1938194 
[Aspergillus oryzae RIB40] 
2.52 3.14 1 1 1 1 477 52.2 
145250995 glutamate decarboxylase 1 [Aspergillus niger 2.73 3.34 2 1 1 1 509 57.7 
 CBS 513.88] 
145237550 
hypothetical protein ANI_1_420064 [Aspergillus 
niger CBS 513.88] 
11.13 2.86 1 1 1 4 560 61.0 
134055132 unnamed protein product [Aspergillus niger] 25.30 5.41 1 1 1 8 314 34.6 
323346802 Sla2p [Saccharomyces cerevisiae Lalvin QA23] 2.52 2.18 1 1 1 1 780 88.3 
323355226 
YFL042C-like protein [Saccharomyces 
cerevisiae VL3] 
2.21 2.41 11 1 1 1 582 66.3 
323347766 Mbr1p [Saccharomyces cerevisiae Lalvin QA23] 2.77 14.19 1 1 1 1 155 17.0 
323335977 Cla4p [Saccharomyces cerevisiae Vin13] 2.60 2.44 1 1 1 1 697 78.0 
317033144 
hypothetical protein ANI_1_2502094 
[Aspergillus niger CBS 513.88] 
2.79 6.40 3 1 1 2 297 31.4 
259481223 
TPA: alpha/beta hydrolase, putative 
(AFU_orthologue; AFUA_6G11570) 
[Aspergillus nidulans FGSC A4] 
2.81 4.04 2 1 1 1 545 60.6 
320581742 
Putative benzil reductase [Ogataea 
parapolymorpha DL-1] 
2.78 9.52 1 1 1 1 252 27.3 
320580900 
GABA-specific high-affinity permease [Ogataea 
parapolymorpha DL-1] 
2.87 2.74 1 1 1 1 584 63.3 
320580712 
heat shock transcription factor, putative [Ogataea 
parapolymorpha DL-1] 
2.50 4.22 1 1 1 1 474 53.2 
62632793 PRP8 protein precursor [Emericella nidulans] 2.69 4.85 3 1 1 1 618 69.4 
153917328 pro-pol protein [Lentinula edodes] 2.14 1.10 1 1 1 1 1274 146.4 
46135973 
hypothetical protein FG09502.1 [Gibberella zeae 
PH-1] 
2.01 2.24 2 1 1 1 402 44.3 
303309969 
SNF2 family N-terminal domain containing 
protein [Coccidioides posadasii C735 delta 
SOWgp] 
2.20 1.13 2 1 1 1 1061 120.0 
303320941 
outer membrane protein, OMP85 family protein 
[Coccidioides posadasii C735 delta SOWgp] 
2.65 2.71 3 1 1 1 516 56.0 
302664294 
CorA family metal ion transporter, putative 
[Trichophyton verrucosum HKI 0517] 
2.60 3.04 4 1 1 1 658 73.3 
302659557 conserved hypothetical protein [Trichophyton 5.96 4.68 6 1 1 2 278 32.4 
 verrucosum HKI 0517] 
302656199 
hypothetical protein TRV_06053 [Trichophyton 
verrucosum HKI 0517] 
2.55 3.46 2 1 1 1 405 44.7 
302662135 
hypothetical protein TRV_03149 [Trichophyton 
verrucosum HKI 0517] 
2.24 1.91 8 1 1 1 680 73.9 
302658633 
filamentation protein (Rhf1), putative 
[Trichophyton verrucosum HKI 0517] 
2.60 0.87 1 1 1 1 1733 191.8 
302500236 
hypothetical protein ARB_01620 [Arthroderma 
benhamiae CBS 112371] 
2.04 4.48 4 1 1 1 335 37.1 
302503871 
hypothetical protein ARB_08007 [Arthroderma 
benhamiae CBS 112371] 
2.06 1.30 4 1 1 1 770 86.3 
302497848 
hypothetical protein ARB_02820 [Arthroderma 
benhamiae CBS 112371] 
2.07 1.39 5 1 1 1 935 102.9 
50288073 hypothetical protein [Candida glabrata CBS 138] 2.58 2.27 1 1 1 1 883 100.2 
146422469 
hypothetical protein PGUG_00549 [Meyerozyma 
guilliermondii ATCC 6260] 
2.93 4.43 2 1 1 1 497 57.0 
146419574 
hypothetical protein PGUG_01419 [Meyerozyma 
guilliermondii ATCC 6260] 
2.81 1.75 2 1 1 1 1145 126.9 
299754782 
hypothetical protein CC1G_02771 [Coprinopsis 
cinerea okayama7#130] 
2.58 3.69 1 1 1 1 406 46.4 
299754218 
alginate lyase [Coprinopsis cinerea 
okayama7#130] 
2.06 5.73 1 1 1 1 506 52.7 
299753991 
DNA mismatch repair protein MSH3 
[Coprinopsis cinerea okayama7#130] 
2.84 1.28 1 1 1 1 1096 121.7 
299747178 GTPase [Coprinopsis cinerea okayama7#130] 2.20 1.24 1 1 1 1 1211 132.0 
299746509 
hypothetical protein CC1G_07524 [Coprinopsis 
cinerea okayama7#130] 
2.01 1.41 4 1 1 1 922 101.9 
170941313 
unnamed protein product [Podospora anserina S 
mat+] 
2.60 1.17 1 1 1 1 1363 148.5 
170940443 
unnamed protein product [Podospora anserina S 
mat+] 
2.60 8.64 1 1 1 1 405 44.7 
170937555 unnamed protein product [Podospora anserina S 2.97 8.71 1 1 1 1 264 29.5 
 mat+] 
25294143 Fum19p [Gibberella moniliformis] 2.42 1.01 1 1 1 1 1489 165.0 
29421288 kinesin [Gibberella moniliformis] 2.09 1.20 4 1 1 1 1087 120.8 
238941410 ZYRO0G12144p [Zygosaccharomyces rouxii] 2.55 3.95 1 1 1 1 456 47.8 
223643511 
pre-rRNA processing protein, putative [Candida 
dubliniensis CD36] 
2.05 3.37 1 1 1 1 326 36.7 
223641306 
fumarylacetoacetate (FAA) hydrolase, putative 
[Candida dubliniensis CD36] 
2.14 4.76 3 1 1 1 231 25.7 
223643592 
DNA topoisomerase 2, putative [Candida 
dubliniensis CD36] 
2.87 1.44 3 1 1 1 1461 165.3 
223642655 
carnitine acetyltransferase, putative [Candida 
dubliniensis CD36] 
2.95 1.35 1 1 1 1 887 100.9 
223641952 
quinone oxidoreductase, putative [Candida 
dubliniensis CD36] 
2.60 6.57 2 1 1 1 335 37.0 
223641634 
protein she4, putative [Candida dubliniensis 
CD36] 
2.53 3.10 1 1 1 1 775 88.5 
223640627 
(FAD-dependent) oxidoreductase, putative 
[Candida dubliniensis CD36] 
2.07 4.25 1 1 1 1 400 44.5 
270120970 
unnamed protein product [Penicillium 
chrysogenum] 
2.53 6.67 1 1 1 1 525 58.9 
269860857 
ABC-type multidrug transport system, ATPase 
and permease component [Enterocytozoon 
bieneusi H348] 
2.10 1.63 1 1 1 1 552 63.6 
269860302 
hypothetical protein EBI_26083 [Enterocytozoon 
bieneusi H348] 
2.42 6.72 1 1 1 1 119 14.3 
269860003 
hypothetical protein EBI_22774 [Enterocytozoon 
bieneusi H348] 
2.63 12.28 1 1 1 1 171 19.9 
255955041 
Pc21g12430 [Penicillium chrysogenum 
Wisconsin 54-1255] 
2.01 2.12 1 1 1 1 709 79.4 
255951838 
Pc24g00250 [Penicillium chrysogenum 
Wisconsin 54-1255] 
2.88 5.93 2 1 1 1 236 25.9 
255934802 Pc12g16300 [Penicillium chrysogenum 2.53 9.56 1 1 1 1 272 28.9 
 Wisconsin 54-1255] 
254567069 
DNA repair protein RAD50 [Komagataella 
pastoris GS115] 
5.56 1.36 2 1 1 2 1323 152.0 
254566629 
hypothetical protein [Komagataella pastoris 
GS115] 
2.52 14.29 2 1 1 1 189 21.5 
68488704 
hypothetical LPF family protein 1 [Candida 
albicans SC5314] 
2.53 15.84 1 1 1 1 101 12.0 
169806415 
protein with WD40 repeat [Enterocytozoon 
bieneusi H348] 
2.82 2.52 1 1 1 1 834 96.3 
164655417 
hypothetical protein MGL_4005 [Malassezia 
globosa CBS 7966] 
2.80 1.76 1 1 1 1 1248 138.7 
154288987 
ubiquitin carboxyl-terminal hydrolase 
[Botryotinia fuckeliana B05.10] 
2.01 4.84 1 1 1 1 310 34.0 
85099370 
hypothetical protein NCU01260 [Neurospora 
crassa OR74A] 
2.52 0.61 1 1 1 1 2307 257.2 
170674512 hypothetical secreted protein [Epichloe festucae] 8.79 4.71 1 1 1 3 531 59.8 
134116156 
hypothetical protein CNBJ0280 [Cryptococcus 
neoformans var. neoformans B-3501A] 
2.67 7.63 1 1 1 1 367 41.3 
154316360 predicted protein [Botryotinia fuckeliana B05.10] 2.09 4.46 2 1 1 1 404 42.1 
154293357 
hypothetical protein BC1G_13701 [Botryotinia 
fuckeliana B05.10] 
2.61 3.83 2 1 1 1 575 64.9 
599968 Ssm4p [Saccharomyces cerevisiae] 2.11 2.81 12 1 1 1 392 44.9 
20086301 
subunit of RNA polymerase II transcription 
factor TFIIH [Candida glabrata] 
2.85 7.69 2 1 1 1 234 27.9 
85690967 
hypothetical protein ECU01_0490 
[Encephalitozoon cuniculi GB-M1] 
2.67 7.20 1 1 1 1 236 26.4 
71003686 
hypothetical protein UM00362.1 [Ustilago 
maydis 521] 
2.64 4.97 1 1 1 1 463 51.6 
32693853 ED24 elicitor protein [Cercospora zeae-maydis] 2.58 4.80 1 1 1 1 271 29.7 
2130983 
acetyl CoA carboxylase [Schizosaccharomyces 
pombe] 
2.08 11.88 1 1 1 1 101 11.6 
 
  
